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Summary
We aimed to identify genetic factors that alter colorectal cancer (CRC) risk, patient 
survival and response to treatment. Using a cohort of 2,186 advanced CRC (aCRC) 
cases and 2,176 healthy controls, we validated a role for loci at 18q21, 8q23, 15q13 
and 8q24 in CRC susceptibility. We also identified a variant in OGG1 that may act as 
a novel low penetrance risk allele. We identified four germline SNPs from 14 genome 
wide associated CRC risk loci that independently altered patient survival 
(rs16892766 at 8q23, HR 1.28, 95% Cl 1.13-1.45, P<0.001; rs9929218 at 16q22, HR
I.46, 95% Cl 1.23-1.74, P=0.002; rs10411210 at 19q13, HR 1.23, 95% Cl 1.08-1.39, 
P=0.001; and, rs10795668 at 10p14, HR 0.71, 95% Cl 0.59-0.86, P=0.001). We 
found that somatic mutations of the KRAS (HR 1.34, 95% Cl 1.18-1.52 P<0.001) and 
BRAF (HR 2.00, 95% Cl 1.61-2.50, P<0.001) oncogenes altered patient survival 
independent of treatment. Through the COIN trial, we found no evidence for 
improved response to cetuximab in patients’ wild-type for KRAS (OS; HR 1.04, 95% 
Cl 0.87-1.23, P=0.67) or all wild-type for KRAS, BRAF and NR AS (OS; HR 1.02,
95% Cl 0.83-1.24, P=0.86). Similarly, PIK3CA mutation status did not correlate with 
response (OS; 1.03, 95% Cl 0.86-1.24, P=0.89). However, we identified a ‘most 
responsive’ cohort (patients wild-type for KRAS, BRAF and NRAS, with £1 
metastatic sites and that received OxFU) that showed improved response (PFS; HR
0.55, 95% Cl 0.35-0.87, P=0.01). Analysis of individual somatic variants revealed no 
significant associations with response. We found that rs9929218 altered response to 
(OR 0.48, 95% Cl 0.31-0.75, P=0.001) and side effects from (OR 4.68, 95% Cl 1.84-
II.9 , P=0.001) standard chemotherapy and response to cetuximab in a KRAS,
BRAF and NRAS mutant dependent manner (OR 1.69, 95% Cl 0.61-4.74, P for 
interaction 0.004). We elucidated the underlying mechanisms at the 8q23 and 16q22 
loci. These data may help to tailor future therapies for patients with aCRC.
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Chapter One - General Introduction
1.1 Colorectal Cancer
Colorectal cancer (CRC) is one of the most common cancers worldwide, with over 
one million new cases diagnosed each year (with incidence looking set to rise with 
lifestyles in Asian and African populations becoming progressively ‘westernised’). It 
is the third most common cancer in the UK with around 106 new cases diagnosed 
each day and with -38,500 registered cases in 2007 (Cancer Research UK, UK 
incidence statistics, 2010). Mortality rates have declined in recent years (Edwards et 
al. 2010) thanks to increased screening, reduction of risk factors and improved 
treatment. Despite these improvements, the disease-specific mortality rate is still 
approximately 33% in the developed world (Wolpin et al. 2008)
Environmental and genetic factors contribute to the development of CRC and either 
can be the predominant cause of the disease. They can also interact, as 
demonstrated by a genetic predisposition that results in an increased susceptibility to 
particular carcinogens in the diet (Menko, 1993). Environmental factors include age - 
90% of CRC cases are over the age of 50. Also, life-style choices such as exercise, 
smoking habit, alcohol intake, and poor diet can contribute to risk. Kolonel and 
colleagues (2004) highlighted the importance of these environmental factors when 
studying Japanese immigrants to Hawaii. Here the incidence of CRC in even the first 
generation of migrants was found to reach increased rates and was likely a result of 
changes in diet. Diets low in fiber and high in red meat, fat and carbohydrates (Chan 
and Giovannucci, 2010) have been associated with increased risk (World Cancer 
Research Fund, 2007).
1.2 Heritable CRC
As presented in Figure 1.1, the majority of CRCs arise sporadically. However, there 
is a considerable heritable component including a number of CRC syndromes. It is 
estimated that the familial category has a two- to three-fold greater risk than the 
general population (Cunningham et al. 2010). Hereditary CRC syndromes have 
important public health implications. Correct diagnosis of an inherited syndrome, on 
the basis of a family pedigree or through molecular characterisation, is essential in
disease management and clinical decision making for further testing of family 
members (Lynch et al. 2007).
1.2.1 High penetrance mechanisms of inheritance
Inherited factors are thought to play a significant role in up to one third of CRCs 
(Lichenstein et al. 2000), but only a minority of these can be accounted for by 
established CRC predisposition genes (Kinzler and Vogelstein 1996). <6% of cases 
carry high-penetrance germline mutations (Aaltonen et al. 2007) such as those found 
in the adenomatous polyposis coli (APC) gene, which cause familial adenomatous 
polyposis (FAP) (Fearnhead et al. 2001). FAP, and other inherited conditions arising 
through high penetrance mutations, are described below;
1.2.1.1 FAP
FAP is an autosomal dominant inherited disorder that affects about 1 in 7000-8000 
individuals (Cunningham et al. 2010; Half et al. 2009), manifesting equally in both 
sexes. Individuals with FAP are predisposed to hundreds to thousands of 
adenomatous polyps within the colon and rectum (Wallis and MacDonald, 1996). 
Whilst these polyps that develop in the second to third decade of life (Kinzler and 
Vogelstein, 1996) are not cancerous, their presence greatly increases the likelihood 
of the individual developing CRC -  left untreated, one or more will progress to 
carcinoma often by the fourth decade of life (Hodgson and Maher, 1999; Kinzler and 
Vogelstein, 1996) and almost all patients will develop CRC if not recognised and 
treated at an early stage. A phenotypically ‘less-severe’ form of FAP also exists, 
termed attenuated-FAP (AFAP). This is characterised by a reduced adenoma burden 
and a later age of adenoma (and thus cancer) development.
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Figure 1.1 -  Pie chart depicting the frequencies of the different forms of CRC. Seventy-five percent of 
CRCs are sporadic in nature, leaving -25% with some form of inherited component. Of the known 
disorders, HNPCC accounts for the most cases (2-6%, of CRCs) with other conditions such as MAP 
and FAP accounting just under 1% each. The GWAS loci individually confer very modest 
contributions to risk but collectively account for -6%  of CRC risk. About 15% of cases are due to an 
unknown familial component but this may be accounted for by epistatic interactions between the other 
known factors.
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1.2.1.1.1 The APC gene
FAP arises through mutations of the APC tumour suppressor gene. The gene 
consists of at least 21 exons (Santoro and Groden, 1997) spanning a region of >100 
kilobase pairs (kbp). The last exon comprises the majority of the coding sequence 
(-77%) and is the location of most germline and somatic mutations.
More than 300 different mutations of APC can contribute to the FAP phenotype and 
these come in the form of insertions, deletions and nonsense mutations that result in 
truncation of the APC protein. The majority of germline mutations result in the 
synthesis of a C-terminally truncated protein (Beroud and Soussi, 1996; Laken et al. 
1999; Powell et al. 1992) or show selection against P-catenin regulating domains 
(Polakis, 2000). Large deletions that cover whole exons, or the whole gene itself, 
have been observed and contribute to -5% of FAP cases (Sieber et al. 2002; Michils 
et al. 2005). Somatic mutations provide the ‘second hit’ that is required for tumour 
formation and are found to cluster within a central region of the gene. This central 
region (known as the mutation cluster region or MCR) lies between codons 1281 and 
1580 and greater than 60% of somatic APC mutations occur here (Cheadle et al. 
2002; De Rosa et al. 2003).
1.2.1.1.2 Wnt Signalling and cancer
The Wnt pathway is critical in controlling important processes such as cell 
proliferation and differentiation. APC is a key part of this pathway, functioning as part 
of a destruction complex that targets P-catenin for degradation. Wnt signals influence 
the stability of this destruction complex that also includes casein kinase 1a (CK1), 
glycogen synthase kinase 3 (GSK3) and the scaffolding protein Axin. The overall 
process is depicted in Figure 1.2. The regulation of Wnt signalling is a critical 
process and its loss is associated with cancer initiation - often through the loss of 
activity of genes encoding members of the destruction complex or activating 
mutations of p-catenin (Sparks et al. 1998) itself. Abnormal levels of p-catenin in-turn 
lead to increased expression of Wnt target genes which contribute to the initiation of 
tumourigenesis.
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Figure 1.2 - Wnt signalling in colonic epithelial cells. (A) In the absence of Wnt, p-catenin is recruited 
to the destruction complex (that includes APC, CK1, GSK3p and Axin). APC and Axin (which provides 
the scaffold for this complex) physically interact with p-catenin, while CK1 and GSK3P phosphorylate 
the N-terminus of the protein (Sakanaka et al. 1999). It is subsequently ubiquitinated by an E3 
ubiquitin ligase called p-TrCP and is proteasomally degraded. This restriction on the levels of 
cytoplasmic p-catenin enables the interaction of the transcriptional repressor Groucho and the 
TCF/LEF machinery and ensures that Wnt target gene transcription is repressed (Daniels and Weis, 
2005). (B) When Wnt binds to the transmembrane receptor Frz and LRP5/6 co-receptors, Axin 
translocates to the cell membrane and interacts with LRP5/6 and Disheveled is phosphorylated by 
CK1, preventing GSK3p from phosphorylating p-catenin (Clevers, 2006). Intracellular p-catenin is 
able to accumulate and translocate to the nucleus where it binds with TCF/LEF transcription factors 
and other components (Pygopus and Bcl9), thus activating the transcription of Wnt target genes. 
These include the polyamine ornithine decarboxylase (ODC) proto-oncogene (Bello-Fernandez et al. 
1993), CCND1 (Tetsu and McCormick, 1999) and EphB (Batlle et al. 2002). Abnormal expression of 
these genes can contribute to the neoplastic transformation of the cell.
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1.2.1.2 HNPCC
Accounting for 2-6% of all CRC cases, HNPCC is the most common hereditary form 
of CRC (Lynch et al. 2006; Hampel et al. 2008). It has an autosomal dominant 
inheritance pattern (Potter, 1999) that manifests at an average age of 45 years 
(compared to 69 years for sporadic CRC in the general population) (Lynch et al.
2009). Tumourigenesis shows a predilection towards proximal colon growth, with 
accelerated development from adenoma to carcinoma (within 2-3 years in HNPCC 
patients as compared to 8-10 years in the general population). Despite this, 
adenomas are rarely present in large numbers (exceptionally more than 10) and 
florid polyposis is not observed (Maher etal. 1991). Amongst HNPCC sufferers, 
there is a high risk of additional CRCs with -30% of those that undergo surgery 
developing a second primary tumour within 10 years of resection (Lynch et al. 2009). 
Sufferers show longer survival periods than other forms of CRC. HNPCC is caused 
by germline mutations in genes involved in the mismatch repair (MMR) pathway -  
mutations in the MSH2 (Fishel et al. 1993), MLH1 (Lindblom et al. 1993), MSH6 
(Miyaki et al. 1997), MLH3 (Wu et al. 2001) or PMS2 (Nicolaides et at. 1994) have 
been linked to this condition.
1.2.1.2.1 DNA mismatch repair
DNA MMR is a cellular repair system that repairs mismatches and insertion-deletion 
loops. During replication, slippage can lead to misalignment of the template and 
synthesis strands, in-turn giving rise to heteroduplex DNA molecules. Microsatellites 
are short repetitive DNA motifs of 1-6 nucleotides in length that are repeated 10-60 
times (Beckmann and Weber, 1992). They are polymorphic in length among 
individuals but are unique and uniform in length in every tissue within an individual 
(Boland and Goel, 2010) and are abundant throughout the genome though are more 
common in non-coding regions. Mismatches can contribute to the microsatellite 
instability (MSI) phenotype that is observed in 15% of CRCs. The MMR system 
repairs the section of the synthesis strand containing the error in a process 
summarised in Figure 1.3.
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Figure 1.3 -  Diagram depicting the human MMR system. Initially the repair machinery must recognise 
base-base mismatches or insertion-deletion loops. In humans this is carried out by two separate 
complexes; MSH2/MSH6 which recognise mismatches and small insertion-deletion loops, and 
MSH2/MSH3 which recognise all sizes of insertion-deletion loops (Culligan et al. 2000). After 
recognition, a MLH1/PMS2 heterodimer is recruited to the damage site and docks to a MSH2 
heterodimer (Jascur and Boland, 2006; Plotz et al. 2006). The complex of MLH1/MLH3 has a largely 
unclear function but may participate in the repair of a subset of mismatches recognised by the 
MSH2/MSH3 complex. Repair continues with the exonuclease 1 (EXOI) mediated degradation of 
DNA until the lesion is removed. Finally, the resulting excision tract is filled in by polymerase 6 (Pol6) 
and the correct nucleotide will be inserted in the original mismatch position, and the remaining nick is 
sealed by ligation.
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1.2.1.2.2 Germline mutations in MMR genes
Mutations within the MLH1 and MSH2 genes account for >95% of HNPCC cases 
(Peltomaki, 2005). The remaining mutations are distributed amongst the other MMR 
genes (Papp et al. 2007). The majority of germline mutations are nonsense or 
frameshift mutations, though missense, splice-site variants and small- and large- 
deletions and insertions have been observed (Kurzawski et al. 2006). Germline 
mutations do not cluster at ‘hot-spots’ within the MMR genes, and the majority of the  
mutations have only been reported once.
1.2.1.2.3 Somatic mutations in HNPCC
The MMR genes act as tumour suppressor genes -  both alleles are required to be 
inactivated to contribute to tumourigenesis since cells heterozygous for a mutation 
function normally (Parsons et al. 1993). Mutational inactivation of the MMR 
machinery leads to deficiencies in the MMR system that causes the MSI phenotype-
1.2.1.2.4 MSI
MSI is observed in the majority of tumours in HNPCC cases, but is only detected in 
-10-15% of sporadic CRCs (Thibodeau et al. 1993; Ionov etal. 1993). Sporadic 
CRCs displaying MSI arise through a process that involves the CpG island 
methylator phenotype (CIMP) (Toyota et al. 1999). CpG islands are clusters of 
cytosine-guanine nucleotides that are often found within the promoter regions of 
coding elements (Issa, 2004). These genes can be silenced through a mechanism in  
which the cytosine residue of this di-nucleotide becomes methylated through the 
action of methyltransferases. One such target of this ‘hypermethylation’ is the MLH7 
gene (Kuismanen et al. 2000). CRCs arising through the CIMP mechanism are 
distinct from HNPCC cases (Nagasaka et al. 2008; Boland et al. 2009).
MMR deficiency leads to an increase in the rate of point mutation accumulation 
across the genome of a cell, with a bias towards mutations in repetitive sequences. 
When microsatellites lying within coding regions of regulatory genes become 
disrupted, MSI can contribute towards the development of cancer.
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1.2.1.3 MAP
The discovery of this condition came about through the study of a British family in 
which three siblings were affected by multiple colorectal adenomas and carcinomas 
but none had an inherited mutation of APC (Al-Tassan et al. 2002). Equal expression 
of both APC alleles was observed and there was no evidence for defective MMR. 
Upon analysis of the somatic status of APC in the patients tumours, an over­
representation of G:C->T:A transversions was observed. The number of 
transversions was compared against those in 811 colorectal carcinomas, and it was 
found that the high-occurrence within the three siblings was statistically significant 
(p=10'12). Based on the knowledge that the E.coli MutY, MutM and MutT 
glycosylases counteract and repair damage resulting from the mispairing of adenine 
with 8oxoG, that result in such G:C->T:A transversions (Steenken et al. 1997), Al- 
Tassan and colleagues screened the human orthologues of these genes; MUTYH, 
OGG1, and MTH1 respectively, for pathogenic mutations. Germline bi-allelic 
mutations of MUTYH were observed in all three affected siblings. These bi-allelic 
mutations were found at Y165C and G382D (though the current nomenclature refers 
to these as Y179C and G396D respectively). The occurrence of these variants in a 
heterozygous, non-biallelic state within phenotypically normal controls suggested 
that their mutagenic effect was recessive. Further carriers of bi-allelic MUTYH 
mutations were found within the adenoma and polyposis setting by Jones (2002) and 
Sieber (2003). Functional analysis of the variants within the E.coli orthologues 
revealed that their presence functionally compromises the protein, with the ability to 
remove adenine being severely depleted in Y165C mutant- and 85% decreased 
within G382D mutant-carriers.
MAP is an autosomal recessive inherited condition that accounts for ~1% of all 
CRCs (Fleishmann et al. 2004). The colorectal phenotype of MAP resembles AFAP 
(<100 polyps) and ‘mild’ FAP (hundreds to thousands of polyps), but not severe FAP.
1.2.1.3.1 MUTYH function
MUTYH is a DNA glycosylase that contributes to the maintenance of genomic 
stability through its role in the base excision repair (BER) of oxidative DNA damage. 
In humans, there are approximately 104 lesions generated per cell, per day as a 
result of oxidative damage to DNA (Ames and Gold, 1991). The main causes of this
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oxidative damage are reactive oxygen species (ROS) which include hydroxyl 
radicals, superoxide and hydrogen peroxide. ROS are by-products of cellular 
metabolism as well as environmental exposures and have been linked to the 
initiation and progression of cancer, as well as degenerative diseases and ageing 
(Klaunig and Kamendulis, 2004). Types of damage resulting from ROS include 
strand-breaks or lesions of individual bases. Nucleotides are susceptible to oxidative 
damage, especially guanine due to its low oxidative potential (Steenken et al. 1997). 
A number of intracellular mechanisms exist to monitor and respond to this damage - 
extensive damage may result in cell death while limited damage can be repaired with 
little consequence to the cell. However, mutations can result from replication if the 
modified bases are not repaired (Lu et al. 2001).
1.2.1.3.2 BER
BER is the main mechanism that protects the cell against oxidative DNA damage 
(Hazra et al. 2007) though it can also repair lesions that result from methylation, 
deamination and hydroxylation (Hoeijmakers 2001). The overall BER process is 
presented in Figure 1.4.
7, 8-dihydro-8-oxoguanine (8oxoG) is the most stable product of oxidative DNA 
damage (Ames and Gold, 1991). 8oxoG can functionally mimic the thymine base, 
and thus readily mispairs with adenine leading to G:C->T:A transversions. It is 
estimated that there are 0.3-4.2 8oxoG bases per 106 guanine bases (Collins et al. 
2004) and high concentrations have been detected in breast, lung, and kidney 
cancers (Malins and Haimanot, 1994; Olinski et al. 1992; Jaruga et al. 1994; 
Okamoto et al. 1994). Thus it is essential that the cell can recognise and remove the 
lesion. Cytosine can also be ‘misincorporated’ opposite 8oxoG but this is observed 
5-200 times less frequently than the mis-incorporation of adenine (Shibutani et al. 
1991). E.coli was first used to study the defence against damage resulting from 
spontaneous 8oxoG. Three key enzymes were identified; MutT, MutM and MutY 
which function as a group of BER glycosylases (Michaels and Miller, 1992). Since 
then, human homologues of these key glycosylases have been identified as 
MTH1/NUDT1 (MutT; Sakumi et al. 1993), OGG1 (MutM; Roldan-Arjona et al. 1997; 
Arai et al. 1997) and MUTYH (MutY; Slupska et al. 1996) which are also critical in 
8oxoG repair, as described in Figure 1.5)
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Figure 1.4 -  Diagrammatic representation of the BER process. Here a DNA glycosylase will 
recognise a damaged base and ‘flip’ it out of the helix by DNA backbone compression. This, in-tum, 
allows the DNA glycosylase to accommodate the base into its active site and cleave it from the sugar- 
phosphate backbone. The resulting apurinic/apyrimidinic (AP) site (which can also occur 
spontaneously by hydrolysis) can also be cleaved 3’ to this site by glycosylases that specifically target 
AP sites. The APE1 endonuclease then processes the DNA in preparation for DNA synthesis. At this 
stage, the repair pathway diverges into short-patch or long-patch BER (Wilson and Bohr, 2007), with 
the former being the more dominant mode in mammals. In short-patch BER, DNA polymerase p 
performs a one-nucleotide gap-filling reaction and removes the 5’ terminal baseless sugar residue via 
its lyase activity. The remaining nick is then sealed by an XRCC1 (X-ray repair cross complementing 
1)/DNA ligase complex. In the long-patch BER pathway, DNA polymerase p incorporates the first 
nucleotide and polymerase 6/e carry out elongation. Following this, a repair patch of two or more 
nucleotides is synthesised from the damaged site, facilitated by proliferating cell nuclear antigen 
(PCNA) and replication factor C (RFC). The displaced DNA flap is then excised by flap endonuclease 
1 (FEN1) before a final ligation reaction is carried out by DNA ligase 1. The above mechanisms occur 
across the genome, with the divergence into the dominant short-patch or minor long-patch repair 
pathways dependent upon which DNA glycosylase is recruited to the damage site, as well as the type 
of damage present and the current cell cycle phase.
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Figure 1.5 -  The roles of human MUTYH, OGG1 and MTH1 in the repair of the 8oxoG (shown as a 
G*) lesion. Presented are the structures and binding patterns of the normal and damaged bases 
during different stages of the repair process. The major enzyme for the repair of 8oxoG is considered 
to be OGG1 (Hirano, 2008). OGG1 (scarlet box) recognises 8oxoG when it is paired with cytosine (as 
shown by point 2) and excises it. The repair site can subsequently be replaced with the correct base, 
G. There are reports that OGG1 may recognise and act upon other lesions, albeit less effectively 
(BjorSs et al. 1997). MUTYH (purple box) has glycosylase activity against a number of DNA 
substrates including the mispairs; A:G, 2-hydroxyadenin (2-OH-A; aka isoguanine):8oxoG, A:8oxoG, 
2-OH-A:G, and 2-OH-A:A (Ohtsubo et al. 2000). Here, it excises the mispaired adenine (as shown by 
point 3), allowing OGG1 a second opportunity to excise 8oxoG from the regenerated 8oxoG:C 
mispair. MTH1 (green box) is an oxidised purine nucleoside triphosphatase that efficiently hydrolyzes 
oxidized dGTP, GTP, dATP and ATP in the nucleotide pool, preventing their incorporation into the 
nascent strand during DNA replication (Nakabeppu et al. 2001). In the case of 8-oxodGTP (dG*TP 
above), MTH1 degrades it to 8-oxodGMP (dG*MP) which, upon further dephosphorylation, is either 
excreted in the urine or recycled (Cooke and Evans, 2007; Hah etal. 2007).
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When mutated, MUTYH has a significantly lower capacity for binding and repair of 
A:8oxoG and 8-oxoadenine:G mispairs (Parker et al. 2005). This defective repair of 
lesions defines the MAP condition. Little is known about the contribution of OGG1 
towards cancers - given the importance MUTYH in predisposition to CRC, it was 
thought that OGG1 may play a similar role based its common role in protection 
against the 8oxoG lesion but little evidence for this has been found. Possibly the 
strongest candidate for an inactivating or disrupting mutation that contributes to 
cancer is the common Ser326Cys variant (Kohno et al. 1998; Dherin et al. 1999), 
though other polymorphisms, with as yet unknown consequences, could contribute 
(Sidorenko et al. 2009). A screen of 167 unrelated patients with multiple colorectal 
adenomas for inherited variants failed to identify any biallelic combinations of rare 
alleles in MTH1 and OGG1 (as well as other BER enzymes NEIL1, NEIL2, NEIL3 
and NTH1) (Dallosso et al. 2007).
1.2.2 Low penetrance mechanisms of inheritance
Beyond the high penetrance mechanisms of inheritance, it has been proposed that a 
substantial proportion of the remaining inherited predisposition to CRC is caused by 
either rare (Fearnhead et al. 2005) or common low penetrance variants.
1.2.2.1 ‘Common-disease rare variant’ hypothesis
In support of the ‘rare variant hypothesis’, Azzopardi and colleagues (2008) have 
shown that individually rare, but collectively common, inherited non-synonymous 
variants in APC play a significant role in multi-factorial inherited predisposition to 
colorectal adenomas (CRAs). The non-synonymous variants I1307K and E1317Q 
had previously been suggested by some studies to predispose to CRAs and CRCs 
(Frayling et al. 1998; Lamlum et al. 2000; Gryfe etal. 1999; Hahnloser et al. 2003), 
while others had not supported these observations (Gismondi et al. 2002; Popat et 
al. 2000). Azzopardi and colleagues confirmed a role for E1317Q as a low 
penetrance variant for predisposition to CRAs by virtue of its significant over­
representation in ‘non-FAP, non-MAP’ patients as compared to controls. Other 
investigators have also reported that rare variants in the Wnt signalling genes AXIN1 
and CTNNB1 and the MMR genes MLH1 and MSH2 contribute to colorectal 
tumourigenesis (Fearnhead et al. 2004)
1.2.2.2 'Common-disease common variant’ hypothesis
In the ‘common-disease common-variant’ model for CRC, the risk associated with 
individual variants is small; however, they make a significant contribution to the 
overall disease burden by virtue of their high frequencies in the population.
Moreover, by acting in concert with each other, they have the potential to 
significantly affect an individual’s risk of developing CRC. Recent years have seen 
the identification of such variants through the use of genome wide association 
studies (GWAS)
1.2.2.3 GWAS of CRC
GWAS have become possible thanks to a number of key factors. Firstly, the 
collection of large and well characterised case and control cohorts have provided 
researchers with study groups large enough to overcome the power issues faced in 
large scale statistical analyses. Secondly the completion of the HapMap project (the 
international HapMap consortium, 2003) has allowed the selection of tag single 
nucleotide polymorphisms (SNPs) that capture much of the variation of the genome. 
Finally, technological advances in platforms used for large-scale genotyping have 
allowed realistic costs and time-scales for researchers when screening large 
numbers of variants across many thousands of samples.
Several studies have conducted multistage GWA and, to-date identified 14 low 
penetrance susceptibility loci for CRC risk (Table 1.1). The emergence of these 
variants has yielded advances in the understanding of the role played by common 
variation in CRC. It is estimated that each locus contributes less than 1% to familial 
risk of CRC (Houlston et al. 2008), in an independent fashion. Using an additive 
model, and considering that an individual will likely carry more than one risk variant, 
the 14 loci collectively account for -6%  of the excess familial risk (Figure 1.1). 
Furthermore, they allow the possibility of developing multi-locus prediction models of 
genetic risk that could be combined with other known risk factors (Tenesa and 
Dunlop, 2009).
14
Locus
Association
SNP/s
Gene Reference
1q41*
rs6691170,
rs6687758
DUSP10 Houlston et 
al. 2010
3q26 rs10936599 MYNN
Houlston et 
al. 2010
8q23 rs16892766 EIF3H
Tomlinson et 
al. 2008
8q24 rs6983267 -
Tomlinson et 
al. 2007
10p14 rs10795668 -
Tomlinson at 
al. 2008
11q23 rs3802842 -
Tenesa et al. 
2008
12q13*
rs11169552, 
rs7136702
LARP4 Houlston at 
al. 2010
14q22 rs4444235 BMP4
Houlston et 
al. 2008
15q13 rs4779584 -
Jaeger et al. 
2008
16q22 rs9929218 CDH1
Houlston et 
al. 2008
18q21 rs4939827 SMAD7
Broderick at 
al. 2007
19q13 rs10411210 RHPN2
Houlston et 
al. 2008
20p12 rs961253 -
Houlston at 
al. 2008
20q13 rs4925386 LAMAS
Houlston et 
al. 2010
Table 1.1 -  Table highlighting the 14 distinct loci associated with CRC identified 
through GWAS. Some SNPs map within or near to genes though in most cases, it is 
unclear as to whether the SNP actually interacts with the gene. *Two SNPs 
associate with risk at these loci.
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1.2.2.3.1 8q24 and the risk mechanism at this locus
The first CRC risk locus to be identified through GWAS was 8q24 (Zanke et al.
2007). A multistage association of 7,480 CRC cases and 7,779 controls highlighted 
the 8q24 locus (especially in a region of linkage disequilibrium (LD) that houses 
SNPs rs6983267 and rs10505477) as being linked to CRC risk. A separate analysis 
(Tomlinson et al. 2007), involving a series of case/control analyses identified 
rs6983267 as the most strongly associated SNP at this locus -  this association also 
included CRC adenoma cases, suggesting that the risk at this locus contributes 
towards tumour initiation. Attention had previously been drawn to the 8q24 region in 
previous studies of CRC - the MYC oncogene, which resides at this locus, was 
amplified in 32% of CRC patients in a study by Augenlicht and colleagues (1997). In 
addition, the tyrosine phosphatise PRL-3 at 8q24 is amplified in CRC metastasis 
(Mollevi et al. 2008). Many other studies of various populations have validated the 
association at this locus (Gruber et al. 2007; Poynter et al. 2007; Li et al. 2008; 
Tuupanen et al. 2008; Berndt et al. 2008; Curtin et al. 2009; Hutter et al. 2010). As 
well as CRC, the 8q24 locus has been linked with other cancers including prostate, 
bladder and breast (Haiman etal. 2007; Kiemeney etal. 2008; Easton etal. 2007). 
Accounting for the various associated cancers, there appear to be at least 5 different 
susceptibility loci at 8q24.
Recent findings have started to shed light on the functional effect rs6983267 might 
be having (Figure 1.6). The risk allele (G) of rs6983267 enhances binding of TCF4 
which in-turn regulates MYC, a target of the Wnt pathway (Tuupanen et al. 2009). 
Further evidence for this interaction was found by Pomerantz and colleagues (2009). 
Using CRC cell lines, the region was confirmed as being a binding site for TCF4, 
with the G allele showing greater binding potential than the T allele. The 
chromosome conformation capture (3C) technique revealed that, despite the large 
genomic distance between the risk region and MYC gene, a physical interaction 
between the two exists -  specifically including the first half of MYC and its promoter. 
Wright and colleagues (2010) confirmed this by revealing that TCF4 physically 
interacts with MYC through the formation of chromosome loops regardless of which 
allele is present at rs6983267. The presence of the G allele, however, correlates with 
increased MYC expression (~2-fold higher than the T allele). Furthermore Sotelo and 
colleagues (2010) demonstrated significantly varied enhancer activity depending
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upon which allele of rs6983267 was present -  contradictory to the above findings, 
the ‘non-risk’ T allele correlated with greater MYC activity than did the risk G allele. 
They suggest that rs6983267 acts to regulate MYC and its oncogenic effects through 
union of intrinsic thresholds that regulate cellular proliferation, and tumour 
suppression. MYC expression, when raised above a certain level, will trigger cellular 
apoptosis (Jiang et al. 2003) but low levels of MYC will drive cellular proliferation 
unchecked.
1.2.2.3.2 18q21 and the risk mechanism at this locus
Shortly after the identification of 8q24 as a CRC risk locus, 18q21 was highlighted as 
housing a variant, rs4939827, that also associates with risk (P=1.0x10'12) (Broderick 
et al. 2007). This variant maps to the third intron of the SMAD7 gene (mothers 
against decapentaplegic homolog 7) which is an intracellular antagonist of TGF8 
signalling that acts by binding the active receptor complex and blocking downstream 
signalling. Since the TGF8 signalling pathway is involved in many critical cellular 
processes including cell growth, apoptosis, cellular differentiation, adhesion and 
migration, and immune response, SMAD7 seemed the most obvious functional 
target for the risk associated allele of rs4939827. The 18q21 locus accounts for 
~0.8% of excess familial risk of CRC. The modest risk at this locus was further 
replicated in the Tenesa’s 2008 study (P=7.8x10'28, OR=1.2) as well as through the 
use of the case/control cohorts of Curtin and colleagues (2009) (P=0.007, OR=0.77) 
and Slattery and colleagues (P<0.01, OR=0.77) (2010).
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Figure 1.6 -  Suggested mechanism through which rs6983267 (in blue) contributes 
to CRC risk despite being >300kb telomeric to the MYC gene. Tuupanen and 
colleagues (2009) initially identified a potential role for the SNP as part of an 
enhancer element using the ‘enhancer element locator’ which identifies potential 
distal enhancer elements through the alignment of conserved mammalian 
sequences (A, Conserved bases are black and represented with an *). This 
highlighted the immediate region surrounding the SNP as a binding site for the Wnt 
regulated transcription factor TCF4. Further studies have replicated this, and shown 
that this region physically interacts with the MYC gene (B).
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As with rs6983267, the causative mechanism through which rs4939827 acts has 
recently been uncovered. Pittman and colleagues (2009) sequenced the entire 
region of linkage disequilibrium surrounding this variant (and other lower risk SNPs 
rs12953717 and rs4464148). They proceeded to genotype any SNPs identified 
through this initial screen in -2,500 CRC cases and -2,500 controls. This led to the 
identification of a previously unlisted variant (minor allele frequency (MAF) of 0.47) 
as the most likely causal variant for CRC risk at this locus (P=5.2x10'6). This 
polymorphism resides in a conserved transcription factor binding site. The novel 
variant (a C>G change) was found to reduce enhancer element binding -  
electrophoretic mobility shift assays (EMSA) revealed a complex that preferentially 
forms when the C allele is present. In addition, the G allele correlated with 
significantly reduced expression of green fluorescent protein (GFP) in construct 
experiments. Finally, the authors highlight the contributory effect towards CRC 
through SMAD7 expression analysis of cancer and adenoma cases, with significantly 
lower expression observed in cancers.
1.2.2.3.3 The remaining GWAS loci
Like those at 8q24 and 18q21, most of the remaining risk variants map to regions of 
seemingly little genomic consequence (i.e. intronic or variants located in ‘gene- 
deserts’) and as yet the functional consequences behind them have not been 
identified. The occurrence of GWAS SNPs (for other conditions as well as CRC) in 
gene-deserf genomic locations poses a large problem for future research. A recent 
meta-analysis revealed that roughly 40% o f -1200 disease associated SNPs lie in 
LD blocks tagging no coding elements (Visel et al. 2009).
Despite the productive output of GWAS in recent years, it remains likely that, outside 
of the top 20-50 most significant SNPs for a particular condition, other variants will 
not be detected without exponential increases in sample sizes analysed, due to 
limitations in power.
1.2.2.4 Pathways of CRC susceptibility
GWAS have identified several components of the TGFp pathway as carriers of risk 
alleles for CRC. These include SMAD7 (18q21), GREM1 (15q13), the bone 
morphogenetic protein genes BMP2 and BMP4 (20p12 and 14q22-23), and RHPN2
(19q13). This overrepresentation of TGFp pathway components suggests a key role 
for this pathway in CRC susceptibility (Tenesa and Dunlop, 2009). This is an 
attractive proposition given the critical role played by the pathway in mechanisms 
such as cellular differentiation, proliferation and migration (Alarmo and Kallioniemi, 
2010). Recently, Carvajal-Carmona and colleagues (2011) partly confirmed the 
importance of the BMP and TGFp pathway in CRC risk. In an analysis of -25000 
cases and an equal number of controls, two new CRC predisposition SNPs at BMP4 
(rs1957636) and BMP2 (rs4813802) were identified that act independently to the 
original predisposition SNPs at these respective loci. In addition, the GWAS SNP 
rs4779584 at GREM1 tags two further independent functional SNPs (rs16969681 
and rs11632715). Taking into account the SMAD gene products that function within 
the BMP and TGFp pathways (including SMAD7), the number of components within 
these pathways that influence risk includes 3 high-penetrance predisposition genes 
(SMAD4, BMPR1A, GREM1) and 7 low-penetrance variants at BMP2, BMP4, 
GREM1, SMAD7 and LAMA5. A recent sequencing project, comparing the exomes 
of MSI and microsatellite stable (MSS) CRC tumours revealed that BMPR1A is 
mutated in both phenotypes highlighting a potential somatic role for this gene.
Further functional work revealed that mutant protein is strongly impaired in its 
signalling function, and that stimulation with BMP2 results in reduced maximum 
activity (Timmermann et al. 2010).
1.3 Colorectal tumourigenesis
The progression of CRC from adenoma to malignancy requires multiple mutations in 
distinct genes, the accumulation of which can take over a decade (Kinzler and 
Vogelstein, 1996). These genes have vital roles in controlling cellular processes 
such as the cell cycle and signalling pathways. Though different genes within the 
same pathway can be mutated in different colorectal cancers, they will generally be 
mutually exclusive within the same tumour (Vogelstein and Kinzler, 2004). An 
example of this are the KRAS and BRAF genes that are part of the ras-raf-MAP 
pathway downstream of the epidermal growth factor receptor (EGFR) (Crook et al.
2009). Though they are mutated in -40-45% and -10% of CRCs respectively, they 
generally do not co-occur. The stages of tumourigenesis are well defined and are 
highlighted in Figure 1.7.
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Figure 1.7 -  Adenoma-carcinoma sequence depicting some of the key events which occur during colorectal tumourigenesis. 
Progression can occur via two main routes; the chromosomal and microsatellite instability pathways. The first step of 
tumourigenesis is the formation of an adenoma. Intermediate to late adenomas (and ultimately carcinomas) will generally acquire 
multiple hits in different pathways (e.g. the Ras-Raf-MAPK and/or TGFp pathways). Some of these mutations occur often (e.g. 
KRAS is mutated in 40-45% of CRCs) while some might be less frequent but occur in a specific setting (e.g. mutations of BRAF are 
common in microsatellite unstable tumours).
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1.3.1 Genomic Instability
The baseline mutation rates (as low as 10'9 per cellular generation (Albertini et al. 
1990)) of the body are typically insufficient to account for the multiple mutations that 
are required in the development of cancer. Genomic instability is a characteristic of 
almost all human cancers and comes in various forms (Negrini et al. 2010) including 
chromosomal instability (CIN) and MSI. Abnormal chromosome numbers and 
structures, as well as abnormal mitoses are associated with CIN and result in genetic 
alterations, while MSI causes genetic alterations through defective DNA MMR 
(Soreide et al. 2009). Instability can also arise through epigenetic silencing of gene 
promoters. Through these mechanisms, genomic instability contributes to 
accumulation of mutations of genes involved in CRC (Grady and Markowitz, 2002).
The majority of CRCs (85%) develop according to the CIN pathway (Kinzler and 
Vogelstein, 1996) which can result from defects in a number of critical processes 
including chromosomal segregation, telomere stability and the DNA damage 
response, though there are likely to be other mechanisms that are as yet unknown. 
These defects ultimately result in gross changes in DNA by increasing the rate of 
chromosomal gains or losses (Kinzler and Vogelstein, 1996; Rajagopalan et al.
2003). Coupled with the karyotypic abnormalities typical in CIN tumours, is the non- 
random accumulation of a series of mutations in oncogenes and tumour suppressor 
genes. It is not clear which is the preceding event in tumourigenesis. It is possible 
that CIN creates the appropriate environment for the accumulation of such mutations 
but equally plausible that these mutations contribute to the de-stabilising of the 
genome. Regardless, the genetic changes appear to be an intrinsic feature of most 
cancers, as evidenced by recent high-throughput sequencing studies showing that 
mutations of DNA repair and replication genes are present in ~60% of cancer cell 
lines (Poulogiannis etal. 2010). Common events coupled with CIN include the allelic 
loss (loss of heterozygosity, LOH) of p53, SMAD4, and APC loci (Terdiman, 2000). 
Deletion of 1p and 8p is also common, though the genes involved with 
tumourigenesis at these loci are unknown. Along with the tumour suppressor genes 
described above, the KRAS, CTNNB1, and PIK3CA oncogenes at 12p12, 3p22 and 
3p26 respectively are often mutated in CIN tumours (Santini et al. 2008; Sparks et al. 
1998; Samuels et al. 2004). Several studies have revealed that CIN occurs at early 
stages of tumourigenesis (Bardi etal. 1997; Stoler et al. 1999), including that of
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sporadic CRC (Shih etal. 2001) and hereditary CRC (Cardoso etal. 2006). There 
are a number of candidates for genes that, when mutated, contribute to the CIN 
phenotype. Indeed, more than 100 genes can lead to CIN in Saccharomyces 
cerevisiae (Pino and Chung, 2010) with only a minority of their human homologues 
having been implicated. Amongst the most likely candidates are genes in pathways 
that ensure correct mitotic segregation of chromosomes (including BUB1, AURKA, 
PLK1, PTTG, APC) and those involved in telomere regulation and DNA damage 
response (including TERC, ATM, BRCA1/2, p53, MRE11).
The next most common form of genomic instability is MSI. Genes that contain coding 
microsatellite repeats are prone to frameshift mutations (Soreide et al. 2006). For 
example, the TGFfi-RII gene is mutated in colorectal tumours with MSI with 
frameshift mutations occurring at specific hot-spots within the coding region 
(Markowitz et al. 1995). Of the 15% of CRCs that display MSI about 3% are 
associated with Lynch syndrome and 12% with sporadic CRC. A common feature of 
sporadic CRC is mutation of BRAF (Figure 1.7). A small proportion of CRCs display 
genomic instability that involves neither CIN nor MSI (Goel etal. 2003) but show 
CIMP.
1.3.2 Cancer genes
The genes that contribute to CRC fall into two separate classes -  oncogenes and 
tumour suppressor genes (Vogelstein and Kinzler, 2002). An oncogene is a gene 
that when mutated becomes constitutively activated (or active when the wild type 
gene would not be). Mechanisms of activation of oncogenes include point mutation 
of residues critical in controlling the resulting proteins activity, chromosomal 
translocations (as caused by CIN), and gene amplifications (Vogelstein and Kinzler,
2004). Only one allele of an oncogene need be somatically mutated for activation.
An example of an oncogene often mutated during the progression to colorectal 
tumourigenesis is KRAS (Figure 1.7). The KRAS gene encodes a protein critical in 
signal transduction through a number of intracellular pathways. As discussed in 
further detail later, the KRAS protein is a membrane-associated GTP-coupled protein 
that is activated by the binding of GTP enabling it to stimulate the MAPK cascade. 
The GTPase activity of KRAS then hydrolyses bound GTP to GDP, in-turn 
inactivating itself. KRAS acts as a signal switch molecule, and its mutation is
considered one of the main steps in the adenoma-carcinoma sequence of CRC 
genesis (Fearon and Vogelstein, 1990). Mutations in KRAS disable endogenous 
GTPase activity, in-turn leading to constitutive activation of downstream signalling 
and contributing to tumourigenesis (Forrester et al. 1987; Grady and Markowitz,
2002). This activation circumvents the need for upstream EGFR signalling. Other 
oncogenes that can contribute to CRC tumourigenesis include CTNNB1 (Morin et al. 
1997), BRAF (Davies et al. 2002), and PIK3CA (Samuels et al. 2006), with the BRAF 
protein having overlapping function with KRAS.
The other class of cancer genes are tumour suppressor genes. Unlike oncogenes, 
mutations of tumour suppressor genes lead to inactivation of the resulting protein -  
often because mutations lead to truncation or nonsense mediated decay (NMD) 
(Storey et al. 1998). Point mutations that target residues vital for the proteins 
function, along with insertions and deletions can result in loss of function. Other 
epigenetic mechanisms including hypermethylation (Baylin etal. 1998) and improper 
localization (Moll etal. 1992; Takahashi and Suzuki, 1994) can also contribute. 
Perhaps the most important tumour suppressor gene inactivated in CRC is APC 
since its loss represents one of the initiating steps of CRC (Powell et al. 1992; 
Groden et al. 1991; Kinzler et al. 1991). Another tumour suppressor gene, that is 
critical in the development of a number of cancers including colorectal, is TP53 
(Hollstein et al. 1991). Tumour suppressor genes act mostly in a recessive fashion -  
with mutations of both alleles being required for inactivation. In sporadic CRC, both 
of these mutations occur somatically, whilst in dominantly inherited forms of CRC 
one allele is mutated in the germline while the second is mutated somatically. In 
FAP, the APC gene has a germline mutation of one allele while a second somatic 
mutation of the other allele leads to CRC through adenoma formation (Fearnhead et 
al. 2001). This is in accordance with Knudson’s two hit hypothesis (Knudson, 1996) 
(as portrayed in Figure 1.8).
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Figure 1.8 -  Diagram depicting Knudson’s two hit hypothesis of tumourigenesis. In 
sporadic disease, two separate sporadic ‘hits’ are required -  one per allele. In 
inherited disease, every cell will contain the first ‘hit’ so only one somatic hit is 
necessary for loss of gene function and progression to tumour formation.
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1.4 Treatment of CRC
Currently, a combination of surgery, radiotherapy and/or chemotherapy is used in the 
treatment of CRC. Despite vast improvements in each of these areas, the disease 
still causes considerable morbidity and mortality. For patients with advanced CRC 
(aCRC), there are currently seven chemotherapeutic agents approved for use in 
routine clinical practice (O’Neil and Goldberg, 2005). These are the fluoropyrimidines 
5-fluorouracil (5FU) and capecitabine, oxaliplatin, irinotecan and the monoclonal 
antibodies cetuximab, panitumumab and bevacizumab. Each is described below. 
These agents function by targeting cellular properties specific to the tumour cell -  for 
example, 5FU blocks the incorporation of specific nucleotides into the growing DNA 
chain which affects rapidly dividing cells (such as tumour cells) whilst cetuximab has 
a more profound effect on cells with increased EGFR signalling. As discussed by 
O’Neil and McLeod (2006), the choice of the first therapy (or combination of 
therapies) administered is critically important in the treatment of CRC, as this likely 
represents the best chance to improve overall outcome of the patient. Indeed, whilst 
most of these agents will initially be beneficial, patients will experience disease 
relapse as drug-resistant tumour cells arise. Thus understanding of the agents most 
likely to elicit a response in patients, and the interactions between these agents, is of 
the utmost importance.
1.4.1 Standard chemotherapy
1.4.1.1 5-Fluorouracil
The synthesis of the fluorinated pyrimidine fluorouracil, by Heidelberger and 
colleagues more than 40 years ago, represents one of the most important landmarks 
in treatment of CRC (Heidelberger et al. 1957). This discovery was inspired by the 
observation that tumour cells in vitro showed greater uptake of uracil than normal 
cells. 5FU is inactive until it is metabolized in the cell, where it is converted into its 
active equivalent, fluorodeoxyuridine monophosphate (FdUMP), by the thymidine 
phosphorylase enzyme (TP). FdUMP, in the presence of the reduced folate 5,10- 
methylene tetrahydrofolate, forms a complex with, and inhibits the thymidylate 
synthase (TS) enzyme, in-turn inhibiting the synthesis of the thymine nucleotide that 
the tumour cell requires for DNA replication, and thus, cell division (Leichman, 2006). 
If not converted to FdUMP, 5FU is enzymatically degraded by dihydropyrimidine 
dehydrogenase (DPD) (McLeod et al. 1998; Omura, 2003).
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Currently, 5FU is the therapeutic mainstay for CRC. Its development, along with that 
of other therapies used today has led to an increase in CRC median survival from ~6 
months in untreated patients to ~20 months. 5FU is administered intravenously as it 
is variably absorbed by the gut and degrades rapidly. Folinic acid (FOL) (also known 
as Leucovorin) is used in addition to 5FU therapy and stabilises the ternary complex 
between 5FU and TS. Through clinical studies, it was found that the combination of 
5FU with FOL doubles tumour response rates, though with little effect on OS 
(Doroshow et a, 1990; Advanced Colorectal Cancer Meta-Analysis Project, 1992).
1.4.1.2 Capecitabine
Capecitabine (Xeloda) is an orally administered alternative to bolus fluorouracil. It is 
rapidly taken up from the gut and metabolised, firstly through hydrolysis to 5-deoxy- 
5-fluorocytidine (5’-DFCR) by hepatic carboxylesterase. This is then converted to 5’- 
deoxy-fluorouridine (5’-DFUR) by cytidine deaminase in the liver and the tumour cell, 
before undergoing a final transformation by TP at the tumour site to active 5FU 
(Schellens, 2007) which in-turn inhibits TS by the same mechanism described 
above. 5FU is preferentially generated at the tumour site due to the higher activity of 
the TP enzyme in tumour tissue compared to normal tissue (Miwa et al. 1998), in­
turn minimising systemic exposure to 5FU. Numerous studies have shown it to be at 
least as active as bolus and infusional 5FU (Twelves et al. 2001; Van Cutsem et al. 
2000; Cassidy et al. 2008), and suitable for use with oxaliplatin (Diaz-Rubio et al. 
2002; Cassidy etal. 2004) and irinotecan (Patt etal. 2007; Bajetta etal. 2003;
Borner et al. 2005; Rea et al. 2005). It has a favourable toxicity profile (Scheithauer 
et al. 2003; Van Cutsem et al. 2005) and is well received by patients who 
understandably prefer oral administration to i.v. treatments (Liu etal. 1997) which 
can have separate complications and inconveniences associated with central venous 
access (i.e. potential for venous thrombosis). Side-effects observed in capecitabine 
treatment include increased thromboembolic events, anaemia, diarrhoea, and hand- 
foot syndrome (HFS; Walko and Lindley, 2005). Hand-foot syndrome is a cutaneous 
condition that involves numbness of the hands and feet due to drug leakage in these 
extremities. At its least extreme, this condition displays discomfort that compromises 
daily life to a small extent, but in worst cases the skin displays blistering, ulceration 
and/or pain that can severely affect day-to-day activities. For this reason, dosage 
adjustment is recommended.
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In the last decade, two new cytotoxic agents have emerged in the treatment of CRC;
1.4.1.3 Oxaliplatin
Oxaliplatin is a diaminocyclohexane-platinum analogue that has been extensively 
studied through Europe and the USA and found to have significant activity in CRC 
(Bleiberg 1998). When administered, oxaliplatin interacts with plasma proteins and is 
distributed throughout the tissues of the body. About 50% of the drug is excreted 
from the body via the kidneys (Cornelia et al. 2009). It works by alkylating DNA, 
forming adducts that inhibit replication and transcription (Woynarowski et al. 1998). 
More specifically, these adducts comprise cross-links between the activated platinum 
species and specific base sequences -  usually two adjacent guanine bases or 
adjacent guanine and adenine bases (Fink etal. 1997). Oxaliplatin activates 
numerous pathways including the p38 and PI3K-PTEN-Akt pathways (Rakitina et al.
2003), as well as the caspases cascade (Griffiths et al. 2004), while damage that 
results from Oxaliplatin is repaired by members of the nucleotide excision repair 
pathway (Arnould et al. 2003).
1.4.1.4 Irinotecan
Irinotecan (also known as CPT-11) is a semi-synthetic analogue of camptothecin that 
works by inhibiting the nuclear enzyme topoisomerase I (topo I) causing S-phase- 
specific cytotoxicity (Liu et al. 2000). Irinotecan must undergo hydrolysis or de- 
esterification to form its active metabolite SN-38 which inhibits topol to an even 
greater extent (Rothenberg, 1997). Carboxylesterase is required for this step. Topol 
normally functions in relieving torsional stress in front of the replication fork, as DNA 
unwinds for normal replication, transcription and repair recombination. To do this, 
Topol cleaves the DNA backbone and forms a covalent enzyme-DNA linkage, 
facilitating the passing of the intact strand through the break to relieve this tortional 
stress, before finally re-sealing the break. These stabilised single-strand breaks are 
thus reversible and do not threaten the cell. However, should an advancing 
replication fork encounter a single-strand break, a double strand break will form. 
These induce phosphorylation of the H2AX histone variant, activate various 
signalling pathways, lead to the irreversible arrest of the replication fork, and cell 
death (Liu etal. 2000; Paillas etal. 2010). Thus, inhibition of Topol by Irinotecan 
prevents ligation of the nicked strands that are met by the advancing replication fork 
that in-turn form irreversible double strand breaks. Evidence also suggests that,
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when present at high concentrations, Irinotecan can induce apoptosis independent of 
the S-phase through a transcriptionally mediated DNA damage model (Morris and 
Geller, 1996)
1.4.2 Targeted therapies against CRC
In CRC treatment, there are two major strategies of targeted therapies - those that 
target angiogenesis and those that inhibit the EGFR pathway. EGFR is a member of 
the erbB or HER transmembrane protein kinase receptor family that acts as the gate­
way for multiple downstream, intracellular signalling pathways including the Ras-Raf- 
MAP and PI3K-PTEN-Akt pathways. Through these pathways, EGFR regulates 
multiple processes including apoptosis, cellular growth, proliferation, differentiation, 
and migration (Woodburn etal. 1999; Scaltriti etal. 2006). Several EGFR ligands 
have been identified including EGF itself, heparin-binding EGF-like growth factor, 
transforming growth factor (TGF), epiregulin, betacellulin, and amphiregulin. The 
receptor is anchored in the cytoplasmic membrane and has a structure consisting of 
an extracellular ligand-binding domain, a short hydrophobic transmembrane region, 
and an intracellular tyrosine kinase domain (Yarden etal. 2001; Hynes etal. 2005). 
Binding of ligand to the receptor induces a conformational change of the receptor 
ectodomain, allowing receptor dimerisation and autophosphorylation of several 
tyrosine residues within the COOH (Carboxy)-terminal of the receptors (Burgess et 
al. 2003; Hubbard et al. 2005). This phosphorylation provides docking sites for 
cytoplasmic proteins of the Ras-Raf-MAP and PI3K-PTEN-Akt pathways. EGFR is 
up-regulated in 60-80% of CRCs (Untawale et al. 1993; Salomon et al. 1995), 
correlating with reduced survival (Mayer et al. 1993). Given this, and its central role 
in normal, and tumorigenic growth, EGFR has been identified as a valid target for 
multiple cancers. In CRC treatment, the monoclonal antibodies cetuximab (Erbitux® 
Merck KGaA) and panitumumab (Vectibix®, Amgen) have been studied as agents 
that blockade EGFR signalling.
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1.4.2.1 Cetuximab
Cetuximab is a recombinant chimeric monoclonal lgG1 antibody that binds the 
extracellular domain of human EGFR, in doing so preventing ligands EGF and TGF- 
a from binding the receptor, and triggering receptor internalisation (Sunada et al. 
1986); thus inhibiting downstream signalling. This is summarised in Figure 1.9. The 
mechanisms by which cetuximab brings about tumour cell death include blocking of 
cell cycle progression (Wu et al. 1996; Peng et al. 1996; Kiyota et al. 2002), 
promotion of apoptosis (Wu etal. 1995; Mandal etal. 1998; Liu etal. 2000; Sclabas 
et al. 2003), inhibition of angiogenesis (Petit etal. 1997; Perrotte etal. 1999; Bruns 
et al. 2000; Martinelli et al. 2010; Pueyo et al. 2010) and metastasis (Huang et al. 
2002; O-charoenrat et al. 1999; O-charoenrat et al. 2000; Bruns et al. 2000) and 
indirectly through antibody mediated cell cytotoxicity (Kawaguchi et al. 2007).
1.4.2.1.1 Side effects of cetuximab
Given the ubiquitous presence of EGF receptors in many tissues, the potential for a 
variety of cetuximab related adverse reactions is high. The most common side-effect 
associated with administration of cetuximab involves dermatological reactions -  
Papulopustulous rash and paronychia present within days of treatment, followed by 
atrophy of the skin (Arnold and Seufferlein, 2010). An estimated 70-100% of patients 
will present with such reactions (Fox, 2006) which reach maximum intensity after 2 to 
3 weeks (Grothey, 2006). This is not surprising considering that the skin contains an 
abundance of EGF receptors -  maintaining the integrity of the epidermis. Locations 
of these rashes most commonly include the face, scalp, and upper torso. Other side- 
effects have also been observed, including alopecia (Martin-Martorell etal. 2008), 
eyelash trichomegaly (Cohen etal. 2011), telangiectasias, oculartoxicities, 
hypomagnesemia, diarrhoea (Fakih and Vincent, 2010) and severe hypersensitivity 
reactions (1-22% of patients; Chung et al. 2008)
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Figure 1.9 -  Diagrammatic representation of the mechanism of action of cetuximab. Normally EG FR  is bound by its ligands such 
as TG Fa and EGF, triggering a cellular signalling cascade that contributes to the regulation of gene transcription and cell cycle 
progression. Cetuximab is a monoclonal antibody that competitively binds to the extracellular component of the EGFR, blocking 
ligand bindings. This in-turn blocks the signalling cascade and as such gene transcription and cell cycle progression are blocked 
within the tumour cell, killing it.
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1.4.2.2 KRAS and response to anti-EGFR therapies
Despite encouraging initial findings that cetuximab could be used successfully as a 
monotherapy (Jonker et al. 2007; Saltz et al. 2004) or in combination with irinotecan 
(Cunningham et al. 2004; Wilke et al. 2008; Sobrero et al. 2008; Arnold and 
Seufferlein, 2010), oxaliplatin/5FU (Arnold etal. 2008) or oxaliplatin/capecitabine 
(Borner et al. 2006), benefit from the drug is still limited to an objective response rate 
between 9 and 20% (Cunningham et al. 2004; Saltz et al. 2004). It was soon 
established that response to cetuximab was influenced by KRAS somatic mutation 
status. As such, mutations of KRAS can be referred to as predictive markers; that is 
a genetic feature that alters a patients response to treatment. Lievre et al (2006) 
initially observed a significant difference in overall survival (OS) between patients 
wild-type (16.3 months) and mutant (6.9 months) for KRAS in a group of 30 
metastatic CRC (mCRC) patients (P=0.016). This finding has since been validated in 
multiple CRC cohorts that tested cetuximab (Van Cutsem et al. 2008; De Roock et 
al. 2008; Karapetis et al. 2008) or panitumumab (Freeman et al. 2008; Amado et al.
2008) and highlights a proportion of patients that will suffer cetuximab associated 
toxicities, with no real benefit. Given the high-frequency of CRCs that are KRAS 
mutant (-40-45%), guidelines are now in place recommending testing of KRAS 
mutation status (specifically ‘hot-spot’ codons 12 and 13) prior to treatment of mCRC 
patients with anti-EGFR agents (Allegra et al. 2009). KRAS mutation status can be 
ascertained through analysis of formalin-fixed paraffin-embedded (FFPE) tissues.
1.4.2.3 EGFR pathway components and resistance to cetuximab
Amongst patients wild-type for KRAS, up to 65% (Allegra et al. 2009) still show 
resistance to anti-EGFR therapies, raising the possibility that the mutation of other 
genes within the Ras-Raf-MAPK and PI3K-PTEN-Akt pathways could play an 
independent role in resistance. BRAF, a serine-threonine kinase that acts as the 
principle effector of KRAS, has also been implicated in anti-EGFR therapy resistance 
(Jhawer et al. 2008; Di Nicolantonio et al. 2008) independent of KRAS status. 
Members of the parallel PI3K-PTEN-Akt pathway have also been studied as 
candidates of resistance. Studies have shown contrasting results for PIK3CA', 
Perrone et al (2009) and Jhawer et al (2008) have offered evidence for resistance in 
the PIK3CA mutant setting, while Prenen et al (2009) failed to show an effect. Also, 
loss of PTEN, a lipid phosphatase that regulates the PI3K-Akt pathway, may lead to
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aberrant Akt signalling, and thus resistance to cetuximab (Frattini et al. 2007;
Perrone et al. 2009; Razis et al. 2008; Bouali et al. 2009; Loupakis et al. 2009; 
Sartore-Bianchi etal. 2009; Laurent-Puig etal. 2009; Negri etal. 2010; Kim etal.
2010). Cell lines that are both Ras/BRAF mutant and PIK3CA mutant/PTEN null 
show maximal resistance to cetuximab as compared to those with mutations in just 
one of the two parallel pathways (Jhawer et al. 2008).
NRAS and KRAS are two of three different isoforms of the Ras protein, with HRAS 
being the third. Despite their structural similarity, the Ras isoforms have been shown 
to differ in their interactions with effectors (Yan et al. 1998) and in their importance 
for viability; in mice knock-out experiments, KRAS is essential for development but 
HRAS and NRAS are not (Johnson et al. 1997). Whilst NRAS is mutated far less 
frequently in CRC, it may still play a role in altering response to cetuximab; patients 
with KRAS, BRAF and NRAS wild-type tumours show significant association with 
outcome after cetuximab treatment (Lambrechts et al. 2009). HRAS mutations are 
not present in CRC (Bamford et al. 2004) and thus do not play a part in anti-EGFR 
therapy resistance.
Recently, De Roock et al (2010a) carried out a thorough combined analysis of the 
KRAS, BRAF, NRAS and PIK3CA genes, and their role in altering response of 
chemotherapy refractory metastatic CRC patients, to cetuximab plus chemotherapy. 
The primary analysis of this study was objective response, as opposed to the usual 
OS, which can be affected by prognostic markers, and progression free survival 
(PFS) (the nature of the study did not allow this). Within KRAS mutant samples, the 
response rate was 6.7% compared with 35.8% in KRAS wild-type samples 
(OR=0.13, 95% Cl 0.07-0.22, P<0.0001). Within this KRAS wild-type group, patients 
mutant for BRAF had a response rate of 8.3% that was significantly different when 
compared to BRAF wild-type patients (38%) (OR=0.15, 0.02-0.51, P=0.0012). This 
was the same for NRAS where mutant patients had a response rate of 7.7% vs 
38.1% in wild-types (OR=0.14, 0.007-0.70, P=0.013). Results for PIK3CA proved to 
be particularly interesting; mutations within exon 9 of the gene were found to have no 
effect on cetuximab, but mutations of exon 20 did play a role in worsening response 
to cetuximab (0% vs 36.8%, P=0.029). OS and PFS were analysed as secondary 
analyses, and results were similar in each case. Based on these results the authors
recommend the ordered testing of KRAS, BRAF, NRAS and PIK3CA exon 20 for 
somatic mutations within patients, suggesting an objective response rate of 41.2% in 
this ‘all wild-type’ group. Whilst interesting, the staggering differences in performance 
between mutant and wild-type groups suggests that the findings may still be 
influenced by the strong prognostic value these mutations carry, even though the 
authors tried to stratify for this effect.
Given that EGFR is the target of this antibody and that it is over-expressed in such a 
high proportion of CRCs, most early studies of cetuximab efficacy required confirmed 
EGFR expression. Moroni and colleagues (2005) observed a significant difference 
(P<0.0001) in increased EGFR copy number status, as analysed by fluorescence in 
situ hybridisation (FISH), between responders and non-responders. This result 
suggested that patients could be selected based upon their EGFR copy number. 
However Personeni and colleagues (2008) warned that, whilst EGFR copy number is 
correlated with response independent of KRAS status (p=0.016) and OS (p=0.005), 
the published criteria used in determining copy number status might lead to mis- 
classification -  for this reason clinical decision making based upon this factor is not 
warranted. Furthermore, studies have attempted but failed to validate the correlation 
between EGFR expression and response to cetuximab (Cunningham et al. 2004; 
Folprechtetal. 2010).
1.4.2.4 Alternative factors affecting response to EGFR targeted treatments
A further predictor of response to cetuximab is its associated side-effect involving 
skin rashes. Saltz et al (2003 and 2004) were amongst the first to suggest that the 
rash might be a measure of sensitivity, after observing superior survival in patients 
with a rash as compared to those without. This observation was also confirmed by 
Cunningham and colleagues (2004). A possible explanation for this phenomenon 
may lie in the presence, or lack thereof, of a CA dinucleotide repeat within the first 
intron of the EGFR gene. Low numbers of this repeat are associated with this rash. 
Studies of head-and-neck cancer cells with a lower number of the dinucleotide had 
high expression levels of EGFR and were more sensitive to another inhibitor of 
EGFR activity, erlotinib (Amador et al. 2004). Steps can be taken to lower the rate of 
severe skin toxicity without compromising the therapeutic efficacy of anti-EGFR 
therapies (Arnold and Seufferlein, 2010). As with EGFR copy number status, a lack
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of uniformity in grading, combined with the fact that time to skin manifestation is so 
variable, means that rashes are not used in clinical decision making.
1.4.2.5 Panitumumab
Panitumumab is a human lgG2 monoclonal antibody that, like cetuximab, is directed 
against EGFR. Panitumumab blocks binding of the EGF and TGF-a ligands, and 
leads to internalisation of the receptor. Unlike cetuximab, panitumumab induces 
arrest of the cell cycle during the G0-G1 interphase. Also, it does not induce the 
antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism (Berardi et al.
2010). It has been the subject of a number of pre-clinical and clinical studies that 
have suggested it to have efficacy as a monotherapy or in combination, in the 
treatment of patients with mCRC (Van Cutsem et al. 2007; Van Cutsem et al. 2008; 
Hecht et al. 2009; Siena et al. 2009; Peeters et al. 2009), in a KRAS dependent 
manner (Amado et al. 2008; Douillard et al. 2009; Peeters et al. 2009). As with 
cetuximab, there is a correlation between skin toxicity and response to panitumumab 
(Van Cutsem etal. 2007; Peeters et al. 2009; Berlin etal. 2007).
Many oncologists view cetuximab and panitumumab as being interchangeable 
though a lack of phase ll/lll data on combined panitumumab therapy means that it is 
usually administered in isolation (Kim, 2009). Studies have attempted to determine if 
panitumumab can be administered as a monotherapy after cetuximab failure. Metges 
and colleagues (2010) show that there is promise for this approach, with 72.7% of 
trial patients (albeit 32 patients in total) showing clinical benefit. Other small studies 
have largely agreed with this observation (Saif et al. 2010; Brugger, 2010) but further 
work is needed to sufficiently validate this is a suitable treatment option.
1.4.2.6 Bevacizumab
Bevacizumab is a humanised monoclonal antibody that targets the vascular 
endothelial growth factor-A (VEGF-A), thus inhibiting blood vessel formation. Though 
it has little efficacy as a single agent, it has displayed promise when used in 
combination with other standard chemotherapeutic agents used in the treatment of 
mCRC (Arnold and Seufferlein, 2010). The first phase II trial to show this involved 
the comparison of 5FU/FOL alone with 5FU/FOL plus bevacizumab in 104 mCRC 
patients (Kabbinavar et al. 2003). It showed improved RR, PFS and OS in the
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combination arm and was followed by a series of other first- and second-line therapy 
studies (Hurwitz et al. 2004; Kabbinavar et al. 2005; Giantonio et al. 2007; Saltz et 
al. 2008) that showed efficacy with a range of alternative partners including 
oxaliplatin and irinotecan.
Whilst the inhibition of individual signalling pathways has shown clear beneficial 
effects, the question remains as to whether multiple signalling pathways can be 
targeted at once. This seems a reasonable hypothesis based on the fact that 
tumours often have multiple genetic changes that affect multiple pathways. Studies 
have trialled the combined use of cetuximab/panitumumab, bevacizumab and 
standard chemotherapy in the treatment of mCRC (Ciardiello et al. 2000; Jung et al. 
2002; Shaheen etal. 2001; Tonra etal. 2006; Saltz etal. 2007). Despite 
encouraging initial findings little evidence has been shown for improved survival in 
this combined treatment approach (Tassinari et al. 2010) regardless of KRAS status 
(Tol etal. 2009).
1.5 Prognostic factors for CRC
Prognostic markers provide information concerning a patient’s outcome regardless of 
treatment given. Individually and collectively, prognostic factors have the potential to 
guide clinical decision making for administration of adjuvant therapy -  especially 
within patients of stage II CRC where the decision to treat or not treat can still 
dramatically alter disease course. Of note, biomarkers can be both prognostic and 
predictive (e.g. hormone receptor status in breast cancer) (Oldenhius et al. 2008). 
The only routinely used prognostic marker for CRC is clinical stage, which combines 
depth of tumour invasion, nodal status and distant metastasis (Walther et al. 2009). 
Other factors thought to influence prognosis include lifestyle (Haydon et al. 2006; 
Reeves et al. 2007), systemic inflammatory response to the tumour (Leitch et al. 
2007) and the tumour immunologic microenvironment (Galon et al. 2006).
Protein and genetic markers have been studied in an attempt to refine prognostic 
prediction for CRC. However, none have been validated sufficiently for clinical 
practice. Some progress has been made in other cancers though -  for example,
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hormone receptor status has been associated with prognosis in breast cancer 
(Dunnwald et al. 2007).
1.5.1 Somatic prognostic markers
Somatic genetic changes are perhaps the most studied markers for prognostic 
influence (Table 1.2) since they offer the most biological rationale for a role in 
defining the course of a cancer. Whilst somatic effects have been found for CRC, the 
results of different studies of specific markers have often been contradictory. The 
prognosis of patients with MSS CRC is stage and grade dependent and tumours with 
identical morphological features display considerable heterogeneity in terms of 
clinical outcome. Meanwhile, a meta-analysis of over 7000 CRC patients, found that 
patients with MSI-positive tumours had significantly improved OS as compared to 
those with MSS CRCs (Popat et al. 2005). MSI could be used as a prognostic 
marker since there are reliable assays for determining MSI status (Pritchard and 
Grady, 2011).
Further studies of prognostic markers have focused on events that occur during the 
adenoma to carcinoma progression of CRC, as presented in Figure 1.7. It has been 
suggested that APC might be suitable as a prognostic marker -  a study of 218 CRC 
patients stratified for MSI status suggested that mutations abolishing p-catenin 
binding sites of the APC gene correlated with shorter survival as compared to 
mutations elsewhere in the gene (P=0.045; Lovig et al. 2002). KRAS mutations also 
play a key role in colorectal tumourigenesis and any prognostic role for it would be 
particularly advantageous since it is already routinely analysed as a marker of 
cetuximab efficacy. A large international consortium has reported that somatic KRAS 
mutations confer poor prognosis (Andreyev et al. 1998), although subsequent 
analyses have suggested that this outcome is limited to the G12V substitution and to 
Stage III patients (Andreyev et al. 2001). Other studies have found no such 
associations (Ince et al. 2005; Ogino et al. 2009; Samowitz et al. 2000; Wang et al. 
2003). BRAF mutations (specifically the common V600E mutation) has been 
reported by various groups to influence survival in patients with different stages of 
disease (Ogino etal. 2009; Farina-Sarasqueta et al. 2010). In addition, PIK3CA 
mutations have been found to influence patient survival (Kato et al. 2007; Ogino et 
al. 2009).
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Somatic prognostic markers
Biomarker
Mutation
Frequency
<%)
Prognosis Evidence Status Reference
MSI -1 5 Favourable Strong
Routine assays 
available but not 
yet used
Popat et al. 
2005
CIN
APC 
(mutations of 
0-catenin 
binding 
regions)
-8 5
>90%
Unfavourable
Unfavourable
Strong
Limited
No
reliable/robust 
assays available
Not used
Walther et al. 
2008
Lovig et al. 
2002
KRAS 40-45 Unfavourable Moderate Not used Andreyev et al. 1998
BRAF -1 0 Unfavourable Moderate/Strong Not used Ogino et al. 2009
PIK3CA
0
 
CM1 Unfavourable Limited Not used Ogino et al. 2009
TP53 -4 0 Unfavourable Limited Not used Russo et al. 2005
18q LOH 50 Unfavourable Moderate Not used Roth et al. 2009
Table 1.2 -  Summary of somatic markers. Shown are select examples of genes that 
have been suggested to have a potential prognostic influence.
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Other common events that occur during CRC progression, such as mutations of 
TP53 (Russo et al. 2005; Munro et al. 2005) and loss of 18q (Popat and Houlston, 
2005; Hailing et al. 1999; Roth etal. 2009) have been studied for prognostic potential 
with mixed success. In the case of 18q LOH, any prognostic effect observed may 
simply represent the molecular phenotype of that particular tumour, since its loss 
correlates so tightly with CIN (Walther et al. 2009).
1.5.2 Germline prognostic markers
The search for germline prognostic factors has primarily focussed on the 
pharmacological pathways involved in the metabolism and mechanism of action of 
the chemotherapeutic agents used in the treatment of CRC (Table 1.3). For 
example, inherited variants in the TS gene, particularly for patients receiving 
adjuvant therapy with 5FU, have been suggested to act as prognostic factors (Dotor 
et al. 2006; Marcuello et al. 2004). The Glutathione S-transferase (GST) genes are 
involved in the detoxification of chemotherapeutic agents. A study of 338 CRC 
patients suggested that copy number variation of GSTM1 associated with survival in 
patients that received chemotherapy (Funke et al. 2010). More recently, investigators 
have sought prognostic factors in pathways that are likely to influence tumour 
progression. For example, the I/EGF superfamily of endothelial growth factors has 
been shown to critically influence tumour-related angiogenesis and VEGF 
polymorphisms have been associated with survival outcome (Kim et al. 2008).
Common polymorphisms of repair pathways genes have been studied for effects on 
patient survival. A study investigating the prognostic impact of 6 8  SNPs from 7 MMR 
genes in 2,068 CRC patients found that the MSH3 intronic SNP rs863221 altered 
patient survival (Koessler et al. 2009). Similarly, a screen of 377 CRC cases was 
also carried out for prognostic factors from BER, nucleotide excision repair (NER) 
and double-strand break repair (DSBR) pathways (Moreno et al. 2006). It showed 
that three polymorphisms were associated with better prognosis (XRCC1 R399Q, 
XRCC3 T141M and MGMT L84F) and one with worse (ERCC1 19007T>C) though 
only the first and last SNPs remained significant after adjustment for multiple testing. 
ERCC1 is an excision nuclease within the NER pathway that has been associated 
with survival in patients administered oxaliplatin (Shirota etal. 2001) and 5FU 
(Metzger etal. 1998) based therapies. The ERCC1-118 C/T (rs11615) polymorphism
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has also been associated with reduced OS in mCRC patients by some groups (Chua 
et al. 2009; Ruzzo et al. 2007; Stoehlmacher et al. 2004), but not by others (Pare et 
al. 2008; Viguier et al. 2005).
The above studies of prognostic markers for CRC have all been hypothesis driven -  
that is, targeted against genes already known to play some part in CRC progression 
and/or drug metabolism. The findings from these studies could be truly 
transformative for a number of reasons. Firstly, whilst the search for prognostic 
factors has largely focused on molecular markers in tumour tissue, germline markers 
have potential to overcome a number of issues facing the use of somatic prognostic 
predictors (e.g. germline DNA is easier to obtain than tumour DNA). Secondly, the 
identification of survival biomarkers might provide further insight into the 
mechanisms through which cancers progress and metastasise. Thirdly, the 
biomarkers identified (and the mechanisms through which they exert their effects) 
might represent novel targets for therapeutic intervention. Finally, survival 
biomarkers will help to inform clinical decision making and ultimately decrease 
mortality associated with cancer.
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Germline prognostic markers
Biomarker Variant
Risk allele 
Frequency 
(%)
Prognosis Reference
TS (1494del6) 1494del6 -3 6 * Favourable Dotor et al. 2006
GSTM1 (copy 
number)
Copy number 
variation Unknown Favourable Funke etal. 2010
-634G>C 20-40 Favourable
VEGF Kim et al. 2008
+936C>T -2 0 Unfavourable
MSH3 rs863221 -35 Favourable Koessler et al. 2009
XRCC1 R399Q -40-45 Favourable Moreno et al. 2006
XRCC3 T141M -61 Favourable Moreno et al. 2006
MGMT L84F -4 Favourable Moreno et al. 2006
19007T>C 60 Unfavourable Moreno et al. 2006
ERCC1
rs11615 -3 5 Unfavourable Chua et al. 2009
Table 1.3 -  Summary of germline variants. Shown are select examples of genes 
(and variants) shown to have a potential prognostic influence.
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1.6 Somatic mutation detection
The ability of KRAS mutations to predict lack of response to cetuximab has led to the 
recommendation of somatic mutation testing by the European Medicines Agency 
(Becquemont et al. 2011). Prior to this, KRAS had been screened as part of 
experimental and clinical trials but not in routine testing. Now somatic analysis of 
KRAS is wide spread in clinical laboratories. However, before mutation analysis can 
be carried out, tumour material must be obtained.
In brief, tumour material is removed via surgery (resection or biopsy) and embedded 
in paraffin as FFPE blocks. Sections can be cut from these blocks, stained and 
visualised for tumour identification. Tumour material is removed from matched 
unstained slides and DNA is extracted. An important consideration when carrying 
this out is the effect of interfering normal tissue. If DNA from normal tissue is present 
in the test sample, it will mask the presence of mutant allele. Thus it is important to 
capture as pure a population of tumour cells as possible. A variety of techniques are 
employed in the removal of tumour material from paraffin sections, including 
macrodissection and laser capture microdissection (LCM). Even using these 
techniques, there will often be some level of contaminating normal material. Also 
when analysing oncogenes, each tumour cell will likely still carry one wild-type allele. 
As such, mutation analysis must still be sensitive enough to detect mutant allele 
against a backdrop of normal allele. Examples of sections abundant in tumour 
material and with sparse pockets of tumour material are shown in Figures 1.10A and 
1.10B. Once tumour material has been obtained, DNA must be extracted for 
mutation analysis.
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Figure 1.10 -  Haematoxylin and Eosin (H&E) stained colon sections containing 
varying am ounts of tumour material (areas containing tumour are highlighted with a 
red, dotted area). (A) Here tumour tissue is abundant and can be easily extracted  
without collecting too much interfering normal tissue. The most appropriate method 
of tum our extraction here would be macrodissection. (B) Here tumour material is 
found in small and sparse globules that are not easy to extract without also picking 
up normal tissue. In order to ensure accurate collection of tumour cells, a precise 
cutting technique such as LCM would be most appropriate.
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1.6.1 Current mutation detection technologies
A variety of methods have been employed for general mutation analysis in recent 
years. Though conformation-based separation techniques such as high performance 
liquid chromatography (HPLC; Mascarenhas et al. 2009), denaturing gradient gel 
electrophoresis (DGGE; Hayes et al. 2000) and single strand conformation 
polymorphism (SSCP; Dillon etal. 2001) are used in mutation screening, the gold 
standard for mutation analysis remains sequencing technologies. The most widely 
used of these is dideoxy sequencing (Brink etal. 2003). However, as well as offering 
limitations in throughput and cost, this technology is not sensitive enough to detect 
mutant allele in samples containing little tumour material. Thus, the use of 
technologies that detect low levels of mutant allele has exploded in recent years. 
These include Solid phase minisequencing (lhalainen etal. 1994; Paunio etal.
1996), digital PCR (Vogelstein and Kinzler, 1999), melting curve analysis (Pritchard 
et al. 2010), and next-generation sequencing (NGS) (Peeters etal. 2010). Each has 
inherent advantages and disadvantages, with sensitivities, labour requirements, turn­
around time, cost and potential for automation and multiplexing (Arcila et al. 2011).
Two alternative techniques are used in this thesis and as such as described in 
greater detail below;
1.6.1.1 Pyrosequencing
Pyrosequencing is a real-time, non-electrophoretic technique that relies upon the 
generation of pyrophosphate as nucleotides anneal to a growing template DNA 
strand. Nucleotides are dispensed in a user-defined order into the reaction mix, with 
those that represent the binding partner of the next nucleotide in the template strand 
annealing. Nucleotides that do not anneal (i.e. not complimentary or excess 
nucleotide) are degraded by apyrase. As nucleotides anneal to a growing synthesis 
strand, pyrophosphate is generated. This is detected as a fluorescent emission, the 
intensity of which gives an indication of the amount of annealed nucleotide. The 
overall process of Pyrosequencing is highlighted in Figure 1.11.
There are a number of advantages in the use of Pyrosequencing. Firstly it offers a 
simple, rapid and quantitative detection system for known mutations and SNPs 
(Poehlmann et al. 2007; Fakhrai-Rad et al. 2002). It can also be used in the
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quantitative analysis of CpG island methylation events (Colella et al. 2003; Tost et al. 
2003). Unlike other sequencing based methods, Pyrosequencing does not require 
the usual clean up step. Instead it requires that the initial PCR be carried out with 
one biotinylated primer. The subsequent biotinylated amplification product is 
immobilised on streptavidin-coated sepharose beads that are captured onto probes 
using Qiagen’s vacuum prep tool, and transferred into the reaction mix for 
sequencing. Also, since the sequencing primer can be placed adjacent to the 
sequence of interest, the overall fragment size of the PCR product does not have to 
be that big, which is desirable when dealing with fragmented FFPE DNA (Okayama 
et al. 2010). Though the typical read length of Pyrosequencing is shorter than that of 
traditional dideoxy sequencing (40-50 nucleotides), this is not an issue when 
screening KRAS since mutations cluster at hot-spots. The technology allows for the 
sensitive analysis of multiple samples (utilising a 24 or 96 well format) in a short 
period which is desirable for clinical use (Poehlmann et al. 2007). In recent years, it 
has been used by various groups in the analysis of KRAS (Ogino et al. 2005; 
Poehlmann et al. 2007; Weichert et al. 2010; Tsiatis et al. 2010) with mutation 
detection sensitivities as low as 3-5% mutant allele.
1.6.1.2 Sequenom
The Sequenom platform is a chip-based matrix-assisted laser desorption-time-of- 
flight (MALDI-TOF) mass spectrometric SNP genotyping technology that relies upon 
single base primer extension, with A, C, T, or G terminators, through the mutation 
site. This generates allele-specific extension products that are spotted onto spectro- 
chips for analysis (Figure 1.12). The difference in mass between mutant and wild- 
type product is resolved by MALDI-TOF, allowing the quantitative comparison of 
alleles.
Originally designed for use in SNP genotyping of amplified DNA fragments (Nelson 
et al. 2004), it has become established in the quantitative analysis of known somatic 
mutations as well as methylation events (Izzi et al. 2010). It has a high multiplexing 
capacity that can be critical when dealing with small amounts of precious clinical 
samples. This is further helped by the fact that only small amounts of input DNA 
(from FFPE tissues) are required (5ng). Assays are limited to 40 reactions due to the 
fact that the mass spectrophotometer has a limited mass detection range which can
only facilitate a certain number of reaction product sizes without overlap occurring. 
Complications such as the increased chance of primer interaction and decreased 
amplification efficiency also impact on the number of reactions that can be run. 
Regardless, the ability to multiplex allows for the screening of less frequent 
mutations (such as BRAF D594V) alongside the more frequent variants. Like 
Pyrosequencing, the sequencing primer can be placed adjacent to the mutation site 
such that the original amplification product does not have to be that big which is 
advantageous when handling fragmented DNA. The multiplexing capacity of 
Sequenom has led to the design of the OncoCarta Panel, which targets 238 simple 
and complex mutations across 19 genes (Pearce et al. 2009). Sequenom has been 
used in numerous studies of KRAS mutation status in CRC using FFPE tissue 
(Fumagalli et al. 2010; Arcila et al. 2011) and has been shown to be sensitive to low 
levels of mutant allele (2.5-10%).
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Figure 1.11 -  Pyrosequencing is a ‘sequence by synthesis’ technology. Nucleotides, added to the reaction in a user-defined order, anneal to a growing 
synthesis strand. This generates pyrophosphate which is detected as a fluorescent emission, the intensity of which is proportional to number of nucleotides 
incorporated. Thus if, as depicted in the above diagram a single C anneals, this will generate a fluorescent emission sufficient to generate one C peak on the 
pyro-diagram. Since T is the next released nucleotide, it will anneal to the A in the template strand and generate a fluorescent emission sufficient to produce a 
T peak. In the final annealing reaction shown, there are two adjacent Ts in the template strand. Thus, two A nucleotides will anneal in turn generating a 
fluorescent emission that is twice the intensity of the previous two examples and a peak that is twice as high.
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1.7 Aims of this thesis
1, To understand the role of somatic mutations within components of the EGFR 
pathway in altering patient response to cetuximab in the treatment of aCRC. To 
compare two techniques in the large scale analysis of somatic variants.
2, To determine the role played by the CRC risk loci in the advanced disease setting. 
To study the underlying tumorigenic mechanism at the 8q23 locus.
3, To identify prognostic and predictive effects for 20 SNPs from CRC risk loci. To 
clarify the mechanism by which the 16q22 locus alters response to cetuximab.
4, To identify novel high penetrance alleles that predispose to CRC from the BER, 
MMR and Oxidative damage repair (OxDR) pathways. To determine the prognostic 
influence of the MAP phenotype.
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Chapter Two - Materials and Methods
2.1 Suppliers
Consumables and equipment used throughout this study were purchased from the 
following companies:
ABgene Ltd (Surrey, UK)
AGOWA (Berlin, Germany),
Ambion (See Applied Biosystems),
Anachem Ltd (Bedfordshire, UK),
Applied Biosystems (Cheshire, UK),
BD Diagnostics (Franklin Lakes, NJ, USA)
Biorad (Hertfordshire, UK),
Cell Signalling Technologies (Danvers, MA, USA),
Clontech (CA, USA)
Eppendorf (Cambrdgeshire, UK),
Eurogentec (Hampshire, UK),
European Collection of Cell Cultures (Salisbury, UK),
Fisher Scientific (Leicestershire, UK),
Fluka Biochemika (Dorset, UK),
GE Healthcare (Buckinghamshire, UK),
Geneservice Ltd (Nottinghamshire, UK),
IKA (Staufen, Germany), 
lllumina (CA, USA),
Imgenex Corp (CA, USA)
Insight Biosight Biotechnology (Santa Cruz, Wembley, UK)
Invitrogen Life Technologies (Strathclyde, UK),
Jencon (See VWR, West Sussex, UK),
Kendro Laboratory Products (Hertfordshire, UK),
Labtech International (East Sussex, UK),
Leica (Wetzlar, Germany),
Lonza Group Ltd (Basel, Switzerland),
Microzone Ltd (Haywards Heath, UK),
Millipore (Hertfordshire, UK),
MJ Research (Massachusetts, USA),
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MWG Biotech (Buckinghamshire, UK),
New England Biolabs (Hertfordshire, UK),
Nunc (See Thermo Fisher Scientific),
Olympus Optical (London, UK),
PALM (Bemried, Germany),
Promega (Hampshire, UK),
Qiagen (West Sussex, UK),
Roche Biochemicals (East Sussex, UK),
Sartorius (Surrey, UK),
Santa Cruz Biotechnologies (Santa Cruz, CA, USA),
Sequenom (CA, USA),
Sigma-Aldrich Ltd (Dorset, UK),
Starlab UK Ltd (Milton Keynes, UK),
Starstedt Ltd (Leicestershire, UK),
Stratagene (California, USA),
Thermo Electron Corp (Hampshire, UK),
Thermo Fisher scientific (MA, USA),
VWR International Ltd (West Sussex, UK),
Zeiss (Oberkochen, Germany).
2.2. Materials
2.2.1 Chemicals
Analytical grade chemicals were purchased from either Sigma-Aldrich Ltd or Fisher 
Scientific unless otherwise stated.
2.2.2 Nucleic acid extraction and purification
QIAamp DNA Micro kits were purchased from Qiagen. Trizol reagent was obtained 
from Invitrogen Life Technologies. RecoverAII Total Nucleic Acid Isolation Kit was 
obtained from Ambion Inc.
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2.2.3 PCR and PCR purification
AmpliTaq Gold DNA polymerase and GeneAmp PCR buffer were obtained from 
Applied Biosystems. Deoxyribonucleotide triphosphates (dNTPs) were purchased 
from GE Healthcare. High purity salt free (HPSF) purified-, and HPLC purified 
biotinylated- oligonucleotide primers were supplied by Eurogentec. Megamix Gold 
was purchased from Microzone. Exonuclease 1 was purchased from New England 
Biolabs and Shrimp Alkaline Phosphatase (SAP) as supplied by GE Healthcare 
respectively. QIAquick PCR purification kits were obtained from Qiagen.
2.2.4 Electrophoresis
Multipurpose agarose was purchased from Roche. Ethidium bromide was supplied 
by Fluka Biochemika whilst the 100bp and 1kb DNA ladders were supplied by New 
England Biolabs and Invitrogen Life Sciences, respectively.
2.2.5 Sequencing
BigDyeTerminator Cycle Sequencing Kit (Version 3.1), POP6  polymer, HiDi 
Formamide and Genescan 500-ROX size standard were all supplied by Applied 
Biosystems. Montage SEQ96 sequencing reaction clean up kits were obtained from 
Millipore and capillary electrophoresis running buffers were purchased from Sigma- 
Aldrich.
2.2.6 Antibodies
All antibodies were purchased from Cell Signalling Technology or Santa Cruz 
Biotechnologies unless otherwise stated.
2.2.7 Restriction enzymes
All restriction endonucleases were supplied, along with the appropriate buffer, by 
New England Biolabs and Pharmacia (Sigma-Aldrich).
2.2.8 Cloning
pGEM-T Easy Vector System I, pGL3 and pRL Renilla luciferase vectors and JM109 
chemically competent E.coli cells were obtained from Promega. Tryptone, yeast 
extract and agar were supplied by BD Diagnostics Ltd. Ampicillin, X-gal (5-bromo-4-
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chloro-3-indoyl-D-galactoside) and IPTG (isopropyl-p-D-thio-galactopyranoside) 
were obtained from Sigma-Aldrich Ltd.
2.2.9 Clinical Material
All tissue and blood samples were obtained with patient consent and ethical approval 
for research in accordance with the guidelines of the COIN Trial.
2.2.10 Cell lines and cell line DNA
The HEK293 cell line was kindly provided by Dr. Andrew Tee.
DNA from cell lines used to determine Pyrosequencer and Sequenom assay 
sensitivities (CAL-62, AsPC1, RPMI-8226, SW620, DLD1, HCT-116, SW948, Colo- 
205, HT117 and HT1197) was kindly provided by various collaborators.
2.3 Equipment
2.3.1 Plastics and glassware
Sterile pipette tips were supplied by Starlab. RNase- and DNAse-free sterile barrier 
tips were obtained from Promega. DistriTips and sterile tips for multi-channel 
pipettes were from Anachem. Sterile individually wrapped 5ml, 10ml and 25ml 
stripettes were from Corning Costar. Bioquote supplied 0.65ml, 1.5ml and 2.0ml 
plastic eppendorfs. Fisher Scientific also supplied 1.5ml eppendorf tubes. The 96 
well Thermo-Fast PCR reaction plates were obtained from Thermo Electron 
Corporation whilst adhesive PCR sealing sheets, 0.2ml plastic strip tubes and 96 
well Thermo-Fast skirted detection plates were purchased from ABgene. Sterile 
universals and petri dishes were obtained from Bibby Sterilin and Sarstedt 
respectively. Glass flasks and beakers were provided by Jencons or Fisher 
Scientific. Optilux 96-well luminometer plates were purchased from VWR 
International. Tissue culture flasks were purchased from Nunc. Slides used for 
sectioning were purchased from VWR. Fifty millilitre falcon tubes were obtained from 
Sarstedt.
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2.3.2 Laser microdissection
Laser capture microdissection was carried out using the PALM Microlaser system 
and visualised using the PALM Robo software.
2.3.3 Thermocycling
Thermocycling was carried out using an MJ Research DNA Engine Tetrad PTC-225 
for PCR.
2.3.4 Electrophoresis
DNA electrophoresis was performed using a Horizon 11.14 gel tank from Invitrogen 
Life Technologies. Visualisation of ethidium bromide stained gels was achieved 
using a BioRad GelDoc XR transluminator. Power packs were supplied by BioRad.
2.3.5 Other equipment
Stained sections of colonic tissue were visualised using a Mirax scanner (Zeiss). 
Quantitation of DNA and RNA was carried out using the NanoDrop ND-8000 
spectrophotometer (Labtech International).
2.3.6 Software
Genotyping data from lllumina was viewed using lllumina’s GenomStudio program. 
Statistical analysis and graphing was carried out using Minitab 15 (Minitab Inc.), 
Microsoft Excel (Microsoft) and SPSS16 (IBM Corp) unless otherwise stated.
When carrying out LCM, slides were visualised using the PALM Robo software 
(v. 1.2.3) (Zeiss).
Assays used for Sequenom analysis were designed using the Massarray Assay 
Design 3.1 software. Sequenom spectra were analysed using the SpectroREADER 
software and transferred to the MassARRAY Typer 4 Analyser. Genotyping was 
performed using the MassARRAY RTTM software. All software was provided 
through Sequenom.
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2.4 Methods
2.4.1 General reagents
All solutions were made using MilliQ water and autoclaved at 15lb/sq.in at 121°C for 
2 0  minutes where necessary.
1XTAE buffer: 0.04M Tris-acetate, 0.001 mM EDTA, pH 8.0 
IXTBSbuffer: 0.15M NaCI, 0.005M Tris, pH 7.6
10mM sodium citrate buffer (for 1L -  2.94g sodium citrate trisodium salt dehydrate, 
1LdH20, pH 6.0
2.4.2 Sectioning of FFPE tissues
FFPE blocks containing tumour material were placed on ice for at least one hour 
prior to sectioning. A fresh blade was used to section each block. Ten micrometre 
sections were cut for LCM use and were placed onto PALM slides. Five micrometer 
sections were also cut for staining (and visualisation) and macrodissection. Care was 
taken to ensure that the stained section represented as faithfully as possible the non­
stained macrodissected slide (i.e. no excess cutting was performed between 
sections). Slides carrying sections were incubated at 36°C for normal slides and 
60°C for PALM slides overnight.
2.4.3 Staining and scanning of sections and identification of tumour material
One of the two 5pm sections was stained using the following protocol; sections were 
deparaffinised by immersion in xylene twice, 100% ethanol twice, 96% ethanol and 
70% ethanol for 2 minutes each. Slides were briefly dipped five times in RNase-free 
distilled water, stained for 1 minute in Mayer’s haematoxylin solution, rinsed for 1 
minute in blueing solution and further stained for 10 seconds in Eosin Y. Slides were 
immersed through an increasing ethanol series for 1 minute each (70%, 95% and 
100% ethanol). Sections were then immersed in DPX solution before having a cover 
slip applied. Slides were then left to dry. Sections used for LCM were stained by the 
same process but were not immersed in DPX and did not have a cover slip applied. 
Instead slides were placed back-to-back in a 50ml Falcon tube and immediately 
frozen (-70°C). This minimalist staining procedure ensured that nucleic acid material 
could still be obtained from stained tumour material for downstream analysis.
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Stained sections were visualised using a Mirax scanner (Zeiss). Slides were scraped 
to remove excess dry DPX solution. Following this, they were placed into cartridges 
as groups of 50 for scanning. High-resolution scanning of each slide took ~45 
minutes. These scans were subsequently analysed to determine the location of 
tumour material. Depending on the amount of tumour tissue available, the most 
appropriate course of tumour extraction (i.e. macrodissection or LCM) was then 
decided upon. For macrodissection, the paired unstained slide was marked in those 
areas that carried tumour material.
2.4.4 Macrodissection
Extra matching sections were cut from each paraffin embedded block at a thickness 
of 5pm. These sections were left unstained. Areas containing large and concentrated 
areas of tumour, identified on the matching stained slide, were drawn around using a 
marker pen on the underside of the slide. Sterile razor blades were then used to 
scratch off the tissue lying within the depicted area. Scrapings were emptied into a 
1.5ml eppendorf tube for later extraction.
2.4.5 Laser capture microdissection (LCM)
Laser micromanipulation provides microscopic high-resolution control of sample 
composition by enabling the selection or rejection of user defined areas. For LCM, 
paraffin embedded tissues were sectioned and stained as detailed above. LCM was 
carried out using a Zeiss Axiovert S100. A pulsed ultra-violet laser is interfaced into 
the microscope and focused through an objective. The laser cuts the tissue without 
the heating of adjacent material and results in a clear-cut gap between the desired 
sample area and the surrounding tissue. After microdissection, the isolated 
specimens are ejected out of the object plane and catapulted directly into the cap of 
a 0.5ml eppendorf tube containing 1pl of mineral oil positioned above the slide.
2.4.6 DNA extraction from FFPE tissue
DNA was extracted from FFPE tissue using the QIAamp DNA micro kit for both 
macrodissected and LCM tumour material. Fifteen microlitres of buffer ATL 
(contents trade secret, CTS) and 10pl of proteinase K were carefully placed into the 
tube (or lid for LCM). Tubes were pulsed vortexed for 15 seconds. Following this,
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tubes were left to incubate at 56°C for at least 16 hours. After the tissue was 
digested, 25|jl of buffer ATL was added to the lysate followed by 50pl of buffer AL 
(CTS) and the tube vortexed for 15 seconds. Fifty microlitres of 100% ethanol was 
added and the solution was applied to a QIAamp spin column and centrifuged at
13.000 rpm for 1 minute. The column was transferred to a clean collection tube and 
500pl of wash buffer AW1 (CTS) was added. The column was re-centrifuged at
13.000 rpm for 1 minute. The eluate was discarded before a second wash was 
carried out using 500pl of buffer AW2 (CTS). The column was re-centrifuged at
13.000 rpm for 3 minutes followed by an extra 1 minute spin into an empty collection 
tube to remove residual ethanol. DNA was eluted into ~40pl of DNAse free water by 
incubating for 1 minute at room temperature and centrifuging at 13,000 rpm for 1 
minute into a clean collection tube. Samples were stored at -20°C.
2.4.7 RNA extraction from FFPE tissue and conversion to cDNA
Cut sections and LCM cuttings were placed into 1.5ml eppendorfs and immersed in 
1ml xylene and mixed for 3 minutes at 50°C on a Thermomixer. Tubes were then 
centrifuged briefly and the xylene discarded. Remaining pellets were washed twice in 
1ml 100% ethanol before being air dried to remove residual ethanol. Digestion buffer 
and protease (100pl and 4pl respectively) were added to each sample before 
incubation at 50°C for 15 minutes then at 80°C for 15 minutes. Following this 120pl 
of isolation additive plus 275pl of 100% ethanol were added to, and mixed with, each 
sample. Sample mixtures were then passed through a filter cartridge and washed in 
700pl of wash 1 (CTS) and 200pl of wash2/3 (CTS) with flow-through being 
discarded at the appropriate stages. In order to isolate RNA, a mixture of 6 pl 10X 
DNase buffer, 4pl DNase and 50pl nuclease-free water was added to each sample 
and left to incubate for 30 minutes at room temperature. The washes with wash 1 
and wash 2/3 were repeated prior to elution of the RNA with 60pl water at room 
temperature.
RNA was converted to cDNA using Applied Biosystems High-Capacity cDNA 
Reverse Transcription Kit. Briefly a mix of 10x RT buffer, 25x dNTP mix (100mM),
10x RTrandom primers, Multiscribe reverse transcriptase, RNase inhibitor and 
nuclease-free water was prepared on ice. Ten microlitres of each RNA samples was
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added to 1 0 pl of the above mix, gently vortexed and centrifuged to bring the tube 
contents to the bottom.
2.4.8 Extraction of DNA from blood samples
DNA was extracted using Qiagen’s QIAamp DNA micro kit. One-hundred microlitres 
of whole blood was transferred into a 1.5ml eppendorf. One hundred microlitres of 
buffer ATL, 10pl proteinase K and 100pl buffer AL were then added respectively and 
the tube pulse-vortexed for 15 seconds. Tubes were incubated at 56°C for 10 
minutes. To each tube, 50pl of 100% ethanol was added prior to it being vortexed for 
15 seconds and incubated at room temperature for 3 minutes. The entire lysate was 
subsequently transferred to a QIAamp MinElute column and centrifuged at 8,000 
rpm for 1 minute with the eluate collected in a collection tube. The column was then 
transferred to a new collection tube, 500pl buffer AW1 added to the column and then 
centrifuged at 8,000 rpm for a further 1 minute. This step was repeated with 500pl of 
buffer AW2. Following this, the tube was centrifuged at 13,000 rpm for 3 minutes to 
dry the membrane and remove ethanol. The column was placed in a fresh collection 
tube and 40pl of distilled water added. This was left to stand for 1 minute before a 
final centrifugation step at 13,000 rpm for 1 minute. DNA samples were stored at - 
20°C.
2.4.9 Quantification of nucleic acids
The concentration of eluted DNA and RNA samples was achieved using ultraviolet 
(UV) spectrophotometry at wavelengths of 260nm and 280nm to determine the 
amount of DNA or RNA present and establish endogenous protein content. An 
absorbance ratio of 1 . 8  at 260nm:280nm was used as an indicator of high sample 
purity.
2.4.10 Polymerase chain reaction (PCR) and RT-PCR
PCR allows the specific in vitro amplification of a defined DNA target sequence in an 
exponential manner. Double stranded DNA templates are heat denatured and 
primers bind specifically to complementary target sites on each strand. Thermostable 
DNA polymerases extend the primers in the 5’ to 3’ direction by incorporating dNTPs
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to create a complementary DNA strand. This cycle is repeated 20 -  40 times 
enabling newly synthesised DNA molecules to be used as templates at each new 
round (Mullis et al. 1986).
Complimentary primer pairs were designed to have melting temperatures within 2°C 
of each, to be between 15 and 25 nucleotides in length, lack repetitive motifs and 
with little predicted dimerization or secondary structure formation.
For standard PCR, 25ng template DNA, 0.25mM dNTPs, 25pmol forward and 
reverse primers, 2pl 10X GeneAmp PCR buffer (100mM Tris-HCI, pH 8.3, 500mM 
KCI, 15mM MgCfe, 0.01% w/v gelatin), and 0.5U AmpliTaq Gold DNA polymerase 
were used in a total volume of 20pl. Cycling conditions were 95°C for 12 minutes, 
followed by 35 cycles of 95°C for 30 seconds, annealing temperature (52°C - 60°C) 
for 30 seconds, 72°C for 30 seconds and a final elongation step of 72°C for 10 
minutes.
For PCR amplification of lower quality LCM extracted DNA, Megamix Gold 
(Microzone Ltd.) was used in place of AmpliTaq Gold DNA polymerase. Half of the 
final reaction volume was made up of the Megamix Gold reagent (CTS), with 25ng 
template DNA, 25pml forward and reverse primers and water making up the 
remaining volume. Cycling conditions were the same as described above.
A 20pl RT-PCR reaction contained 1ng cDNA, 0.25mM dNTPs, 25pmmol forward 
and reverse primers, 2pl 10X GeneAmp PCR buffer (100mM Tris-HCI, pH 8.3, 
500mM KCI, 15mM MgCI2, 0.01% w/v gelatine), and 0.5U AmpliTaq Gold DNA 
polymerase. Cycling conditions were 95°C for 12 minutes, followed by 35 cycles of 
95°C for 30 seconds, 58°C for 30 seconds, 72°C for 30 seconds and a final 
elongation step of 72°C for 10 minutes.
2.4.11 Agarose gel electrophoresis
Agarose gels were prepared with 1X TAE buffer to various concentrations between 
1.25-2%. Ethidium bromide (0.05pg/ml) was added to the gel to allow for DNA 
visualisation since it is a DNA intercalating agent that fluoresces under UV light at a
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wavelength of 300nm. Three microlitres of loading dye (15%w/v ficol, 10mM Tris pH 
8 , 1mM EDTA, 0.2% Orange G) was added to each sample before loading and 
electrophoresis was performed in 1X TAE buffer at 100V. 1kb or 100bp DNA ladders 
were used to predict fragment sizes. DNA was visualised on a UV transilluminator 
and photographed using the Bio-Rad XR system.
2.4.12 Restriction digest
Restriction digests were performed using enzymes from New England 
Biolabs/Pharmacia at 1 or 2 units per digest, in the appropriate buffer. Digests were 
carried out using 10pl of PCR product, run at 37 or 60°C overnight and visualised on 
an agarose gel.
2.4.13 PCR purification
PCR products were purified using an ExoSap method. In a 5pl reaction, 3pl of PCR 
product was combined with 10U exonuclease I and 0.5U SAP. The sample was 
incubated at 37°C for 15 minutes to allow for digestion of excess primers and 
removal of phosphates groups from dNTPS before denaturation of the enzymes at 
80°C for 15 minutes.
2.4.14 Cycle sequencing and purification
Sanger sequencing uses dideoxynucleotide triphosphates (ddNTPs) which lack the 
3’ hydroxyl group present in deoxyribose sugars. As a result of this, ddNTPs can be 
efficiently incorporated into a nascent strand by DNA polymerases but prevent 
further extension of the growing chain (Sanger etal. 1977). In automated sequencing 
the reaction can take place within a single tube because each ddNTP is labelled with 
a different fluorophore. The template DNA is denatured and bound by a single 
specific primer. DNA polymerase extends this primer by incorporating either an 
unlabelled dNTP or chain terminating ddNTP at each position. The relative 
concentrations of dNTPs and ddNTPs are such that the labelled products formed 
differ in size by one nucleotide. Capillary electrophoresis is used to separate the 
single stranded DNAs, with smaller fragments migrating fastest through the polymer 
and passing through the laser beam first. The emitted wavelength of light is detected
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and used to determine the ddNTP incorporated at a particular position. The order of 
the nucleotides provides a sequence read of up to ~500bp.
Sequencing reactions were performed using the BigDye Terminator Cycle 
Sequencing kit (Version 3.1) according to the manufacturer’s instructions. A total 
reaction volume of 10pl contained 0.6pl -  1.5pl purified PCR product (~5ng), 1pl 
Terminator ready Reaction Mix (labelled ddNTPs and dNTPs, AmpliTaq DNA 
polymerase FS, MgCI2and Tris-HCI buffer, pH 8 ), 1.6pmol primer and 1.5pl BigDye 
terminator buffer (CTS). Cycle sequencing conditions were 25 cycles of 96°C for 10 
seconds, 50°C for 5 seconds and 60°C for 3 minutes and 30 seconds.
The Montage SEQ96 Sequencing Reaction Cleanup Kit was used to purify 
sequencing reactions. Twenty microlitres of injection solution (CTS) was mixed with 
the reaction and transferred to a filter plate. A vacuum was applied until the wells 
were empty, then a further 25pl injection solution was added and the vacuum applied 
again to ensure that all the contaminating salts and unincorporated dyes terminators 
were filtered out. Purified sequencing products were re-suspended in 25pl injection 
solution by shaking for 6  minutes. Samples were run on either an ABI 31000 or ABI 
3730 Genetic Analyser.
2.4.15 Rapid amplification of cDNA ends (RACE) of PCR products
RACE was performed using human colonic Marathon-ready cDNA (Clontech) -  pre­
prepared libraries of adaptor-ligated cDNA. By using a primer specific to the target 
sequence of interest, in combination with a primer specific to the adaptor sequence, 
it is possible to amplify the transcript of interest. Downstream applications such as 
sequencing allow determination of the 5’ and/or 3’ ends of the cDNA (named 
5’RACE and 3’RACE respectively). Primers used in RACE reactions are required to 
be 23-28 nucleotides in length, have a GC content of 50-70%, and have a melting 
temperature of greater than or equal to 65°C. For RACE amplification 36pl water, 5pl 
10X cDNA PCR reaction buffer, 1pl dNTP mix (10mM) and 1pl Advantage 2 
polymerase mix (50X) are mixed by vortexing for each reaction. This mix is added to 
a separately prepared mix of 5pl Marathon-ready cDNA, 1 pi of the appropriate 
adaptor primer (10pM) and 1pl of the appropriate gene specific primer (10pM). 
Cycling conditions were 94°C for 30 seconds, five cycles of 94°C for 5 seconds,
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72°C for 4 minutes, five cycles of 94°C for 5 seconds, 70°C for 4 minutes and 
twenty-five cycles of 94°C for 5 seconds, 68°C for 4 minutes.
RACE products were analysed on an agarose gel by electrophoresis, and 
sequenced as described above.
2.4.16 Real-time PCR
As the name suggests, this technique allows precise real-time monitoring of PCR 
products as they are generated, through the use of fluorescent probes. Targeted 
Taqman assays were purchased from Applied Biosystems and used in gene 
expression analysis, along with Taqman Universal PCR master mix. The human 
B2M gene was used as an endogenous control for all reactions. One hundred 
nanograms of cDNA was added to each gene expression reaction in a total 20pl 
volume. Thermal cycling and expression analysis were performed using Applied 
Biosystems 7500 Fast Real-Time PCR system. Thermal cycling conditions were an 
initial step of 50°C for 2 minutes and 95°C for 10 minutes, followed by forty cycles of 
denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 1 minute. 
Each gene expression reaction was performed in triplicate (for both target and 
endogenous control assays). PCR specificity of the assay was tested by running the 
expression product on a 1.5% agarose gel to ensure that only one band was visible. 
Calibration curves were generated for all samples used and PCR efficiencies 
calculated to ensure levels between 90-110%.
2.4.17 MSI analysis
The microsatellite status of CRC tumour DNA was determined using the BAT25 and 
BAT26 markers. Amplification of these was carried out using specifically designed 
primers. Sequences for these were; BAT25F (5’ FAM labelled -  
TCGCCTCCAAGAATGTAAGT, BAT25R -  TCTGCATTTTAACTATGGCTC, BAT26F 
(5’ HEX labelled) -  TGACTACTTTTGACTTCAGC, BAT26R -  
AACCATTCAACATTTTTAACC.
The MSI test was standardised using DNA extracted from HCT-166 and Calul (MSI 
and MSS [microsatellite stable] respectively) cell lines. Tumour DNA was serially 
diluted to test the sensitivity of the assay. Amplification of BAT products was
62
performed in 12pl reaction volumes containing 4pl of H20, 6pl of Megamix Gold, 10 
pmol of each primer, and 20-30ng of tumour DNA. Thermocycling was performed at 
95°C for 10 minutes, followed by thirty-five cycles of 95°C for 1 minute, 60°C for 1 
minute and 72°C for 1 minute, followed by a final extension of 72°C for 7 minutes.
One microlitre of PCR product was diluted in 180pl H20  and this was used for 
subsequent analysis. Microsatellite analysis was carried out using Applied 
Biosystem’s 3100 genescan software, with the microsatellite signal standardised 
against a ROX marker diluted in Hi Dye Formamide.
2.4.18 Immunohistochemistry
The avidin-biotin complex (ABC) method was used for immunohistochemical (IHC) 
analysis. This method utilises the unique properties of the large glycoprotein avidin 
and the vitamin biotin which have an extremely high affinity for one another. Biotin 
can in turn be conjugated to a variety of biological molecules such as antibodies, 
whilst avidin can be labelled with peroxidise or fluorescein. The technique involves 
three main steps; application of unlabelled primary antibody, application of 
biotinylated secondary antibody and application of a complex avidin-biotin peroxidise. 
The peroxidase is then developed by 3,3’-diaminobenzidine (DAB) or other 
substrates to produce a coloured end product. The main advantage of this method is 
the amplification of the original antibody signal due to avidin having four binding sites 
for biotin, therefore amplifying the signal many fold.
Five micrometer thick paraffin sections containing colorectal tumour tissue were 
deparaffinised and rehydrated by immersion in xylene twice, 100% ethanol twice, 70% 
ethanol, 50% ethanol and water for 5 minutes each. For antigen retrieval, sections 
were boiled in 10mM citrate buffer (pH 6.0) for 10 minutes and gently rinsed under 
running tap water. Endogenous peroxidase activity was blocked with 0.3% hydrogen 
peroxide for 10 minutes followed by one 1XTBS wash for 5 minutes. Immunostaining 
was performed in a humidity chamber using the rabbit/goat VECTASTAIN ELITE 
ABC horse- and goat-radish peroxidise kits respectively. Sections were encircled 
with a wax ring and blocked with goat normal serum for 20 minutes. Primary 
antibodies were applied and incubated overnight at 4°C, followed by three 5 minute 
washes in 1XTBS. A biotinylated secondary antibody was applied and incubated for 
30 minutes followed by three 5 minute 1XTBS washes. ABC was incubated for 30
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minutes followed by three 5 minute washes in 1XTBS. Sections were developed 
using DAB, counterstained in Gills haematoxylin for 1 minute, and blued in tap water. 
Sections were finally dehydrated by immersing in 50% ethanol, 70% ethanol and 100% 
ethanol twice (all 5 minutes each), cleared in xylene for 10 minutes, mounted with 
DPX and air dried. Slides were viewed with an Olympus BX51 microscope. All 
incubations were at room temperature unless otherwise stated.
2.4.19 Bacteriological methods
2.4.19.1 Bacteriological media and solutions
Unless otherwise stated, solutions were sterilised by autoclaving. LB -  Broth; 5g 
Bacto Tryptone, 2.5g yeast extract and 2.5g NaCI in 500ml dH20. LB agar: 5g Bacto 
Tryptone, 2.5g yeast extract, 2.5g NaCI and 8g Bacto Agar in 500ml dH20. Where 
appropriate, LB medium had ampicillin added to a final concentration of 100pg/ml,
IPTG to 0.5mM and 80pg/ml of X-gal. SOC medium -  2g Bacto Tryptone, 0.5g yeast 
extract, 1ml 1M NaCI, 0.25ml 1M KCI, 1ml 2M Mg2+ stock (filter-sterilised) and 1ml 
2M glucose (filter-sterilised).
2.4.19.2 Ligation reactions
For pGEM-T easy vectors;
Purified PCR product was ligated with the pGEM-T easy vector (Promega) according 
to the following conditions; 5pl of 2X rapid ligation buffer (T4 DNA ligase), 1pl of 
pGEM-T easy vector (50ng), 1 pi T4 DNA ligase (3 Weiss units/pl) were used in a 
reaction with an amount of PCR product defined by the following equation;
ng of insert = nq of vector x kb size of insert x insert vector molar ratio 
kb size of vector
Ligations were carried out either at room temperature for 1 hr or 4 °C overnight.
For pGL3 vectors;
The region of interest was PCR amplified using primers containing restriction digest 
sites for subsequent cloning. The pGL3 vector was digested with the appropriate 
restriction enzymes in order to generate compatible ends for cloning with them.
64
During digestion, vector DNA was treated with calf intestinal alkaline phosphatase 
(CIP) to prevent vector closing. Ligation was carried out using 1pl of digested vector, 
3pl of digested PCR product, 5pl 2x ligase buffer and 1pl ligase (3U/pl). Reaction 
mixes were incubated at 15°C for 24 hours.
2.4.19.3 JM109 highly competent Cell Transformation
Transformation of JM109 highly competent E.coli was mediated via a heat shock 
process which led to semi-permeabilisation of the cell membrane enabling the 
uptake of ‘naked’ DNA molecules from the surrounding environment into the cell.
Two microlitres of each ligation reaction were placed into 1.5ml eppendorf tubes on 
ice, with 50pl of just thawed JM109 cells subsequently added. After gentle mixing, 
samples were placed on ice for 20 minutes. Each sample was heat shocked by 
placing in a 42°C water bath for exactly 50 seconds and incubated on ice for 2 
minutes. The cells were incubated at 37°C with agitation at 225rpm for 1.5 hour after 
adding 950pl of SOC medium. One-hundred mincrolitres of the growing suspension 
was spread onto LB agar plates containing ampicillin, X-gal and IPTG. The 
transformation plates were incubated at 37°C overnight (>16 hours).The pGEM-T 
easy vector carries the LacZ gene which encodes for the enzyme p-galactosidase 
and so it is possible to identify colonies that contain the insert according to their 
colour. Cells containing vector without the insert will produce p-galactosidase which 
leads to the formation of blue colonies because of the utilisation of the enzymes’ 
substrate Xgal. Cells that contain the vector with the successful insert will appear 
white since the insert disrupts the LacZ gene and p-galactosidase is not produced.
2.4.19.4 Plasmid minipreps
High quantity plasmid DNA was prepared using QIAprep Spin Miniprep Kit according 
to the manufacturer’s instructions. Around 5-1 Opg of plasmid DNA is generated from 
1.5ml overnight LB cultures. The extraction process involves alkaline lysis of cells 
accompanied by gentle mixing which releases intact plasmid DNA denatures 
proteins. Neutralisation and adjustment of the conditions to a high salt medium 
facilitate binding of DNA to the spin column. High salt conditions cause proteins to 
denature and chromosomal DNA and cellular debris to precipitate whilst plasmid
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DNA stays in solution and binds to the silica-gel membrane of the column. The 
column/membranes are washed to remove trace nucleases, carbohydrates and salts 
before the DNA elution.
Clones that successfully carried the correct insert were grown in 3ml of liquid LB 
containing ampicillin (50pg/ml) at 37°C with agitation (170rpm) for ~15 hours. Cells 
were centrifuged at 13,000rpm for 1 minute and re-suspended in 250pl of Buffer P1 
(100pg/ml RNase A, 50mM Tris/HCI and 10mM EDTA). Two hundred and fifty 
microlitres of Buffer P2 (200mM NaOH, 1% SDS) was added and the tubes were 
gently inverted 4-6 times to mix. Three hundred and fifty microlitres of Buffer N3 (3M 
potassium acetate) was then added, the tubes were gently inverted 4 - 6  times and 
centrifuged at 13,000rpm for 10 minute. The supernatant was added to a QIAamp 
column and centrifuged at 13,000rpm for 1 minute. The column was washed with 
500pl of Buffer PB (CTS) and then centrifuged at 13,000rpm for 1 minute. The 
column was washed with 750pl of Buffer PE (containing ethanol and CTS) and 
centrifuged at 13,000rpm for 1 minute. Residual ethanol from Buffer PE was 
removed by centrifuging the column twice at 13,000rpm for 1 minute. DNA was 
eluted into 30pl of H20 after placing the column in a fresh 1.5ml eppendorf tube and 
centrifuging at 13,000rpm for 1 minute.
2.4.20 Tissue culture
HEK293 adherent cells were grown and maintained in Dulbecco’s modified eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% pen- 
strep. When cells reached £80% confluence they were passaged according to the 
following process. Initially cells were briefly washed with 5ml PBS before being 
washed with 1ml of Trypsin-EDTA for ~1 minute in order to detach them from the 
side of the tissue culture flask. Cells then had 2ml of Trypsin added and were 
incubated at 37°C for 1-3 minutes. The trypsinised cells were transferred into two 
separate falcon tubes in a final volume of 10ml media (DMEM plus 10% FBS) which 
were subsequently centrifuged at 1,200rpm for 7-10 minutes.
Following centrifugation, the medium was removed leaving a cell pellet at the bottom 
of the falcon tube. This was re-suspended in a volume of medium suitable for 
downstream applications, with care taken to ensure cells were sufficiently mixed with
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the medium. This mix was evenly divided between the appropriate numbers of flasks 
and incubated at 37°C with C 02.
2.4.20.1 Transient transfection
Cells were seeded into 96 well plates at 2.5x104 cells per well and allowed to reach 
50-80% confluence. Media was then aspirated and replaced with 100pl complete 
growth medium. In parallel to this, 0.5pg of DNA was diluted with 100pl of Opti-MEM 
I reduced serum media without serum (Invitrogen). For each well, 0.35pl of 
Lipofectamine LTX reagent (Invitrogen) was added to the DNA:Opti-MEM mix, mixed 
and incubated at room temperature for 30 minutes. Following this, 20pl of the 
DNA:Lipofectamine LTX reagent complex was added to each well. The plate was 
gently agitated and then left to incubate for a further 24 hours before subsequent 
assaying was carried out.
2.4.20.2 Luciferase assay
HEK293 cells were transfected with 100ng of pGL3 (transformed with the insert of 
interest) and 0.5ng of pRL (both from Promega) in a 96 well plate. The media was 
removed and cells washed with 50pl of phosphate buffered saline (PBS). This was 
immediately removed and replaced with 20pl of 20% diluted lysis buffer. The plate 
containing the cells was centrifuged at 2,000 rpm for 30 seconds. This was stored at 
-80°C ready for use.
Luciferase assays were carried out using an Applied Biosystems TR 717 Microplate 
luminometer. A dual-luciferase reporter assay system was used that allowed the 
comparison of the activities of firefly and Renilla luciferases through sequential 
measurement. The firefly luciferase reporter was measured first by the addition of 
50pl of Luciferase Assay Reagent II (LAR II). Following this the reaction was 
quenched and the Renilla luciferase reaction initiated by the addition of Stop & Glo 
reagent. Reactions were repeated at least six times to ensure accurate 
measurement. The relative activities of the two luciferase reactions give an indication 
of the expression levels in the pGL3 vector.
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Chapter Three - High-throughput somatic profiling of the Ras-Raf-MAPK and 
PI3K-PTEN-Akt pathways in advanced colorectal cancer and correlations with
response to cetuximab
3.1 Introduction
Patients vary in their response to chemotherapy. Inherited factors play a significant 
role in this response, with germline changes in drug metabolism, transport and target 
genes all being implicated (Dotor et al. 2006; Marcuello et al. 2004; Kim et al. 2008). 
In recent years, a role for somatic (tumour based) mutations in altering response has 
been sought and the introduction of therapies that target the EGFR has shed 
considerable light into this area. EGFR acts as the gate-way for multiple downstream, 
intracellular signalling pathways including the Ras-Raf-MAPK and PI3K-PTEN-Akt 
pathways. Through these pathways, EGFR regulates multiple processes including 
apoptosis, cellular growth, proliferation, differentiation and migration (Woodburn, 
1999). Cetuximab is a monoclonal antibody that binds to the extracellular binding 
domain of EGFR. In doing so, it prevents the ligands EGF and TGF-a binding to the 
receptor and triggers receptor internalisation; thus inhibiting downstream signalling. 
Response to cetuximab has been shown to be limited to patients with CRCs wild- 
type for KRAS, BRAF, NRAS and exon 20 mutations in PIK3CA (De Roock et al. 
2010a). Given the high-frequency of CRCs that are KRAS mutant (~40-45%), 
guidelines are now in place that recommend testing of KRAS mutation status prior to 
treatment with anti-EGFR agents (Allegra et al. 2009). However, recent data has 
suggested that not all somatic mutations within specific target genes affect response 
to cetuximab. For example, patients treated with cetuximab and with G13D in KRAS 
have longer OS and PFS as compared to patients with other KRAS-mutated tumours 
(De Roock etal. 2010b).
Here we tested two mutation detection platforms, Pyrosequencing and Sequenom, 
for high-throughput somatic profiling of the Ras-Raf-MAPK and PI3K-PTEN-Akt 
pathways in aCRCs from patients in Arms A (oxaliplatin and 5FU-based 
chemotherapy) and B (chemotherapy plus cetuximab) of the COIN trial. We 
determined if there was improved response (OS or PFS) to cetuximab in patients 
wild-type for KRAS. We further analysed KRAS in combination with BRAF and 
NRAS and determined response to cetuximab in patients carrying a mutation in any
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or none of these genes. We determined if PIK3CA mutations reduced response to 
cetuximab. We also determined if mutations of any of the above genes carried a 
prognostic effect.
3.2 Materials and Methods 
3.2.1 The COIN trial
COIN (Continuous vs. INtermittent therapy) is a MRC funded fully accrued national 
trial run through the MRC clinical trials unit (CTU). Tim Maughan was the chief 
investigator of the study. COIN represents the largest trial of the addition of an EGFR 
targeted monoclonal antibody (cetuximab) to chemotherapy (oxaliplatin and a 
fluoropyrimidine) in the first line treatment of aCRC.
3.2.2 Patient Samples
All 2,445 patients, from 111 centres across the UK and Republic of Ireland, were 
randomised in a 1:1:1 ratio to receive either continuous oxaliplatin-based 
chemotherapy (Arm A), continuous chemotherapy plus cetuximab (Arm B), or 
intermittent chemotherapy (Arm C), in first line treatment. All patients chose between 
oral capecitabine (OxCap; two thirds of patients) or infusional 5FU (OxFU; one third) 
as the partner for oxaliplatin (Figure 3.1). Patients had either previous or current 
histologically confirmed primary adenocarcinomas of colon or rectum, together with 
clinical or radiological evidence of advanced and/or metastatic disease, or had 
histologically/cytologically confirmed metastatic adenocarcinomas, together with 
clinical and/or radiological evidence of a colorectal primary tumour. All patients gave 
fully informed consent for their samples to be used for bowel research. Samples 
were collected as FFPE blocks. Results described herein are for patients from Arms 
A and B of the trial.
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Figure 3.1 - COIN trial patients were randomised between three equally sized trial 
arms. Patients in Arm A received a standard chemotherapeutic backbone of OxFU or 
OxCap, patients in Arm B received the standard chemotherapeutic backbone plus 
cetuximab, and patients in Arm C received standard chemotherapy but in an 
intermittent fashion (as part of a separate analysis not considered here). Second-line 
treatment was irinotecan based therapy or entry into another trial.
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3.2.3 Drug administration
OxCap was a 3 weekly regimen of intravenous (IV) oxaliplatin 130 mg/m2 over 2 
hours followed by oral capecitabine twice daily for two weeks. The initial dose of 
capecitabine was 1000mg/m2, but was reduced to 850 mg/m2 in a protocol 
amendment for Arm B patients only after 1775 (73%) patients had been randomised 
to all arms, when a toxicity analysis showed the grade 3/4 diarrhoea rate was higher 
than expected (30%) (Adams et al. 2009). OxFU was a 2 weekly regimen of IV I- 
folinic acid 175 mg or d,l-folinic acid 350 mg over 2 hours given concurrently with 
oxaliplatin 85 mg/m2 over 2 hours, followed by IV bolus 5-FU 400 mg/m2 then 5-FU 
2400 mg/m2 infusion over 46 hours administered via an ambulatory pump via a 
central venous line. In Arm B cetuximab was given in an initial IV dose of 400 mg/m2 
over 2 hours and subsequently at 250 mg/m2 over 1 hour once a week.
Treatment was continued until disease progression, development of cumulative 
toxicity, or patient choice. Patients were allowed to discontinue one or more agents 
within the regimen for toxicity while continuing on the remaining agent(s).
3.2.4 Sample size
The primary analysis of COIN A vs B was planned to take place when 511 OS 
events (deaths) had been observed among patients wild-type for KRAS. In this 
molecularly selected cohort a higher hazard ratio of 0.76 could be detected at 87% 
power with a two-sided alpha of 0.05.
3.2.5 Processing FFPE CRCs, DNA extraction and MSI analyses
5pm sections were cut from FFPE CRCs using a microtome. One section was 
stained with Hematoxylin and Eosin and visualised with a Mirax scanner. Samples 
containing concentrated pockets of tumour material were macrodissected using a 
second unstained 5pm section. For samples containing limited regions of tumour, 
LCM was performed using 10pm sections cut onto a PALM membrane slide (Carl 
Zeiss) and incubated at 56°C for 24 hours. To improve section adherence PALM 
slides were exposed to UV (254nm) for 30 minutes, incubated in poly-L-Lysine 
(0.1%w/v) for 5 minutes, and allowed to dry at 60°C for at least 4 hours. Sections 
were deparaffinised with 100% xylene for 2 minutes (twice), followed by 100%, 95% 
and 70% ethanol washes for 1 minute. Slides were then dipped 5-6 times in RNase-
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free distilled water, stained for 1-2 minutes in Mayer’s Hematoxylin solution, rinsed 
for 1 minute in blueing solution, stained for 10 seconds in Eosin Y, washed in 70%, 
95%, and 100% ethanol for 1 minute each and air dried. Slides were viewed and 
LCM with a Zeiss Axiovert S100 inverted microscope using the PALM Robo software 
(v.1.2.3). DNA was extracted from macrodissected and LCM tumour material using 
QIAamp DNA Microkits according to the manufacturer’s instruction and eluted in 50pl 
nuclease-free water. MSI-status was determined using the markers BAT-25 and 
BAT-26.
3.2.6 Identification of somatic mutation ‘hot spots’ and mutant cell lines
We queried the Catalogue Of Somatic Mutations In Cancer (COSMIC) database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic) for known common mutations in 
KRAS, BRAF, NRAS and PIK3CA in CRCs. Cell lines known to carry variants within 
these genes were identified using the Sanger Cancer Cell Line Project 
(http://www.sanger.ac.uk/genetics/CGP/CellLines/). We tested the sensitivity of 
Pyrosequencing and Sequenom to detect low levels of mutant alleles using the cell 
lines CAL-62 (heterozygous c.34G>C, p.G12R in KRAS), AsPC1 (homozygous 
c.35G>A, p.G12D in KRAS), RPMI-8226 (homozygous c.35G>C, p.G12A in KRAS), 
SW620 (homozygous c.35G>T, p.G12V in KRAS), DLD1 (heterozygous c.38G>A, 
p.G13D in KRAS), HCT-116 (heterozygous c.38G>A, p.G13D in KRAS and 
heterozygous c.3140A>G, p.H1047R in PIK3CA), SW948 (heterozygous c.182A>T, 
p.Q61L in KRAS and heterozygous c.1624G>A, p.E542K in PIK3CA), Colo-205 
(heterozygous c.1799T>A, p.V600E in BRAF), HT117 (heterozygous c.182A>G, 
p.Q61R in NRAS) and HT1197 (heterozygous c.1633G>A, p.E545K in PIK3CA).
DNA extracted from cell lines was quantified using a nanodrop spectrophotometer 
and serially diluted with wild-type DNA to generate known levels of mutant compared 
to wild-type, alleles (50, 25, 12.5, 10, 8, 6, 4, 2 and 0%). All dilutions were prepared 
and analysed in triplicate.
3.2.7 Pyrosequencing
For codons 12 and 13 of KRAS, we initially used the amplification primers 5’- 
GGCCTGCTGAAAATGACTGA-3’ and 5‘-AGAATGGTCCTGCACCAGTAATA-3’ 
together with extension primer 5’-CTTGTGGTAGTTGGAGC-3’; however, this assay 
was subsequently modified by using the extension primers 5’-
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TGTGGTAGTTGGAGCTG-3’, 5’-TGTGGTAGTTGGAGCT-3’ and 5’- 
TGGTAGTTGGAGCTGGT-3’, as previously described (Ogino et al. 2005). For 
codon 61 of KRAS, we used the amplification primers 5’- 
CTTTGGAGCAGGAACAATGTC-3’ and 5’-CTCATGTACTGGTCCCTCATTG-3’ 
together with the extension primer 5’-ATTCTCGACACAGCAGGT-3\ and for codon 
600 of BRAF we used the amplification primers 5’-
TGCTTGCTCTGATAGGAAAATGA-3’ and 5’-CAGGGCCAAAAATTTAATCAGTG-3’ 
together with the extension primer 5’-Ai I I IGGTCTAGCTACA-3’. Reverse primers 
were biotinylated and purified by HPLC. All other primers were unmodified and 
purified by standard SePOP desalting. PCR was performed in 50pl reaction volumes 
containing 25pl Megamix Gold, 10-20ng DNA and 10pM of primers. Thermocycling 
was performed at 95°C for 10min, followed by 38 cycles of 95°C for 30s, 57°C for 
30s, and 72°C for 1min, followed by a final extension of 72°C for 10min. 10pl of each 
PCR product was run on a 1.2% agarose gel to confirm amplification, while the 
remaining 40pl was used for Pyrosequencing (Qiagen).
For Pyrosequencing, PCR products were immobilised onto Streptavadin sepharose 
beads, which were then captured onto probes using Qiagen’s vacuum prep tool. 
Probes, with the vacuum maintained, were washed in 70% ethanol, denaturation 
solution and wash solution. After removing the vacuum, beads were released into a 
sequencing primer/annealing buffer mix. Samples were heated to 80°C for 2 min and 
allowed to return to room temperature before being placed into the Pyrosequencer 
(PyromarkID 96 well format) and run using pre-defined assay conditions. Pyrograms 
were analysed by two independent observers.
3.2.8 Sequenom
Two hundred base pairs of sequence upstream and downstream of each mutation 
were downloaded from Ensembl to design the genotyping assays using the 
Sequenom MassARRAY Assay Design 3.1 software. In total, three multiplex assays 
were designed. Details of primer sequences are shown in Table 3.1. Multiplex PCR 
was performed in 5pl reaction volumes containing 0.5U of Taq polymerase, 5-10ng 
of genomic DNA, 100nM of PCR primers and 500|jM of dNTP. Thermocycling was 
performed at 95°C for 15 min, followed by 45 cycles of 94°C for 20s, 56°C for 30s 
and 72°C for 60s, followed by a final extension of 72°C for 3min. Unincorporated
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dNTPs were deactivated using 0.3U of SAP at 37°C for 40min, and primer extension 
was carried out using 7-14pM of each extension primer, 1U of iPLEX termination mix 
and 1U of iPLEX enzyme. Reactions were cycled at 94°C for 30s, followed by 40 
cycles of 94°C for 5s, 52°C for 5s and 80°C for 5s, followed by a final extension at 
72°C for 3 min. After the addition of a cation exchange resin to remove residual salt 
from the reactions, 20pl of water was added and the extension product was spotted 
onto a matrix pad (3-hydroxypicolinic acid) of a SpectroCHIP (Sequenom). After 
analysing the SpectroCHIPs using a Bruker MALDI-TOF mass spectrometer, spectra 
were processed by the SpectroREADER software and transferred to the 
MassARRAY Typer 4 Analyser (Sequenom). Genotyping was performed using the 
MassARRAY RTTM software (Sequenom). Automated calls were validated by 
manual review of the raw mass spectra.
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Mutation Forward Primer (5’-3’) Reverse Primer (5’-3’) Extension Primer (S’-3’)
KRAS G35ACT ACGTT GGAT GCT GTAT CGT CA ACGTT GGAT GAGGCCT GCTG AACTTGTGGTAGT
G12D/A/V AGGCACTCT AAAATGACTG TGGAGCTG
KRAS G38ACT ACGTTGGATGCTGTATCGTCA ACGTT GGAT GAGGCCTGCTG GCACT CTT GCCTA
G13D/A/V AGGCACTCT AAAATGACTG CG
KRAS A182CGT ACGTT GGAT GT GGAGAAACCT ACGTT GGAT GCAT GTACT GGT GGATATTCTCGAC
Q61P/R/L GTCTCTTGG CCCTCATTG ACAGCAGGTC
A KRAS A183CT ACGTT GGAT GT GGAGAAACCT ACGTT GGAT GCAT GTACT GGT ATT GCACT GTACT
S Q61H/H GTCTCTTGG CCCTCATTG CCTCo BRAF T1799A ACGTT GGAT GT GAT GGGACC ACGTT GGAT GT CTT CAT GAAG CCCACTCCATCGA
Y V600E CACTCCATCG ACCTCACAG GATTTC
NRAS G34AT ACGTT GGAT GGACT GAGTACA ACGTT GGAT GAGT GGTT CTGG GT GCGCTTTT CCC
1 G12S/C AACTGGTGGT ATTAGCTGGA AACACCAC
PIK3CA G1624A ACGTT GGAT GGCT CAAAGCAA ACGTT GGAT GACTTACCT GT G ATTTCTACACAGA
E542K TTTCTACAC ACTCCATAG TCCTCTCTCT
PIK3CA G1633A ACGTT GGAT GGCT CAAAGCAA ACGTT GGAT GACTTACCT GT G TCCATAGAAAATC
E545K TTTCTACAC ACTCCATAG TTTCTCCTGCT
PIK3CA A3140GT ACGTT GGAT GT GAGCAAGAG ACGTTGGATGCCAATCCATTT GAAACAAAT GAAT
H1047R/L GCTTTGGAGT TTGTTGTCC GATGCAC
KRAS G34ACT ACGTTGGATGCTGTATCGTCA ACGTT GGAT GAGGCCT GCTG TGTGGTAGTTGGA
G12S/R/C AGGCACTCT AAAATGACTG GCT
KRAS G37ACT ACGTT GGAT GAGGCCT GCTG ACGTT GGAT GGCT GTATCGTC CACTCTTGCCTAC
G13S/R/C AAAATGACTGA AAGGCACTCT GC
A BRAF A1781G ACGTT GGAT GT GAT GGGACC ACGTT GGAT GT CTT CAT GAAG CACT GTAGCTAGA
S D594V CACTCCATCG ACCTCACAG CCAAAA
S NRAS C181A ACGTT GGAT GGT GGTTATAGA ACGTT GGAT GTATT GGTCTCT ACAGACTGGATA
Y 061K TGGTGAAACCT CATGGCACTG CAGCTGGA
NRAS A182C ACGTT GGAT GTATT GGT CT CT ACGTT GGAT GGT GGTTATAGA T GGCACT GTACT C
2 061P CATGGCACTG TGGTGAAACCT TTCT
PIK3CA A1634CG ACGTT GGAT GGCT CAAAGCAA ACGTT GGAT GACTTACCT GT G AGAGCCT CT CT CT
E545A/G TTTCTACAC ACTCCATAG GAAATCACTG
PIK3CA C1636A ACGTTGGATGCCTGTGACTCC ACGTT GGAT GGAACAGCT CAA TCCATAGAAAATC
Q546K ATAGAAAATC AGCAATTTC TTTCTCCT
KRAS G35ACT ACGTT GGAT GGCT GTATCGTC ACGTT GGAT GAGGCCT GCTG CTCTTGCCTACGC
G12D/A/V AAGGCACT CTT AAAAT GACT GAA CA
KRAS A182CGT ACGTT GGAT GCT CAT GTACT G ACGTTGGATGGATGGAGAAAC ATTGCACTGTACT
Q61P/R/L GTCCCTCATTG CTGTCTCTTGG CCTCT
BRAF A1781G ACGTT GGAT GAT GGGACCCA ACGTTGGATGTTTCTTCATGA GACTGTAGCTAGA
A D594V CT CCAT CGAGATT AGACCT CACAG CCAAAA
S NRAS G34ACT ACGTT GGAT GAGT GGTT CTGG ACGTT GGAT GGACT GAGTACA CGCI 11 ICCCAACS G12S/R/C ATTAGCTGGAT AACTGGTGGTG ACCACA
Y NRAS A182CGT ACGTTGGATGGTATTGGTCTC ACGTT GGAT GCAAGT GGTTAT ATCCTGGCACTGT
Q61P/R/L TCATGGCACTG AGATGGTGAAAC ACTCTTCT
3 PIK3CA G1624A ACGTT GGAT GGCT CAAAGCAA ACGTT GGATGGCACTTACCT G TCCACACAGATCC
E542K TTTCTACACAG TGACTCCATAG TCTCTCT
PIK3CA G1633A ACGTT GGAT GGCACTTACCT G ACGTT GGAT GGCT CAAAGCAA TAGAAAATCTTTC
E545K TGACTCCATAG TTTCTACACAG TCCTGCT
PIK3CA A3140GT ACGTTGGATGCCAATCCATTT ACGTTGGATGCTGAGCAAGA T GT CCAGCCACC
H1047R/L TTGTTGTCCAGC GGCTTTGGAGTA ATGA
Table 3.1 - Primers used in Sequenom analysis of KRAS, BRAF, NRAS and PIK3CA. 
Mutation column refers to the target gene and nucleotide change; for example, 
KRAS_G35ACT primers allowed for the analysis of KRAS at the thirty fifth nucleotide 
of the transcript. A G to A, C or T substitution would be detected. The corresponding 
amino acid changes are also listed. The nature of the assay designs meant that 
some nucleotides were assayed more than once.
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3.2.9 Sanger Sequencing
Sanger sequencing of codons 12 and 13 of KRAS was performed using the primers 
5-AAAAGGTACTGGTGGAGTATTTGA-3’ and 5’-
CATGAAAATGGTCAGAGAAACC-3’, codon 61 of KRAS was sequenced using 5’- 
CTTT GGAGCAGGAACAAT GT C-3’ and 5’-CT CAT GTACT GGTCCCT CATT G-3’, and 
codon 600 of BRAF was sequenced using 5VW3TCTTCATAATGCTTGCTCTG-3’ 
and 5’-TGAl l I l l GTGAATACTGGGAAC-3’. Single stranded DNA and excess 
dNTPs were removed using ExoSAP at 37°C for 30min, followed by 80°C for 15min. 
Cycle-sequencing was performed using Big Dye Mix at 95°C for 10s, followed by 
twenty-five cycles of 95°C for 10s, 50°C for 5s, 60°C for 200s. Reactions were 
purified using the Millipore sequencing clean-up plate and analysed on an ABI Prism 
3100 genetic analyzer.
3.2.10 Statistical Analyses
Analyses were conducted according to a predefined statistical analysis plan which 
was approved by the COIN trial management group. All randomised patients were 
included in the analyses, based on the intention-to-treat principle. All P-values are 2- 
sided and were not adjusted for multiple testing. Time-to-event curves for analysis of 
OS and PFS were estimated using the Kaplan-Meier method. Hazard ratios, 
confidence intervals and P-values were estimated using the log-rank method.
Worst toxicity experienced overall was compared between treatment arms using a 
chi-squared test. For exploratory interaction analyses a Cox proportional-hazards 
model was fitted separately for each of the covariates to predict PFS in the all wild- 
type population. All of the above statistical analyses were carried out by David Fisher.
The chi-square test (with Yate’s correction) was used for comparison of genotype 
groups.
3.3 Results
3.3.1 Determining the sensitivities of the assays
For Pyrosequencing, we initially designed an assay with a single extension primer to 
detect mutations at codons 12 and 13 of KRAS. However, we found that the
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mutation G12C was not robustly detected in samples with 25% mutant alleles, so the 
assay was redesigned to a three extension primer system (Ogino et al. 2005). This 
modified assay robustly detected G12A and G12D in samples with 12.5% mutant 
alleles, G12C and G13D in samples with 6% mutant alleles and G12V in samples 
with 2% mutant alleles. Sequenom robustly detected G12C in KRAS in samples with 
6% mutant alleles, V600E in BRAF and Q61R in NRAS in samples with 10% mutant 
alleles, Q61L in KRAS and E542K, E545K and H1047R in PIK3CA in samples with 6% 
mutant alleles and G12V in KRAS in samples with 4% mutant alleles (Table 3.2,
Figure 3.2).
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Mutant Allele (%)
gene mutation
Cell line 
used 50 25 12.5 10 8 6 4 2 0
Py
ro
se
qu
en
ci
ng
KRAS G12A RPMI-8226 Y Y Y X X X X X X
KRAS G12C CAL-62 Y Y Y Y Y Y X X X
KRAS G12D ASPC1 Y Y Y X X X X X X
KRAS G12V SQ620 Y Y Y Y Y Y Y Y X
KRAS G13D DLD1 Y Y Y Y Y Y X X X
Se
qu
en
om
KRAS G12C CAL-62 Y Y Y Y Y Y X X X
KRAS G12V SQ620 Y Y Y Y Y Y Y X X
KRAS Q61L SW948 Y Y Y Y Y Y X X X
BRAF V600E COLO-205 Y Y Y Y X X X X X
NRAS Q61R HT1197 Y Y Y Y X X X X X
PIK3CA E542K SW948 Y Y Y Y Y Y X X X
PIK3CA E545K HT1197 Y Y Y Y Y Y X X X
PIK3CA H1047R HCT-116 Y Y Y Y Y Y X X X
Table 3.2 - Chart depicting the sensitivity of Pyrosequencing and Sequenom to 
detect somatic mutations in KRAS, BRAF, NRAS and PIK3CA. Mutant allele that 
could be detected with confidence is indicated by a green Y while mutant allele that 
could not be detected is indicated by a red X.
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Figure 3.2 - Diagrams representing detection sensitivities for KRAS G12C and G12V using A, 
Pyrosequencing (single extension primer system), B, Pyrosequencing (multiple extension primer 
system), and C, Sequenom platforms. Cell lines containing the relevant mutation were diluted with 
wild-type DNA to concentrations of 50%, 25%, 12.5%, 8%, 6%, 4%, 2% and 0% mutant alleles. 
Arrows highlight the peak relating to the mutant allele. Traces from A highlight the difficulty in 
identifying the presence of mutant peaks beyond 12.5% mutant alleles, compared to traces from B 
and C where de novo peaks are generated.
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3.3.2 Tumour samples
We collected FFPE tumour blocks from 1489/1630 (91.3%) patients from Arms A 
and B of COIN. One-hundred and seventy-three (11.6%) blocks contained 
insufficient tumour material for processing. For the remaining samples, 1245 (94.6%) 
were from the primary CRC, 51 (3.9%) were from liver metastases and 20 (1.5%) 
were from the lymph metastases.
3.3.3 Comparison of Pyrosequencing and Sequenom
We screened for somatic mutations in KRAS (codons 12, 13 and 61) and BRAF 
(codon 600) using both Pyrosequencing and Sequenom, and in BRAF (codon 594), 
NRAS (codons 12 and 61) and PIK3CA (codons 542, 545, 546 and 1047) using just 
Sequenom. In total, 1,091 samples were successfully analysed for KRAS mutations 
by both technologies and 5803/5860 (99.0%) genotype calls were concordant. For 
BRAF V600E, 884 samples were successfully analysed by both technologies and 
869/884 (98.3%) genotype calls were concordant (a breakdown of concordance 
according to individual nucleotides of KRAS and BRAF is provided in Table 3.3). 
Twenty-six out of 57 samples with discordant KRAS calls and 8/15 samples with 
discordant BRAF calls were successfully Sanger sequenced to infer genotype. For 
the remaining calls where Sanger sequencing failed, the mutant genotype was 
selected (since there was an obvious mutant trace via one technology). Both 
technologies had high genotype success rates; 1263 of a possible 1308 (96.6%) 
samples successfully analysed for Sequenom and 1122/1190 (93.6%) for 
Pyrosequencing.
3.3.4 Frequency and distribution of somatic mutations identified
In total, for KRAS we successfully genotyped 1294/1316 samples (98.3%), for BRAF 
1291/1308 samples (98.7%), for NRAS 1290/1308 samples (98.6%) and for PIK3CA 
1256/1308 samples (96.0%). We detected twelve KRAS mutations (G12A, G12D, 
G12V, G12C, G12R, G12S, G13C, G13D, G13V, Q61H, Q61L and Q61R), six BRAF 
mutations (D594G, V600E and four that were uncharacterised), five NRAS mutations 
(G12C, Q61K, Q61L, Q61R and one that was uncharacterised) and five PIK3CA 
mutations (E542K, E545K, Q546K, H1047L, H1047R). Overall, KRAS mutations 
were found in 565/1294 aCRCs (43.7%), BRAF mutations in 102/1291 aCRCs 
(7.9%), NRAS mutations in 50/1290 aCRCs (3.9%), and PIK3CA mutations in
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156/1256 aCRCs (12.4%). Of the PIK3CA mutant samples, 107 samples had an 
exon 9 mutation and 50 samples had an exon 20 mutation (1 sample had a mutation 
in both exons). In those samples where genotypes were missing for rare mutations 
(those with cumulative frequencies <1%), but where all other mutations were 
successfully tested as wild-type, then an overall call of wild-type was made at that 
locus. The frequencies of individual variants and overlap of mutations across genes 
are shown in Table 3.4 and Figure 3.3 respectively. MSI was found in 44/969 (4.5%) 
successfully analysed CRCs. No tumours had mutations in KRAS and BRAF, 
although we did find a small number carrying both KRAS and NRAS mutations 
(11/565, 1.9%). Mutations in both KRAS and PIK3CA were frequently observed 
(90/565 (15.9%)) -  analysis of PIK3CA mutations within this group revealed that 
exon 9 mutations significantly co-occurred with KRAS mutations (67/565 (11.86%) in 
KRAS mutant versus 40/729 (5.49%) in KRAS wild-type; X2=13.583, P=0.0002) but 
exon 20 mutations did not (24/565 (4.25%) in KRAS mutant versus 24/729 (3.29%) 
in KRAS wild-type; X2=0.519, P=0.4711) (Figure 3.4). There was no evidence for any 
individual or group of mutations of KRAS or PIK3CA accounting for this significant 
association. MSI occurred within all mutation sub-groups though there was a 
significant association between MSI and mutations of BRAF (9/102 (8.82%) in BRAF 
mutant versus 35/1189 (2.94%) in BRAF wild-type; X2=7.227, P=0.0072) (Figure 3.5).
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Gene Nucleotide Mutation
No. samples 
successfully 
sequenced 
by both 
technologies
No. of 
calls that 
agree with 
consensus
Call 
success 
rate (%)
No.
incorrect
calls
(Pyro)
No.
incorrect
calls
(Sequenom)
G12C 0 1
34 G12R 1106 1099 99.37 1 0
G12S 1 4
G12A 2 0
35 G12D 1109 1079 97.29 9 3
KRAS
G12V 9 7
37 G13C 1102 1098 99.64 4 0
38
G13D
1100 1088 98.91
3 8
G13V 0 1
182
Q61L
812 811 99.88
0 0
Q61R 1 0
183 Q61H 631 628 99.52 1 2
BRAF 1799 V600E 884 869 98.30 14 1
Table 3.3 -  Table highlighting the sensitivity of Pyrosequencing and Sequenom 
towards individual mutations of KRAS and BRAF. Pyro - Pyrosequencing
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Arm A Arm B Total
no. of samples with no. of samples with no. of samples with
Gene Mutation mutations/no. mutations/no. mutations/no.
successfully analysed successfully analysed successfully analysed
KRAS G12A 23/635 (3.62%) 11/659(1.67%) 34/1294 (2.63%)
KRAS G12D 74/635(11.65%) 94/659 (14.26%) 168/1294 (12.98%)
KRAS G12V 59/635 (9.29%) 82/659 (12.44%) 141/1294(10.90%)
KRAS G12C 23/635 (3.62%) 14/659 (2.12%) 37/1294 (2.86%)
KRAS G12R 6/635 (0.94%) 5/659 (0.76%) 11/1294 (0.85%)
KRAS G12S 14/635 (2.20%) 20/659 (3.03%) 34/1294 (2.63%)
KRAS G13C 3/635 (0.47%) 2/657 (0.91%) 5/1292 (0.39%)
KRAS G13D 56/635 (8.82%) 54/659 (8.19%) 110/1294(8.50%)
KRAS G13V 0/635 (0%) 1/659 (0.15%) 1/1294 (0.08%)
KRAS Q61H 5/518 (0.97%) 8/541 (1.48%) 13/1059(1.23%)
KRAS Q61L 2/633 (0.32%) 3/656 (0.46%) 5/1289 (0.39%)
KRAS Q61R 3/633 (0.47%) 3/656 (0.46%) 6/1289 (0.47%)
Total
KRAS
268/635 (42.20%) 297/659 (45.07%) 565/1294 (43.66%)
BRAF V600E 50/631 (7.92%) 40/660 (6.06%) 90/1291 (6.97%)
BRAF D594G 7/622 (1.13%) 5/655 (0.76%) 12/1277 (0.94%)
Total
BRAF
57/630 (9.05%) 45/661 (6.81%) 102/1291 (7.90)
NRAS G12C 0/621 (0%) 11/653(1.68%) 11/1274 (0.86%)
NRAS Q61K 10/612(1.63%) 12/634(1.89%) 22/1246(1.77%)
NRAS Q61L 2/633 (0.32%) 5/652 (0.77%) 7/1285 (0.54%)
NRAS Q61R 6/633 (0.95%) 3/652 (0.46%) 9/1285 (0.70%)
Total
NRAS
18/631 (2.85%) 32/659 (4.86%) 50/1290 (3.88%)
PIK3CA E542K 20/612 (3.27%) 22/634 (3.47%) 42/1246 (3.37%)
PIK3CA E545K 27/613 (4.40%) 29/636 (4.56%) 56/1249 (4.48%)
PIK3CA Q546K 3/610 (0.49%) 10/629(1.59%) 13/1239(1.05%)
PIK3CA H1047L 10/615 (1.63%) 13/632 (2.06%) 23/1247 (1.84%)
PIK3CA H1047R 13/615(2.11%) 14/632 (2.22%) 27/1247 (2.17%)
Total
PIK3CA
71/617(11.51%) 85/639 (13.30%) 156/1256 (12.42%)
Table 3.4 -  Summary of mutation frequencies across all four genes analysed. 
Frequencies are displayed for Arms A and B of COIN, and combined. Total numbers 
per locus to do not exactly match individual numbers since: (i) for KRAS, four 
samples contained two independent mutations and four other samples contained 
uncharacterised mutations, (ii) for NRAS, one sample contained an uncharacterised 
mutation and, (iii) for PIK3CA, five samples contained two independent PIK3CA 
mutations.
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NRAS mutant 
samples 50
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samples 565
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samples 102
Figure 3.3 - Venn diagram depicting the overlap between tumours carrying different mutations in our 
cohort. KRAS mutant samples are depicted in dark green, BRAF mutant samples in yellow, NRAS 
mutant samples in blue, and PIK3CA mutant samples in purple.
A P=0.0002
KRAS mutant KRAS wild-type
498 67 68940
}IK3CA exon 
9 mutant
B
P-0.4711KRAS mutant KRAS wild-type
541 705
PIK3CA exon 
20 mutant
Figure 3.4 -  Venn diagram depicting the overlap between KRAS and PIK3CA mutations according to 
exon. (A) There is a significant overlap between PIK3CA exon 9 mutations and KRAS mutations 
(X2=13.583, P=0.0002) that is not present in KRAS wild-type tumours. (B) There is no significant 
overlap between PIK3CA exon 20 mutations and KRAS mutant or wild-type states. One patient had a 
mutation of both exons.
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P=0.0072
BRAF mutant
1154
MSI
44
Figure 3.5 -  Venn diagram depicting the overlap between BRAF mutations and MSI (X2=7.227, 
P=0.0072) that is not present in BRAF wild-type tumours.
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3.3.5 Analysis of somatic mutation status and response to cetuximab
3.3.5.1 KRAS mutation status and response to cetuximab
We found no evidence for improved OS in patients with KRAS wild-type tumours 
administered cetuximab (median survival 17.0 months) as compared to those that 
did not receive cetuximab (median survival 17.9 months) (HR 1.04, 95% Cl 0.87- 
1.23, P=0.67) (Figure 3.6A). Nor was there evidence of an improvement or decline in 
OS in patients with KRAS mutant tumours administered cetuximab (HR 0.98, 95% Cl 
0.81-1.17, P=0.80) (Figure 3.6B). Similarly for PFS, patients with KRAS wild-type 
(HR 0.96, 95% Cl 0.82-1.12, P=0.60) (Figure 3.6C) and mutant tumours (HR 1.06, 
95% Cl 0.90-1.26, P=0.47) (Figure 3.6D) failed to show a benefit from cetuximab use.
3.3.5.2 KRAS, BRAF and NRAS mutation status and response to cetuximab
Analysis of patients wild-type for all of KRAS, BRAF and NRAS also revealed a lack 
of benefit from cetuximab in terms of OS (median OS 20.1 versus 19.9 months, HR 
1.02, 95% Cl 0.83-1.24, P=0.86) (Figure 3.7A) and PFS (HR 0.92, 95% Cl 0.78-1.10, 
P=0.36) (Figure 3.7C). There was no improvement or decline in response to 
cetuximab in patients with a mutation of any of these gene (HR 1.00, 95% Cl 0.85- 
1.18, P=0.96) (Figure 3.7B).
Exploratory analysis of the COIN trial data identified a subset of patients most likely 
to gain benefit from cetuximab treatment. These were patients that were ‘all wild-type’ 
for KRAS, BRAF and NRAS, received OxFU (HR 0.72, P=0.04) instead of OxCap 
(HR 1.02, P=0.88, P for interaction^. 10) and had 0/1 metastatic sites (HR 0.73, 
P=0.03) instead of 2 or more (HR 1.07, P=0.56, P for interaction^.04). This 
subgroup of patients, deemed the most responsive cohort, showed significant benefit 
for PFS (n=96, HR 0.55, 95% Cl 0.35-0.87, P=0.01) and a trend towards improved 
OS (HR 0.63, 95% Cl 0.38-1.05, P=0.076) (Figure 3.8).
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Figure 3.6 -  Kaplan-M eier curves of O S in (A) KRAS wild-type, (B) KRAS mutant 
patients, and PFS in (C) KRAS wild-type, (D) KRAS mutant patients. OxFp indicates 
that patients received oxaliplatin plus a fluoropyrimidine (5FU or capecitabine).
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Figure 3.7  -  Kaplan-M eier curves of O S in (A) KRAS, BRAF and NRAS wild-type, (B) 
KRAS, BRAF and NRAS mutant patients and PFS  in (C ) KRAS, BRAF and NRAS 
wild-type samples, (D) KRAS, BRAF and NRAS mutant patients. OxFp indicates 
that patients received oxaliplatin plus a fluoropyrimidine (5FU  or capecitabine).
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Figure 3.8 -  Kaplan-Meier curves of OS (A) and PFS (B) in the most responsive 
cohort. These patients were wild-type for KRAS, BRAF and NRAS, had <1 
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3.3.5.3 PIK3CA mutation status and response to cetuximab
We found that patients with PIK3CA wild-type tumours did not show improved OS or 
PFS upon treatment with cetuximab, regardless of chemotherapy regimen (OS HR
1.01, 95% Cl 0.88-1.16, P=0.89 [any chemotherapy] and HR 0.95, 95% Cl 0.75-1.21, 
P=0.68 [OxFU]; PFS HR 0.98, 95% Cl 0.87-1.11, P=0.79 [any chemotherapy] and 
HR 0.88, 95% Cl 0.70-1.09, P=0.23 [OxFU]). We also found that patients with 
PIK3CA wild-type tumours did not show improved OS or PFS, regardless of somatic 
KRAS status (OS HR 1.03, 95% Cl 0.86-1.24, P=0.75 and PFS HR 0.91, 95% Cl 
0.77-1.07, P=0.25 [KRAS wild-type]) (Figures 3.9 and 3.10).
3.3.5.4 MSI status in COIN patients
There was a slight suggestion of an adverse effect on survival from cetuximab 
treatment among patients with MSI, but this did not reach significance due to the 
very small numbers (n=44; OS HR 1.26, 95% Cl 0.64-2.48, P=0.50; PFS HR 1.21,
95% Cl 0.65-2.28, P=0.55).
3.3.5.5 Individual somatic status and response to cetuximab
We also determined whether any individual mutations were consistently associated 
with an improvement or a decline in response to cetuximab within the full cohort and 
in those patients treated with OxFU (Figure 3.11). Several trends were observed, 
although all bar one were statistically insignificant. As expected, most somatic 
mutations were consistently associated with a poor response to cetuximab, for 
example patients with G12D in KRAS showed a decline in PFS in response to 
cetuximab (HR 1.29, 95% Cl 0.94-1.77, n=168 [any chemotherapy] and HR 1.42, 95% 
Cl 0.78-2.60, n=48 [OxFU]), as did patients with E542K in PIK3CA (HR 1.37, 95% Cl 
0.73-2.59, n=42 [any chemotherapy] and HR 1.37, 95% Cl 0.42-4.48, n=14 [OxFU]). 
However, patients with G12V in KRAS showed a modestly improved PFS in 
response to cetuximab (HR 0.92 95% Cl 0.65-1.31, n=141 [any chemotherapy] and 
HR 0.78, 95% Cl 0.43-1.41, n=55 [OxFU]) as did patients with E545K in PIK3CA (HR 
0.82, 95% Cl 0.47-1.42, n=56 [any chemotherapy], HR 0.75, 95% Cl 0.29-1.92, n=20 
[OxFU]).
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Figure 3.9 - Kaplan-M eier curves of OS in (A) PIK3CA wild-type, (B) PIK3CA mutant 
patients, and PFS in (C) PIK3CA wild-type, (D) PIK3CA mutant patients. OxFp  
indicates that patients received oxaliplatin plus a fluoropyrimidine (5FU or 
capecitabine).
91
IDr-
d
> o
££  3 o
CO
oo
oO ,
lO
o '
5 o
E lO ,d
w
m
CN
d
oo
o
OS
PIK3CA, Wild-type 
KRAS, Wild-type
H R =1.03 (0.86, 1.24) 
P=0.75
B
OS
PIK3CA, Mutant 
KRAS, Wild-type
H R =1.13 (0.61, 2.08) 
P=0.69
12 18 24 30 36 42 48
Time (months)
12 18 24 30 36 42 48
Time (months)
Interaction HR=1.08 (0.57, 2.04); P=0.81
 Arm A (OxFp)
 Arm B (OxFp + cetux)
PFS
PIK3CA, WiId-type 
KRAS, W ld-type
HR=0.91 (0.77, 1.07) 
P=0.25
PFS
PIK3CA, Mutant 
KRAS, Wild-type
H R =1.39 (0.81, 2.38) 
P=0.23
12 18 24 30 36 42 48 0 6 12 18 24 30 36
Time (months) Time (months)
Interaction HR=1.55 (0.89, 2.68); P=0.12
42 48
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Figure 3.11 - Forest plots depicting PFS hazard ratios for individual mutations within KRAS, BRAF, NRAS and PIK3CA genes for patients that received any 
chemotherapy (Left; There was insufficient data to estimate the effects of KRAS G13C, G13V and NRAS G12C) and those that received only OxFU (Right; 
There was insufficient data to estimate the effects of KRAS G12R, G13C, G13V, Q61H, Q61R, NRAS G12C, Q61L, Q61R and PIK3CA Q546K). After 
correction for multiple testing, all observations were non-significant (P>0.999).
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It has been suggested that patients with KRAS p.G13D-mutated tumours treated 
with cetuximab have longer OS and PFS as compared to patients with other KRAS- 
mutated tumours. However, we found that patients with G13D treated with cetuximab 
showed no difference in OS (HR 1.04, 95% Cl 0.68-1.59, P=0.86 [any 
chemotherapy]) or PFS (HR 1.11, 95% Cl 0.76-1.63, P=0.59 [any chemotherapy];
HR 1.07, 95% Cl 0.51-2.24, P=0.86 [OxFU]) as compared to wild-types (OS; HR 
1.04, 95% Cl 0.87-1.23, P=0.67, P for interaction 0.99 and PFS; HR 0.96, 95% Cl 
0.82-1.12, P=0.60, P for interaction 0.40) and as compared to patients with other 
KRAS mutations (OS; HR 0.96, 95% Cl 0.78-1.18, P=0.72, P for interaction 0.79 and 
PFS; HR 1.05, 95% Cl 0.87-1.27, P=0.61, P for interaction 0.76).
Recent data (De Roock et al. 2010a) has highlighted how mutations of different 
exons of PIK3CA might alter response to cetuximab in different ways. Considering 
individual mutations from these exons (E542K, E545K and Q546K at exon 9 and 
H1047L and H1047R at exon 20), we show no evidence for differential effects on 
response.
3.3.6 Prognostic impact of somatic mutations
Irrespective of treatment received, median OS was shorter in those patients who had 
mutations in any of KRAS, BRAF and NRAS (n=706, 13.6 months) than among 
those whose tumours were all wild-type in these oncogenes (n=581, 20.1 months; 
log-rank test P<0.001, Figure 3.12). If the mutational type is separated, median OS is 
shorter in those patients who had mutations in BRAF (n=102, 8.8 months) than 
among those with a mutation in KRAS (n=548, 14.4 months) or NRAS (n=38, 13.8 
months). A global test for differences in these curves was highly significant (P<0.001) 
as was a test for trend (P<0.001, Figure 3.13). A prognostic effect of patients’ tumour 
mutation status was also observed on PFS, with median PFS time ranging from 5.6 
months for patients who were BRAF mutant to 9.0 months for those patients with 
KRAS, NRAS and BRAF all wild-type.
We found no prognostic effects for PIK3CA mutations over PFS (any mutation [HR 
1.06, 95% Cl 0.89-1.26, P=0.50] or split between exons 9 [HR 1.09, 95% Cl 0.89- 
1.33, P=0.43] and 20 [HR 0.98, 95% Cl 0.73-1.33, P=0.91]).
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Figure 3.12 -  OS of patients with a mutation in any of KRAS, BRAF and NRAS 
versus those all wild-type, irrespective of treatment.
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Figure 3.13 -  OS of patient all wild-type across KRAS, BRAF and NRAS (green) 
versus those wild-type for BRAF but with a mutation of KRAS (purple), those wild- 
type for BRAF but with a mutation of NRAS (blue) and those with only a mutation of 
BRAF (orange line).
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3.4 Discussion
Here, we tested Pyrosequencing and Sequenom for high-throughput somatic 
mutation detection. We found that both assays robustly detected low levels of mutant 
alleles (provided that the Pyrosequencing extension primers were designed to 
generate de novo peaks) with all mutations tested being detected in samples with 
12.5% mutant alleles. This equated to a tissue sample containing at least 25% 
tumour tissue, which is easily achievable after macrodissection or LCM. Previous 
studies have also suggested that these platforms have equal mutation detection 
sensitivities, with superior detection limits as compared to traditional Sanger 
sequencing (Thomas et al. 2007). Our analyses based on over 6,700 somatic 
genotypes, showed that both platforms had over 98% genotype concordance and 
high genotype success rates. However, the main advantage of the Sequenom 
platform is the ability to multiplex the reactions and herein we describe a 3-assay 
system to screen for a total of 33 somatic mutations within the Ras-Raf-MAP and 
PI3K-PTEN-Akt pathways. We propose that this validated system can now be 
introduced into routine clinical diagnostic practice.
We found no benefit for the addition of cetuximab to standard oxaliplatin and 
fluoropyrimidine based therapy in patients that were wild-type for KRAS. As 
expected, there was also no evidence for response in patients that carried a 
mutation of KRAS. Since other components of the RAS-RAF-MAPK signalling 
cascade have been implicated in altering response to cetuximab, we tested BRAF 
and NRAS in addition to KRAS. However, even this all wild-type cohort did not show 
any evidence of a benefit from addition of cetuximab. Through exploratory analysis, 
we have shown that cetuximab improved PFS in patients with <1 metastatic sites, 
KRAS, BRAF and NRAS wild-type tumours and where the partner chemotherapy 
was OxFU (HR 0.55, 95% Cl 0.35-0.87, P=0.01). The implications of this most 
responsive cohort are discussed in chapter 07.
It has recently been reported that patients with PIK3CA exon 20 mutations treated 
with cetuximab have worse response rates, PFS and OS as compared with wild-type 
patients (DeRoock etal. 2010a). Therefore, we considered whether PIK3CA 
mutations might have a similar effect in our cohort. We did not find any detrimental 
effect for carriers of exon 20 mutations nor did we find that patients with PIK3CA
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wild-type tumours (or those with exon 20 wild-type tumours) had improvements in 
OS or PFS upon treatment with cetuximab, regardless of chemotherapy regimen or 
somatic KRAS status. There was a significant association between PIK3CA exon 9 
mutations and KRAS. The reason for this association may lie in the independent 
biological roles played by the different mutations of PIK3CA. Exon 9 mutations lie in 
the helical domain of the protein while exon 20 mutations lie in the kinase domain 
(Zhao et al. 2008). Though mutations of both exons result in activated Akt signalling, 
they have different requirements for interaction with the PI3K regulatory subunit p85 
and with GTP bound Ras. Specifically, the gain of function coinciding with exon 9 
mutations requires interaction with GTP bound Ras but is independent of binding to 
p85. Conversely, mutations of exon 20 require p85 binding but are independent of 
GTP bound Ras. As such, it has been suggested that mutations in these two 
domains represent two entirely distinct mutational states which differ in protein 
surface charge and conformational properties. This may explain the differences in 
cetuximab efficacy observed in the original De Roock (2010a) study, as well as the 
various other conflicting studies of PIK3CA (as discussed in chapter 1). In further 
support of there being distinct mutational states, the two exons have differing effects 
over breast cancer survival (Kalinsky et al. 2009; Lai et al. 2008).
It has also recently been reported that different somatic mutations within the Ras- 
Raf-MAP pathway have differential effects on response to cetuximab, with patients 
with KRAS p.G13D-mutated tumours benefiting from treated with cetuximab (De 
Roock et al. 2010b). However, we failed to find any such differences. Indeed, 
patients with G13D in KRAS treated with cetuximab trended towards worse OS and 
PFS, regardless of chemotherapy regimen or KRAS status. It may be that the 
observation of De Roock and colleagues is a consequence of the use of small 
cohorts of patients harbouring individual somatic mutations or a lack of control for 
confounding factors; of their pooled analysis of seven trials, only one (CO. 17) 
randomised for cetuximab and in this group the effect of G13D was not significant.
Here we report that strongly significant prognostic roles were observed for mutant 
KRAS and BRAF with median survival ranging from 20.1 months for ‘all wild-type’ 
patients to 14 months for patients with a mutation of KRAS and 8.8 months for those 
with a BRAF mutation. The prognostic role of these genes (especially KRAS) had
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been the subject of much debate prior to the completion of the COIN trial (as 
discussed in chapter 1). This data argues in the favour of these genes carrying 
important prognostic impact which should be considered in future trials as 
stratification factors or inclusion/exclusion criteria.
3.4.1 Future work
There is still much that is not understood about what causes patients to respond or 
not respond to certain treatments. The results of the COIN trial, combined with that 
of other clinical trials suggest that the correct clinical use of cetuximab in the 
treatment of CRC is still not entirely understood. Further studies will consider other 
components of the signalling pathways that operate downstream of EGFR such as 
PTEN, Akt, as well as those that operate in parallel pathways (e.g. IGF). Though not 
validated here, it is possible that individual mutations of these key genes could have 
different effects upon response. Larger cohorts with greater power will allow for a 
much greater understanding of the roles they play.
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Chapter Four - A variant in the EIF3H promoter influences colorectal cancer 
risk, patient survival and response to treatment
4.1 Introduction
Each year in the UK, more than 37,500 people are diagnosed with CRC 
(http://info.cancerresearchuk.org), with over a million new cases worldwide. The five- 
year relative survival rates for male and female CRC patients in the UK have 
doubled between the early 1970s and mid-2000s (from -22-27% to -50-55%) as a 
result of earlier diagnosis and better treatment (http://info.cancerresearchuk.org) 
(Rachet et al. 2009). Still there remains a need for improvements in the diagnosis 
and treatment of the disease. The search for risk factors (both high- and low- 
penetrance) of CRC is an ongoing effort that has provided some clues as to the 
aetiology of the disease.
High-throughput arrays for single nucleotide polymorphisms (SNPs) have opened 
new avenues for marker discovery by moving from hypothesis-driven targeted 
research to unbiased screens of the whole genome (Walther et al. 2009). To-date, 
these arrays have generally been used to search for disease susceptibility alleles by 
GWAS. Several studies have conducted multistage GWA for CRC and identified 
fourteen low penetrance susceptibility loci mapping across the genome. The role of 
these variants in aCRC with metastatic disease is unknown. Furthermore, none of 
these variants have been shown to affect patient outcome or response to treatment.
Here, we analysed twenty-two SNPs across ten of the fourteen loci identified from 
GWAS for CRC or that were highly significant in a subsequent meta-analysis, in a 
large collection of aCRC patients that had been recruited into the randomised 
controlled trials (RCTs) COIN and COIN-B, together with 2,176 healthy controls. We 
tested SNPs that contributed to the advanced setting for their prognostic potential 
and determined the underlying mechanism of action at 8q23.
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4.2 Materials and Methods
4.2.1 Samples
We analysed 2,186 blood DNA samples from patients with aCRC from COIN (2,073 
samples) and COIN-B (113 samples). Please refer to section 3.2.1 and Figure 3.1 for 
details of COIN samples. COIN-B is a MRC-funded, open-label, UK national phase II 
trial, examining intermittent chemotherapy plus cetuximab (target accrual of 158 
patients). All patients gave fully informed consent for their samples to be used for 
bowel research. We also analysed 2,176 blood DNA samples from healthy controls 
from the UK Blood Services collection of Common Controls (UKBS collection).
These samples were selected from a total of 3,092 samples within the UKBS 
collection that best matched the patients with aCRC in terms of place of residence 
within the UK. The UKBS samples had appropriate ethical approval. 
Clinicopathological features are described in Table 4.1.
4.2.2 Genotyping
Genotyping of twenty-three previously identified CRC risk alleles was performed by 
lllumina's Fast-Track Genotyping Services (San Diego, CA) using their high 
throughput BeadArray™ technology. Genotyping of rs28649280 was carried out by 
Geneservice (Nottingham, UK) using a TaqMan assay (Applied Biosystems) while 
rs16888589 was genotyped by Kbiosciences (Herts, UK).
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COIN COIN-B Total cases Controls
(%) (%) (%) (%)
n = 2073 113 2186 2176
Age at diagnosis 
(aCRC)/Sampling 
(controls)
Mean
<20
20-49
61.54 
1 (0.0) 
232 (11.2)
61.16
0
13(11.5)
61.51 
1 (0.0) 
245(11.2)
43.7 
64 (2.9) 
1317(60.2)
50-59 549 (26.5) 27 (23.9) 576 (26.3) 602 (27.7)
60-69 845 (40.8) 49 (43.4) 894 (40.9) 193 (8.9)
70-79 435 (21.0) 22(19.5) 457 (20.9) 0
80-89 9(0.1) 2(1.8) 11 (0.5) 0
Missing 2(0.1) 0 2(0.1) 0
Sex Female 698 (33.7) 48 (42.5) 746 (34.1) 1074 (49.4)
Male 1375 (66.3) 65 (57.5) 1440 (65.9) 1102 (50.6)
WHO-PS 0 969 (46.7) 58 (51.3) 1027 (47.0) -
1 951 (45.9) 46 (40.7) 997 (45.6) -
2 153 (7.4) 9 (8.0) 162 (7.4) -
Primary Site Colon 1119(54.0) 37 (32.7) 1156 (52.9) -
Rectum 653 (31.5) 32 (28.3) 685 (31.3) -
RSJ 297 (14.3) 10(8.8) 307 (14.0) -
Other 3(0.1) 34 (30.1) 37(1.7) -
Missing 1 (0.0) 0 1 (0.0) -
Number of 
metastatic sites
0
1
14 (0.7) 
737 (35.6)
1 (0.9) 
43 (38.1)
15(0.7) 
780 (35.7)
-
2 815(39.3) 50 (44.2) 865 (39.6) -
£3 507 (24.5) 19(16.8) 526 (24.1) -
Metastatic sites Liver only 459 24 483 _
Liver + Nodal 691 34 725 -
Liver + Lungs 594 24 618 -
Liver +
Peritoneum 202 9 211 -
Liver + Other 184 15 199 -
No Liver 520 33 553 -
Table 4.1 - Clinicopathological data for cases (COIN and COIN-B) and controls. 
Abbreviations: RSJ - Rectosigmoid Junction
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4.2.3 RT-PCR and RACE
RT-PCR was carried out using human colonic first strand cDNA (Stratagene) with 
forward primers in either the first (RT1F 5’-GCACAAAGGATACCGCCTGGAAAG-3’) 
or second (RT2F 5 -CTTCCTGTCTGCTTGGAAAGATGG-3’) predicted EIF3H exons 
in combination with reverse primers in exons 2 (RT2R 5’- 
GGCCATCTATCTGCACTTGCTTCAC-3’), 3 (RT3R 5’- 
C AAAGT CAGCAT CAT CCT CT GT GT GC-3’), 4 (RT4R 5’- 
AGGAGTGCCCGGGTAACGAATGAG-3’) and 5 (RT5R 5’- 
CCTTTAGTGAGAGAGATCCTTGGGCAGT-3’). Products were analysed on 2% 
agarose gels. RACE was performed on human colonic Marathon ready cDNA using 
the primers (RT2R) and (RT4R). Products were cloned into pGEM-T Easy, 
transformed into JM109 E.coli and sequenced.
4.2.4 DNA and RNA extraction from FFPE CRCs and MSI analyses
10pm sections were cut from FFPE CRCs and stained with haematoxylin and eosin. 
Tumour material was obtained by macrodissection or laser capture microdissection. 
DNA was extracted using DNA microkits and analysed for MSI using the markers 
BAT-25 and BAT-26. RNA was extracted using the ‘RecoverAII Total Nucleic Acid 
Isolation’ Kit (Ambion) and converted to cDNA using the High-Capacity cDNA 
Reverse Transcription kit (Applied Biosystems).
4.2.5 Real-Time PCR
EIF3H targeted Taqman assays Hs01052033_m1 (spanning exons 2 and 3), and 
Hs00186779_m1 (spanning exon 6 and 8) (Applied Biosystems) were used in gene 
expression analysis, along with Taqman Universal PCR master mix. Human B2M 
was used as an endogenous control (Kheirelseid etal. 2010).
4.2.6 Immunohistochemistry
Immunohistochemistry was carried out using primary antibodies against EIF3H 
(D9C1, Cell signalling), FGF-2 (sc-79; Santa Cruz Biotechnology), C-myc (sc-40; 
Santa Cruz Biotechnology) and cyclin-D1 (sc-8396; Santa Cruz Biotechnology). 
Staining was scored blind with respect to the genotypes.
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4.2.7 Luciferase assay
The potential EIF3H promoter region was PCR amplified using the primers; (LUC 
ASSAY F4 -  5’-ACTAAGCTTATACCGCCTGGAAAGAAGGT-3’; LUC ASSAY R4 - 
5’- TACTGCCATGGCCAAGCAGACAGGAAGAAAGA-3’ and ligated into a reporter 
construct which was then transformed into JM109 E.coli. The luciferase vector and 
internal control plasmid DNA (Promega’s pRL-CMV), were transiently transfected 
into Human Embryonic Kidney 293 cells. Six replicates were transfected with each 
reporter construct and each transfection experiment was repeated at least four 
times. The relative luciferase activity was determined by comparing luciferase activity 
of pGL3 constructs against a pRL control reporter.
4.2.8 Statistical analyses
Single marker, haplotype and interaction association analyses were performed using 
PLINK software (Purcell et a/. 2007). To correct for multiple testing, we carried out 
10,000 permutations taking into account the LD between the markers. Case-only 
analysis of the clinicopathological data was performed using step-wise regression 
analyses using SPSS statistical software. Gender, WHO performance status (PS), 
number of metastatic sites, liver only metastases and MSI were analysed using 
logistic regression (coded as 0/1), age at diagnosis was analysed using linear 
regression and the primary site was analysed using nominal regression. This 
analysis was performed by Dr. Valentina Moskvina.
A Cox survival model was used, with OS as the outcome. The model-building 
process was: (i) each SNP was entered into a univariate model to test for individual 
prognostic value, (ii) all SNPs were entered into a single multivariate model to test 
for prognostic value independent of one-another, (iii) all SNPs were added to a 
model containing the known prognostic factors (WHO PS, number of metastatic 
sites, white blood cell [WBC] count, alkaline phosphatase levels and KRAS and 
BRAF mutation status) to determine whether they had additional prognostic value,
(iv) all SNPs and known prognostic factors were entered into a closed-test procedure 
multiple fractional polynomial (FP) model in order to construct the most efficient 
model (a P-value of 0.05 was used for all covariates for selection in the model).
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Prognostic analysis of toxicity (Arms A and C) -  gastrointestinal toxicity was defined 
as a per-patient maximum recorded CTC grade 3-5 for nausea, vomiting or 
diarrhoea and compared against a per-patient maximum CTC grade of 0-1. 
Haematological toxicity was defined as a per-patient maximum recorded CTC grade 
3-5 for platelets, haemoglobin, WBC or neutrophils and compared to a per-patient 
maximum CTC grade of 0-1. Skin toxicity was defined as a per-patient maximum 
recorded CTC grade 3-5 for nail changes, skin rash or hand-foot syndrome and 
compared to a per-patient maximum CTC grade of 0-1. For all toxicities, patients 
with a CTC grade of 2 were excluded in order to have a stronger differentiation 
between the most and least severe groups. All survival and toxicity based statistical 
analyses were run by David Fisher of the MRC CTU.
Statistical analyses for the real-time RT-PCR assays was performed using Bland- 
Altman (Bland and Altman, 1986) and two-sample T tests, and for the 
immunohistochemical staining using Mantel-Haenszel Chi-Squared tests.
Differences in relative luciferase activity were assessed using the Mann-Whitney 
test.
4.3 Results
4.3.1 Genotyping
Twenty-four SNPs that had been identified from GWAS as being associated with 
CRC (Tomlinson etal. 2007; Broderick etal. 2007; Jaeger etal. 2008; Tenesa etal. 
2008; Tomlinson et al. 2008; Houlston et a/. 2008) or that were significant at P< 10'5 
in a subsequent meta analysis (Houlston et al. 2008), were analysed with lllumina’s 
Assay Design Tool to determine their potential for locus conversion on the 
GoldenGate platform. One SNP (rs4951039) failed in silico locus conversion. The 
remaining twenty-three SNPs were genotyped in our case-control series (Figure 4.1). 
rs7837328 failed genotyping. For the remaining 22 SNPs, genotyping concordance 
rates for duplicate samples was 100% (1022/1022 genotypes were concordant), 
GenTrain scores ranged from 0.665 to 0.9655 and the overall genotyping success 
rate was 99% (95027/95964 genotypes were called successfully).
104
4.3.2 Associations with aCRC
We found that eleven SNPs representing five different loci were significantly over­
represented in aCRC cases or healthy controls at the 5% level (Table 4.2). After 
adjustment for multiple testing, rs16892766 at 8q23, rs10808555 and rs7014346 at 
8q24, rs4779584 at 15q13, and rs4939827 and rs12953717 at 18q21 remained 
significantly over-represented (Table 4.2). For each of these loci at least two SNPs 
were genotyped, therefore we tested whether combinations of SNPs at each locus 
altered risk. Using step-wise logistic regression analysis on the basis of an additive 
model, we found that only a single SNP at each locus was responsible for the 
disease association (rs4939827 at 18q21, rs16892766 at 8q23, rs4779584 at 15q13 
and rs10808555 at 8q24) with the other SNPs being in LD and moderately correlated 
with these risk alleles (rs12953717 tagged rs4939827 [^=0.623, D-0.931], 
rs11986063 and rs6983626 tagged rs16892766 [1^=0.427 and 0.746, D’=0.720 and 
0.932, respectively], rs10318 tagged rs4779584 [1^=0.550, D-0.748], and rs6983267 
and rs7014346 tagged rs10808555 [r^O.312 and 0.608, D’=0.824 and 0.840, 
respectively]).
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Figure 4.1 - Cluster plots of rs4939827 (18q21), rs16892766 (8q23), rs4779584 
(15q13), and rs10808555 (8q24), generated by lllumina’s GoldenGate assay.
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Cases Controls
OR Minor Major
SNP
number Chromosome
Position 
(build 37)
GenTrain
Score
allele
(A)
allele
<B) AA AB BB MAF AA AB BB MAF P-value
Corrected
P-value
rs4939827 18q21 46453463 0.8975 0.85 C T 433 1082 666 0.45 504 1113 558 0.49 0.000114 0.0027
rs16892766 8q23 117630683 0.7024 1.33 C A 15 396 1772 0.10 14 299 1862 0.08 0.000183 0.0034
rs4779584 15q13 32994756 0.7922 1.21 T C 123 737 1323 0.23 81 677 1413 0.19 0.000286 0.0059
rs12953717 18q21 46453929 0.665 1.15 T C 359 1064 419 0.48 311 1086 516 0.45 0.000439 0.0097
rs10808555 8q24 128409511 0.8554 1.15 C T 313 992 877 0.37 257 959 959 0.34 0.001923 0.0378
rs7014346 8q24 128424792 0.8166 1.14 A G 369 1030 784 0.40 314 993 866 0.37 0.002487 0.0477
rs10795668 10p14 8701219 0.7972 0.87 A G 196 909 986 0.31 226 968 889 0.34 0.003336 0.0635
rs6983267 8q24 128413305 0.7725 0.89 T G 439 1035 704 0.44 483 1067 617 0.47 0.00565 0.1029
rs11986063 8q23 117640315 0.9655 1.22 T C 22 427 1734 0.11 20 352 1801 0.09 0.005696 0.1034
rs10318 15q13 33025979 0.8188 1.16 T C 118 720 1345 0.22 78 692 1405 0.19 0.00596 0.1092
rs6983626 8q23 117802148 0.8584 1.18 T C 27 429 1727 0.11 19 376 1780 0.10 0.017557 0.2788
rs1862748 16q22 68832943 0.8914 0.92 T C 196 904 1083 0.30 214 944 1016 0.32 0.058368 0.6613
rs7259371 19q13 33534641 0.9362 1.11 A G 89 660 1431 0.19 82 602 1483 0.18 0.067813 0.7128
rs355527 20p12 6388068 0.7663 1.08 A G 261 990 932 0.35 236 956 983 0.33 0.07512 0.7486
rs961253 20p12 6404281 0.8814 1.07 A C 305 1034 843 0.38 281 1008 886 0.36 0.125169 0.8985
rs9929218 16q22 68820946 0.9119 0.93 A G 174 886 1121 0.28 181 930 1064 0.30 0.144065 0.9279
rs4444235 14q22 54410919 0.6814 1.06 C T 513 1059 607 0.48 459 1105 611 0.47 0.211965 0.9799
rs3802842 11q23 111171709 0.8738 1.06 C A 224 916 1043 0.31 216 874 1085 0.30 0.224882 0.9852
rs10411210 19q13 33532300 0.8834 1.07 T C 25 380 1778 0.10 23 356 1795 0.09 0.343304 0.9988
rs4951291 1q32 204006538 0.7298 0.95 T C 29 512 1636 0.13 29 538 1600 0.14 0.356811 0.9993
rs10749971 11q23 111189158 0.8868 1.02 G A 316 1018 847 0.38 309 1008 858 0.37 0.667828 1
rs11213809 11 q23 111135745 0.7223 1.01 A G 263 949 969 0.34 269 927 979 0.34 0.894664 1
Table 4.2 -  GWAS SNPs for CRC analysed in the advanced disease setting and healthy controls.
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For rs4939827 (OR 0.85, 95% Cl 0.78-0.93), the minor allele was associated with a 
decreased risk of CRC in a dose-dependent manner (ORhet 0.88, 95% Cl 0.76-1.03, 
ORhom 0.72, 95% Cl 0.61-0.85). For rs16892766 (OR 1.33, 95% Cl 1.14-1.55), 
genotype-specific ORs were most compatible with an over-dominant model 
(O R a c v s  a a  1.39, 95% Cl 1.18-1.64; O R a c v s .c c  1 24, 95% Cl 0.59-2.60). For 
rs4779584 (OR 1.21, 95% Cl 1.09-1.35), the minor allele was associated with an 
increased risk of CRC in a dose-dependent manner (ORhet 1 39, 95% Cl 1.03-1.88; 
ORhom 1.62, 95% Cl 1.21-2.17). A similar risk pattern was also observed for 
rs 10808555 (OR 1.15, 95% Cl 1.05-1.26; ORhet 118, 95% Cl 0.98-1.42; ORhom 1.33, 
95% Cl 1.10-1.61). We tested for potential haplotype effects for all markers at each 
of the significant loci. Although we found potential haplotype effects at the 8q24 and 
18q21 loci, the changes in risk were small and insignificant after correction for 
multiple testing.
Using case-only logistic regression analysis, we tested for associations between 
clinicopathological variables such as gender, age at diagnosis, WHO PS, primary 
site, number and location of metastatic sites and MSI, and the genotypes of 
rs4939827, rs16892766, rs4779584 and rs10808555. Although a number of 
associations were observed including rs4779584 and age at diagnosis and WHO 
PS, rs9929218 and number of metastatic sites, rs961253 and liver metastasis and 
rs7259371 and location of the primary tumour, none remained significant after 
correction for multiple testing.
4.3.3 Associations with patient survival
We tested whether rs4939827, rs16892766, rs4779584 or rs10808555 influenced 
patient survival by utilising clinical data from COIN. We found no imbalances in the 
frequencies of the four SNPs tested between the three treatment arms. We have 
previously shown that KRAS, BRAF and NRAS mutations are found in 42.27%, 
9.01% and 3.56% of the CRCs from patients in COIN (all trial Arms; Maughan et al. 
2011). We found no differences between the frequencies or the genotype 
distributions of the SNPs according to KRAS, BRAF and NRAS mutation status 
(Table 4.3).
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KRAS BRAF NRAS
wild-type mutant wild-type mutant wild-type Mutant 
N (%) N (%) N (%) N (%) N (%) N (%)
rs4939827
T T 311 202 469 43 498 161 1 (31%) (28%) (30%) (28%) (30%) (26%)
TC 480 372 774 77 813 32(49%) (52%) (50%) (51%) (50%) (52%)
CC 198 142 307 32 326 13(20%) (20%) (20%) (21%) (20%) (21%)
Total 989 716 1,550 152 1,637 61(100%) (100%) (100%) (100%) (100%) (100%)
rs16892766
AA 813 564 1,241 134 1,323 51(82%) (79%) (80%) (88%) (81%) (84%)
AC 170 148 299 17 303 10(17%) (21%) (19%) (11%) (19%) (16%)
CC 7(1% ) 4(1% ) 11 (1%) 1 (1%) 12(1%) 0 (0%)
Total 990 716 1,551 152 1,638 61(100%) (100%) (100%) (100%) (100%) (100%)
rs4779584
CC 603 416 927 91 977 37(61%) (58%) (60%) (60%) (60%) (61%)
CT 340 249 533 55 566 22(34%) (35%) (34%) (36%) (35%) (36%)
T T 47 51 91 6 95 2I I (5%) (7%) (6%) (4%) (6%) (3%)
Total 990 716 1,551 152 1,638 61(100%) (100%) (100%) (100%) (100%) (100%)
rs10808555
T T 400 292 636 55 655 33I I (40%) (41%) (41%) (36%) (40%) (54%)
TC 447 320 687 78 747 18(45%) (45%) (44%) (51%) (46%) (30%)
CC 143 104 228 19 236 10(14%) (15%) (15%) (13%) (14%) (16%)
Total 990 716 1,551 152 1,638 61(100%) (100%) (100%) (100%) (100%) (100%)
Table 4.3 - Genotype distributions of rs4939827, rs16892766, rs4779584 and 
rs10808555, and KRAS, BRAF and NRAS mutation status
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We tested for, but did not find, any effect for rs4939827, rs4779584 or rs10808555 
on OS (Figure 4.2, Table 4.4). However, for rs16892766, we found that patients 
carrying one or more of the minor alleles (AC or CC) showed a significant decline in 
OS as compared to patients carrying the AA genotype (HR 1.27, 95% Cl 1.12-1.44, 
P<0.001), equating to a median decrease in life expectancy of 2.9 months (Figure
4.2, Table 4.4).
To determine whether this finding was influenced by the type and duration of 
treatment, we evaluated rs16892766 according to trial Arm. The effects were 
significant across Arms A and B (HR 1.32, 95% Cl 1.06-1.64, P=0.012 and HR 1.45, 
95% Cl 1.17-1.79, P=0.001 respectively); however for patients treated with 
intermittent oxaliplatin and fluoropyrimidine chemotherapy (Arm C), the effect did not 
reach statistical significance (HR 1.10, 95% Cl 0.89-1.36, P=0.367), suggesting that 
rs16892766 may influence survival based upon an interaction with treatment.
We have previously shown that the WHO PS, number of metastatic sites, WBC 
count, alkaline phosphatase levels and KRAS and BRAF mutation status are 
independent prognostic factors affecting OS in patients with aCRC. We tested a 
multivariate model including these known prognostic factors and found that patients 
carrying one or more of the minor alleles for rs16892766 showed a significant 
decline in OS, independent of the known prognostic factors (Table 4.5).
4.3.4 Prognostic effects on response to and side effects from 12 weeks of 
chemotherapy
We tested to see if any of rs4939827, rs16892766, rs4779584 and rs10808555 
altered response to and side-effects from 12 weeks of oxaliplatin and 
fluoropyrimidine therapy (COIN Arms A and C only). We found no significant 
observations. Similarly, we tested these SNPs for a predictive effect on response to 
and side effects from 12 weeks of cetuximab treatment (COIN Arm B vs. Arms A and 
C combined) but found no significant observations.
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4.3.5 Delineating the mechanism underlying rs16892766
rs16892766 at 8q23.3 lies 26.4kb downstream of EIF3H, whereas the weaker CRC- 
associated SNPs rs6983626 and rs11986063 lie 34.1 kb upstream and 16.7kb 
downstream, respectively (Figure 4.3). Apart from a predicted transcript 
(UTP23/C8orf53) no other genes lie within this region, suggesting that EIF3H may 
play a direct role in colorectal tumourigenesis and survival outcome.
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Figure 4.2 - Kaplan-Meier curves for the effect of rs4939827, rs16892766, 
rs4779584, and rs10808555, on OS.
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Genotype(s) n HR (95% Cl) P-value
rs4939827
>1 minor alleles 
Homozygous minor allele
TC/CC
CC
1,431
403
1.00 (0.89-1.12) 
1.02 (0.89-1.17)
0.954
0.761
rs16892766
£1 minor alleles 
Homozygous minor allele
AC/CC
CC
389
13
1.27(1.12-1.44) 
1.00 (0.54-1.89)
<0.001
0.989
rs4779584
£1 minor alleles 
Homozygous minor allele
c t  r u
TT
825
115
0.97 (0.87-1.08) 
0.99 (0.79-1.24)
0.574
0.931
rs10808555
£1 minor alleles 
Homozygous minor allele
TC/CC
CC
1,234
298
0.96 (0.86-1.07) 
1.00 (0.86-1.16)
0.422
0.972
Table 4.4 -  Univariate analyses use Cox proportional-hazards models with the 
outcome of OS. Hazard ratios should be interpreted as the hazard in the genotype 
group indicated versus all other patients with a valid test result for that SNP.
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Variable HR (95% Cl) P-value
rs16892766 AC and CC vs. AA 
CC vs. AC and AA
1.28(1.13-1.45) 
1.24 (0.64-2.42)
<0.001
0.528
WHO PS 1 vs. 0
2 vs. 0
1.26(1.12-1.41)
1.73(1.39-2.16)
<0.001
<0.001
No. of metastatic 
sites
£2 vs. 0 or 1 1.26(1.12-1.42) <0.001
WBC ^10,000/pl vs. 
<10,000/pl
1.50(1.33-1.71) <0.001
Alkaline
phosphatase
>300U/I vs. <300U/I 1.71 (1.47-1.99) <0.001
KRAS status Mutant vs. wild-type 1.37(1.12-1.55) <0.001
BRAF status Mutant vs. wild-type 2.34(1.93-2.84) <0.001
Table 4.5 - Multivariate model including known prognostic factors. Table shows the 
results from a single, multivariate, Cox model with the outcome of OS (n=1,704 
patients).
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Figure 4.3 - Regional plot of the 8q23 region. Shown are the association statistics 
(as -logi0P) together with relative positions of EIF3H and UTP23.
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4.3.6 EIF3H sequencing
To identify potential pathogenic variants within EIF3H that were linked to 
rs16892766, we sequenced the entire EIF3H open reading frame and flanking 
intronic sequences in 124 aCRC cases (15 with the rs16892766-CC genotype, 94 
with the AC genotype and 15 with the AA genotype) and 126 healthy controls (14 
with the CC genotype, 97 with the AC genotype and 15 with the AA genotype). By 
using a total of 250 samples, we had over 90% power (0.05 significance level) to 
detect rare variants with MAFs of 0.005. In silico analyses of the EIF3H locus 
predicted two main transcripts which differed in their 5’ sequences; the largest 
transcript EIF3H-202 spanned 9 exons and contained an additional upstream exon 
as compared to EIF3H-201 (Figure 4.4). In total, we identified a single variant (IVS1- 
24 C>T) in one control sample and a common polymorphism (rs28649280) in the 
first predicted intron.
4.3.7 Analysis of rs28649280 in aCRC cases and controls
We genotyped rs28649280 in 2,186 cases with aCRC and 2,176 UKBS healthy 
controls (Figure 4.5). The genotype success rate was 96.5% and the concordance 
rate for duplicated samples was 100%. We found that rs28649280 conformed to the 
Hardy Weinberg equilibrium (P=0.867) and the minor allele was significantly over­
represented in cases (MAF=0.11) as compared to controls (MAF=0.095, P=0.022). 
Genotype-specific ORs (OR 1.18, 95% Cl 1.025-1.359) were most compatible with a 
multiplicative model of disease susceptibility (ORhet 1.21, 95% Cl 0.66-2.21; ORh0m 
1.42, 95% Cl 0.78-2.57). We observed that rs28649280 was in moderate LD with 
rs16892766 (^=0.441, D-0.734) and a logistic regression model for increased risk 
with both SNPs combined was not more significant as compared to rs16892766 on 
its own (P=0.84). We did not observe any associations between the 
clinicopathological variables and rs28649280 genotype.
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EIF3H-201 
EIF3H-202
Figure 4.4 - Diagrammatic representation of the predicted EIF3H transcripts (boxes 
represent exons and dotted lines represent splicing patterns). EIF3H-201 starts at 
exon 2, whilst EIF3H-202 starts at exon 1 and splices within exon 2. The positions of 
the primers used for RT-PCR and RACE are indicated.
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Figure 4.5 - Cluster plot defining the rs28649280 genotype of 2,186 aCRC cases 
and 2,176 UKBS healthy controls.
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4.3.8 rs28649280 influences OS and response to treatment
We found that under a univariate analysis, patients carrying one or more of the minor 
alleles for rs28649280 (CT or TT) showed a significant decline in OS as compared to 
patients carrying the CC genotype (HR 1.26, 95% Cl 1.12-1.43, P<0.001 and HR 
1.30, 95% Cl 1.13-1.49, P<0.001, after adjusting for known prognostic factors) 
(Figure 4.6). rs28649280 and rs16892766 were very similar in their prognostic 
strength under univariate and multivariate analyses both with and without other 
known prognostic variables.
We also examined rs28649280 for its potential prognostic effect on response to 12 
weeks of treatment with oxaliplatin and fluoropyrimidine (COIN Arms A and C only). 
We found that patients carrying one or more of the minor alleles showed a significant 
decline in 12 week response as compared to patients carrying the CC genotype (OR 
0.65, 95% Cl 0.48-0.87, P=0.004 and OR 0.60, 95% Cl 0.43-0.83, P=0.002, after 
adjusting for known prognostic factors). rs28649280 was not associated with 
gastrointestinal, haematological or skin toxicities. We also tested whether 
rs28649280 might act as a predictive factor for the addition of cetuximab (COIN Arm 
B vs. Arms A and C combined). rs28649280 was not found to be predictive factor in 
terms of 12-week response (x2=3.04, 2 d.f., F^O.218).
4.3.9 Role of rs16888589 in influencing OS
Recently, it has been suggested that rs16888589, which is in strong LD with 
rs16892766, acts as an allele specific, long-range, repressor of EIF3H transcription 
(Pittman et al. 2010). We typed rs16888589 in patients from COIN and COIN-B and 
found that it had similar prognostic effects to rs28649280 and rs16892766 on OS 
(HR 1.21, 95% Cl 1.07-1.37, P=0.002) and 12-week response to treatment (OR 
0.72, 95% Cl 0.54-0.97, P=0.031).
4.3.10 RT-PCR and RACE
We investigated the mechanism of action of rs28649280. First, we clarified the 
structure of EIF3H to determine whether the 1st predicted exon was transcribed 
within the colon. We carried out RT-PCR using cDNA from healthy colonic tissue 
using primers spanning exons 1-5 of EIF3H (Figure 4.4). We failed to generate any 
product using primers within the first predicted exon, but did generate products from
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the downstream exons (Figure 4.7, left). We also carried out 5’RACE on normal 
colonic cDNA, cloned and sequenced the products (Figure 4.7, right). These results 
confirmed that the first predicted exon was not transcribed within the colon and that 
the transcription start site was 14bp upstream from the predicted kozak translation 
initiation site in EIF3H-201 (Figure 4.8). rs28649280 therefore lies within a potential 
promoter region, 78bp upstream of the transcription start site used within the colon.
4.3.11 In silico analysis of the EIF3H promoter
We analysed the potential EIF3H promoter region used in the colon for transcription 
factor binding sites using TFSEARCH and determined their conservation through 
evolution by analysis of human, chimpanzee, dog, rhesus macaque, mouse and rat 
sequences using ClustalW. rs28649280 was found to lie in a potential Sp1 binding 
site (CCGCCCY) and the whole 7bp sequence was fully conserved in all species 
examined (Figure 4.8). Other conserved basal transcription factor binding sites 
(including CREB and Ets) were found adjacent to the Sp1 site, in support of this 
region acting as a promoter (Figure 4.8).
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Figure 4.6 - Kaplan-Meier curve depicting the effect of rs28649280 on OS. There 
was a difference in median OS of 2.9 months between the two groups.
M 1
Figure 4.7 - Left. 2% agarose gel of RT-PCR products using normal colonic cDNA 
as a template. Wells correspond to the reactions with the primers RT1F and RT3R 
(1), RT1F and RT4R (2), RT2F and RT3R (3), and RT2F and RT4R (4) as presented 
in Figure 4.4. M -  1kb marker. No products were generated with a forward primer in 
exon 1, indicating that this predicted exon was not transcribed within the colon.
Right 2% agarose gel of the 5’RACE product generated using RT4R. M -  500bp 
marker.
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Figure 4.8 - Species conservation of the EIF3H promoter. Species included were Pan troglodytes / chimpanzee (Pan), Homo 
sapiens / human (Homo), Macaca mulatta / rhesus macaque (Macaca), Canis lupus familiaris / dog (Canis), Mus musculus / mouse 
(Mus), Rattus norvegicus / rat (Rattus). Bases identical in all six species are indicated with an asterisk. Potential regulatory 
elements are shaded; SP1 sites - green, CREB site -  purple, Ets site - blue. The location of rs28649280 is indicated with red text 
and arrow. The transcription start site is coloured in scarlet and the translated sequence is shaded in grey (predicted initiator ATG 
boxed).
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4.3.12 Luciferase expression analysis
A luciferase construct, containing a 136bp region upstream of the EIF3H 
transcription start site that included rs28649280, showed promoter activity as 
compared to empty vector (P=0.0021). This construct, containing the major C allele 
of rs28649280, was further compared against one containing the minor T allele 
(Figure 4.9). Construct containing the minor allele showed significantly increased 
expression levels as compared to that containing the major allele (P=0.0003).
4.3.13 EIF3H expression and protein analyses
We tested whether rs28649280 or rs16892766 affected EIF3H expression levels by 
examining RNA extracted from FFPE CRCs using two different EIF3H Taqman 
assays. Bland-Altman analysis of the data confirmed a strong correlation between 
the two assays. Although EIF3H was expressed in most tumours, we did not observe 
any differences in expression levels in CRCs from patients with the rs28649280-TT 
as compared to the -CC genotypes or from patients with the rs16892766-CC as 
compared to the -AA genotypes (Figures 4.10 & 4.11). EIF3H is thought to alter 
protein synthesis of several oncoproteins (Zhang et al. 2008); however, we did not 
find any differences in the levels of cyclin-D1, c-Myc, FGF-2 or in EIF3H itself, by 
immunohistochemical analysis of CRCs from patients with a range of rs28649280 
and rs16892766 genotypes.
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Figure 4.9 -  Box and whisker plot depicting the differences in expression levels 
between reporter construct containing the major C allele of rs28649280, and 
construct containing the minor T allele. There is a significantly increased relative 
luciferase activity in the latter (P=0.0003)
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Figure 4.10 - Bar chart of EIF3H expression levels in CRCs from patients with rs28649280-CC and -TT genotypes. Fold differences in expression levels were
calculated relative to sample 1 (homozygous for the major allele). Each sample was analysed twice with two different assays (assay Hs01052033_m1, 
spanning exons 2 and 3 of EIF3H, is displayed in grey bars and assay Hs00186779_m1, spanning exons 6 and 8 of EIF3H, is displayed in black bars).
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Figure 4.11 - Bar chart of EIF3H expression levels in CRCs from patients with rs16892766-AA and -C C  genotypes. Each sample 
was analysed twice with two different assays (see legend to Figure 4.10).
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4.4 Discussion
To-date, the search for germline prognostic factors for CRC has focussed on the 
pharmacological pathways of the chemotherapeutic agents used in the treatment of 
this disease and in the pathways that are likely to influence tumour progression. 
High-throughput SNP arrays are now likely to transform marker discovery towards 
unbiased screens of the whole genome (Walther et al. 2009). So far, such arrays 
have primarily been used to search for disease susceptibility alleles. Here, we 
analysed twenty-two SNPs that have been identified from GWAS as being 
associated with CRC risk or that were significant at P<10'5 in a subsequent meta­
analysis, in the advanced disease setting. We failed to assay two of these SNPs 
(rs4951039 and rs7837328). However, rs4951039 at 1q32 is in complete association 
with rs4951291 (^=1, D’=1) which was successfully genotyped and found not to be 
associated with aCRC. Furthermore, rs7837328 at 8q24 tagged rs10808555 
(r2=0.50, D -0.82) and rs7014346 (^=0.83, D’=1) both of which were genotyped and 
shown to be over-represented in aCRC. In total, we found that six SNPs 
(representing loci at 8q23, 8q24, 15q13 and 18q21) were significantly over­
represented in either aCRC cases or healthy controls, with a single SNP of those 
tested at each locus driving the observed associations. We tested these SNPs for 
their prognostic potential and found that rs16892766 at 8q23 influenced OS.
We have attempted to elucidate the underlying mechanism of disease susceptibility 
and patient survival at 8q23. We identified a SNP, rs28649280, which was 
characterised as lying within a potential Sp1 promoter element of EIF3H, 78bp 
upstream of the transcription start site used in the colon. We showed that 
rs28649280 acted as a novel CRC-susceptibility allele and was associated with 
reduced OS and poor response to treatment. EIF3H encodes one of thirteen 
subunits of eukaryotic translation Initiation Factor 3 which is involved in the 
regulation of translation through its interaction with the 40S ribosome and other 
initiation factors. Five subunits of EIF3, including H, have oncogenic potential (Zhang 
et al. 2007) which is thought to be mediated via overexpression of these subunits 
leading to increased protein synthesis of numerous oncoproteins (Zhang et al. 2008).
EIF3H has been postulated to be responsible for polysome loading of mRNAs 
carrying upper ORFs (uORFs). These are found in the 5’ leader sequences of genes
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and inhibit translation initiation through a number of potential mechanisms (Sachs 
and Geballe, 2006). Critically, uORFs are found to cluster amongst mRNAs encoding 
regulatory proteins such as transcription factors and proto-oncogenes (Kozak, 1991). 
Current data suggests that EIF3H counteracts the inhibitory effects of uORFs, as 
well as preferentially boosting the translation of long mRNAs (Kim et al. 2007) in-turn 
defining a select group of mRNAs that undergo EIF3H dependant translation. Thus 
alterations in levels of EIF3H could conceivably lead to the altered translational state 
of numerous regulatory proteins. Indeed, such alterations have been observed for 
oncoproteins including cyclin D1, C-Myc, FGF2 and ornithine decarboxylase (Zhang 
et al. 2008).
We found that the minor allele of rs28649280 was associated with increased 
expression in a reporter gene assay system; however, we found no difference in the 
expression levels of EIF3H or in protein levels of FGF-2, C-myc and cyclin-D1 in 
CRCs from patients carrying the rs28649280 or rs16892766 risk alleles. Therefore, it 
is likely that the dysregulation of EIF3H expression and the downstream 
consequences that drive colorectal tumourigenesis, are masked by other cellular 
abnormalities that occur during progression to metastatic carcinoma. Further studies 
are therefore warranted to help unravel the mechanism through which EIF3H 
predisposes to CRC and affects patient outcome. Nonetheless, our findings raise the 
possibility that EIF3H may represent a suitable target for therapeutic intervention.
Though no studies have been conducted specifically targeting EIF3H, the related 
eukaryotic initiation factor 4E (EIF4E) has successfully been tested as a target in the 
pre-clinical setting. EIF4E binds the 5’ cap of cellular mRNAs and delivers them to 
the elF4F translation initiation complex. Like EIF3H, EIF4E enhances translation of a 
select set of mRNAs -  including elements that are critical in regulating a number of 
cellular processes, which are in-turn up-regulated when EIF4E is over expressed 
(e.g. cyclin-D1 (Rosenwald etal. 1993) and C-myc (De Benedetti etal. 1994)). Over­
expressed EIF4E ultimately leads to transformation of cells (Lazaris-Karatzas et al. 
1990; Zimmer etal. 2000) and increased EIF4E expression has been linked with 
initiation and progression of specific human malignancies including breast (Li et al. 
1997; Li etal. 1998), head and neck (Nathan et al. 1997), lung (Seki et al. 2002), and 
colorectal cancer (Rosenwald et al. 1999; Berkel et al. 2001). As shown by Graff and
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colleagues (2007), EIF4E can be targeted with antisense oligonucleotides (ASO). 
ASO targeting of EIF4E mRNA led to repression of EIF4E regulated proteins 
including VEGF, cyclin D1, c-myc and ultimately led to suppression of tumour 
growth. Moreover, tests of the effects of ASOs on normal tissue showed that, despite 
a clear reduction in the levels of EIF4E, there was little to no adverse effects. Initial 
clinical trials of ASOs are currently ongoing. Agents that inhibit the interaction of 
EIF4E with one of its functional partners, EIF4G, are also currently being tested as 
novel therapies (Moerke etal. 2007; Tamburini etal. 2009). Other novel approaches 
include inhibitors of phosphorylation of EIF4E (Topisirovic et al. 2004) and the use of 
agents that interfere with the EIF4E-5’ cap interaction (Kentsis et al. 2004; Assouline 
et al. 2009) have been employed with mixed success. It can be envisioned that 
similar approaches (Hsieh and Ruggero, 2010) could potentially be adopted in the 
therapeutic suppression of EIF3H in the treatment of CRC.
4.4.1 Future work
The functional mechanisms behind the 14 loci associated with CRC risk through 
GWAS have only just started to be understood. In the case of the association 
demonstrated at 8q23, further work is needed to confirm that EIF3H is indeed 
responsible for altering risk (and prognosis) of CRC. Recently, fine-mapping of the 
association signals at 8q23, 16q22 and 19q13, combined with data from expression 
quantitative trait loci (eQTL) databases suggest that the genes with the greatest 
biological plausibility for altering risk are not tagged by SNPs with the strongest 
association signal (Carvajal-Carmona et al. 2011). For example, the authors find that 
the SNPs with the greatest association signals at 8q23 alter expression of UTP23 
and not EIF3H.
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Chapter Five - Multiple colorectal cancer susceptibility alleles affect patient 
survival and rs9929218 in E-cadherin predicts response to cetuximab
5.1 Introduction
As described in chapter 1, screens for inherited genetic factors that affect prognosis 
have suggested that pharmacological pathways may play an important role.
However, the majority of prognostic biomarkers described to-date have not been 
confirmed in subsequent studies suggesting that many of the initial observations are 
false-positives due to the use of small, under-powered, sample sets and a lack of 
use of appropriate validation cohorts (Tejpar et al. 2010; Buyse et al. 2010). As 
discussed in chapter 4, one of the four validated CRC risk loci was shown to affect 
patient survival and response to treatment. Beyond this, no variants at the remaining 
loci have been shown to influence patient survival or to have a predictive effect on 
chemotherapy or drug response.
The treatment of aCRC is improving. Average survival has increased from ~6 
months with best supportive care alone, through 10-12 months with 5FU-based 
regimens (Maughan etal. 2002) and up to 16-20 months with oxaliplatin and 5FU 
(Douillard et al. 2000, Saltz et al. 2000). In addition, cetuximab has been shown to 
improve OS in patients with CRC in whom other treatments have failed (Jonker et al. 
2007). However, cetuximab efficacy is thought to be dependent upon an absence of 
somatic mutations in members of the EGFR signalling cascade such as KRAS and 
BRAF (De Roock et al. 2010). Despite these advances, around half of all patients 
still fail to respond to first line treatment (Allegra et al. 2009).
Here, we analysed SNPs from 12 CRC risk loci in a large collection of aCRC patients 
that had been recruited into the randomised controlled trials COIN and COIN-B. We 
tested for their prognostic effects on OS and response to, and side-effects from, 
chemotherapy, and for their predictive effects to cetuximab. We used independent 
training and validation cohorts to identify robust biomarkers and investigated the 
underlying mechanisms at 16q22.
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5.2 Materials and Methods
5.2.1 Samples
We analysed 2,281 blood DNA samples from unrelated patients with aCRC from 
COIN (2,083 samples) and COIN-B (198 samples). For details of COIN patient 
clinicopathological features, and chemotherapeutic regimens applied, please refer to 
section 3.2.1, Figure 3.1 and Table 4.1. COIN-B patients were randomised 1:1 to 
receive intermittent oxaliplatin-based chemotherapy together with intermittent 
cetuximab (Arm D) and intermittent oxaliplatin-based chemotherapy together with 
continuous cetuximab (Arm E) (Figure 5.1). In all patients, treatment was identical for 
the first 12-weeks apart from the choice of oral capecitabine or infusional 5FU 
(patient/clinician choice) together with the randomisation of ± cetuximab. For the 
Arms with intermittent therapy, all treatment was stopped from 12-weeks (apart from 
continuous cetuximab in Arm E) if there was complete response (CR), partial 
response (PR) or stable disease (SD) and re-initiated upon disease progression 
(DP). There was no statistical difference in OS and PFS between any of the COIN 
Arms (Chapter 3, Maughan et al. 2011, Adams et al. 2011), and KRAS, BRAF and 
NR AS somatic mutation status did not affect response to cetuximab (Chapter 3; 
Maughan etal. 2011).
5.2.2 Genotyping
Genotyping of twelve previously identified CRC risk alleles (rs6691170 and 
rs6687758 at 1q41, rs10936599 at 3q26, rs4444235 and rs1957636 at 14q22, 
rs9929218 at 16q22, rs10411210 at 19q13, rs961253 at 20p12, rs10795668 at 
10p14, rs3802842 at 11q23, rs4925386 at 20q13 and rs6983267 at 8q24) was 
performed by lllumina's Fast-Track Genotyping Services (San Diego, CA) using their 
high throughput BeadArray™ technology. Genotyping of rs4925386 at 20q13, 
rs16260 at 16q22, rs4813802 at20p12 and, rs16969681 and rs11632715 at 15q13 
was carried out by KBioscience (Herts, UK) using their KASPar technology. 
Genotyping of rs11169552 and rs7136702 at 12q13 was carried out by Geneservice 
(Nottingham, UK) using a TaqMan assay (Applied Biosystems).
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COIN-B 5FU or capecitabine |
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N = l l l Cetuximab
COIN-B 5FU or capecitabine 1 Until
Arm E oxaliplatin 1 progression
N=115 Cetuximab ■
Second-line
Therapy
Treatment 
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Irinotecan or 
entry into 
another trial
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Figure 5.1 - Treatment schedules for patients in COIN-B (COIN treatments are 
described in section 3.2.1 and Figure 3.1). COIN-B patients were randomised to 
receive intermittent oxaliplatin-based chemotherapy together with intermittent (Arm 
D) or continuous (Arm E) cetuximab. In all COIN and COIN-B patients, treatment 
was identical for the first 12-weeks apart from the choice of oral capecitabine or 
infusional 5FU (patient/clinician choice) together with the randomisation of ± 
cetuximab.
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5.2.3 Statistical analyses
All SNPs were tested for their genotypes being consistent with the Hardy-Weinberg 
equilibrium (HWE) using a Pearson chi-square test. LD was examined using the 
open-source program Haploview version 4.2 (Barrett etal. 2005). To identify robust 
biomarkers and to minimise the identification of false-positives, all analyses were 
carried out with equally-sized, independent, ‘training’ and ‘validation’ sets, defined 
randomly but stratified for treatment arm and fluoropyrimidine partner, and balanced 
for all previously identified prognostic factors (WHO PS, number of metastatic sites, 
WBC count, alkaline phosphatase levels and KRAS and BRAF mutation status; 
Maughan et al. 2011). Significance levels were set at 5% (P<0.05) in both the 
training and validation phases, with effects in the same direction. Only SNPs 
significant in the training set were analysed in the validation set. SNPs passing both 
stages were tested by meta-analysis of the training and validation results using 
inverse-variance and fixed-effects. All analyses were adjusted for stratification 
factors and known prognostic factors. Two models were applied (i) the effect of at 
least one minor allele versus no minor alleles (Aa/aa vs. AA) and, (ii) the effect of 
two minor alleles versus one or no minor alleles (aa vs. Aa/AA).
For prognostic effects on OS, we combined then randomly split patients from all 
arms of COIN (OS data were not available from COIN-B) to form the training and 
validation sets. A Cox survival model was used. SNPs passing training and 
validation phases were re-analysed by treatment Arm to determine whether 
treatment influenced OS. All significant SNPs and known prognostic factors were 
entered into a closed-test procedure multiple fractional polynomial model with 
P<0.05.
All COIN and COIN-B patients had identical treatment regimes for the first 12 weeks 
apart from the addition of cetuximab (Figures 3.1 and 5.1). For prognostic effects on 
toxicity after 12 weeks of treatment, we combined then randomly split patients from 
Arms A and C of COIN (excluding those patients receiving cetuximab) to form the 
training and validation sets. For predictive effects on 12 week response to and side- 
effects from cetuximab, we combined then randomly split patients from Arm B of 
COIN with all of those from COIN-B (standard chemotherapy plus cetuximab) and
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compared these groups to patients similarly combined then split from Arms A and C 
of COIN (standard chemotherapy without cetuximab).
Twelve-week response was defined as PR or CR versus SD, PD or a blank field in 
the clinical return form (CRF), recorded between 56 and 112 days (8 and 16 weeks) 
from randomisation. If no CRFs were available between those time limits, then 
patients were excluded from the analysis. Twelve-week toxicity was defined as the 
maximum toxicity recorded in any CRF returned within 112 days (16 weeks) of 
randomisation. Definitions of all other toxicities have been previously described in 
section 4.2.8. All prognostic and predictive analyses were carried out by David 
Fisher.
5.3 Results
5.3.1 Genotyping
We genotyped seventeen CRC-risk alleles identified from GWAS (Tomlinson et al.
2007, Broderick etal. 2007, Jaeger etal. 2008, Tenesa etal. 2008, Tomlinson etal.
2008, Houlston etal. 2008, Houlston etal. 2010, Carvajal-Carmona in submission), 
representing 12 loci (a single SNP at seven loci and two SNPs at five loci; Houlston 
etal. 2008, Houlston etal. 2010, Carvajal-Carmona in submission), in 2,281 
unrelated patients from COIN and COIN-B using three different platforms. Twelve 
SNPs were genotyped using the lllumina GoldenGate platform of which one 
(rs4925386) failed genotyping. For the remaining 11 SNPs, genotyping concordance 
rates for duplicate samples was 100% (1,210/1,210), GenTrain scores ranged from 
0.6814 to 0.9500 and the overall genotyping success rate was 99.34% 
(23,981/24,141) genotypes were called successfully). Four SNPs, rs4925386, 
rs4813802, rs16969681 and rs11632715 were genotyped using KASPar technology 
with a genotype success rate of 98.88% (8,928/9,029 genotypes called successfully) 
and concordance rate for duplicate samples of 100% (376/376). Two SNPs,
rs11169552 and rs7136702 were genotyped using Taqman assays with a genotype 
success rate of 95.52% (4176/4372 genotypes called successfully) and concordance 
rate for duplicate samples of 100% (188/188). All SNPs, apart from rs7136702 
(P=0.027), had genotype distributions consistent with the HWE and we found no 
imbalances in the frequencies of the SNPs between the treatment arms or according
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to the somatic KRAS, BRAF and NRAS mutation status of the CRCs (42.27%,
9.01% and 3.56% of the CRCs were KRAS, BRAF and NRAS mutant, respectively; 
Maughan et al. 2011).
5.3.2 Prognostic effects on patient survival
We have previously reported on the prognostic and predictive effects of rs16892766, 
rs4939827 and rs4779584, as discussed in chapter 4. We did not observe any effect 
of rs6983267, rs11169552, rs6691170, rs6687758, rs10936599, rs4444235, 
rs961253, rs3802842, rs1957636, rs16969681 or rs11632715 on OS within the 
training phase. Although rs7136702, rs4925386 and rs4813802 were significant in 
the training phase, all failed validation (Table 5.1). In contrast, rs9929218, 
rs10411210 and rs10795668 significantly influenced OS within both the training and 
validation phases under a univariate model (Table 5.1). After meta-analysis of the 
combined data, we found that patients homozygous for the minor allele (AA) of 
rs9929218 (equating to ~8% of patients) showed a significant decline in OS as 
compared to patients with the AG or GG genotypes (HR 1.46, 95% Cl 1.23-1.74, 
P=0.002 after correction for heterogeneity), with a median decrease in life 
expectancy of 4.3 months (Table 5.1, Figure 5.2). Similarly, for rs10411210, patients 
carrying the TC or TT genotype had worse OS as compared to those with the CC 
genotype (HR 1.23, 95% Cl 1.08-1.39, P=0.001); median decrease in life 
expectancy of 2.5 months. For rs10795668, patients carrying the AA genotype had 
an improved OS as compared to those with the AG or GG genotypes (HR 0.71, 
0.59-0.86, P=0.001); median increase in life expectancy of 6.2 months.
To determine whether these findings were influenced by the type and duration of 
treatment, we evaluated these variants according to trial Arm. For rs9929218 and 
rs10411210 the effects were significant across Arms A and B (Table 5.2); however 
for patients treated with intermittent oxaliplatin and fluoropyrimidine chemotherapy 
(Arm C), the HRs did not reach statistical significance, suggesting that these alleles 
may influence survival based upon an interaction with oxaliplatin and 
fluoropyrimidine treatment. In contrast, the effect of rs10795668 was most significant 
in patients from Arm C (HR 0.64, 95% Cl 0.47-0.88, P=0.005), suggesting that this 
prognostic factor was likely to be independent of treatment (Table 5.2).
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We have previously shown that the WHO PS, number of metastatic sites, WBC 
count, alkaline phosphatase levels and KRAS and BRAF mutation status are 
independent prognostic factors affecting OS in patients from COIN (Maughan et al. 
2011). We therefore applied a multivariate model including rs9929218, rs10411210 
and rs10795668 and the known prognostic factors, and showed that all of these 
SNPs independently influenced OS.
It is possible that the drop-out of associations from the training to validation phases 
might be due to the phenomenon known as the winner’s curse. This states that in 
genetic association studies there is likely to be an over-estimation of true genetic 
effect sizes (Xiao and Boehnke, 2009). This occurs as a result of ascertainment bias; 
that is, a bias resulting from the selection of only those associations that are 
significant in the initial data set for further analysis. As such, replication cohorts are 
likely to be underpowered to detect the same association.
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rs6983267 
rs11169552 
rs7136702 
rs6691170 
rs6687758 
rs10936599 
rs4925386 
rs4444235 
rs9929218 
rs10411210 
rs961253
3notype(s) n
Training phase 
HR (95% Cl) P-
value
n
TT/TG 689 1.02 (0.88-1.19) 0.755 _
TT 220 1.15(0.97-1.36) 0.104 -
CT/TT 479 1.01 (0.88-1.16) 0.889 _
TT 76 1.11 (0.85-1.45) 0.431 -
CT/TT 577 1.05 (0.91-1.22) 0.489 .
TT 135 1.30(1.06-1.50) 0.012 154
TG/TT 682 0.92 (0.80-1.07) 0.293 _
TT 163 0.93 (0.77-1.13) 0.485 -
AG/GG 400 0.90 (0.78-1.04) 0.171 _
GG 55 1.04(0.78-1.38) 0.801 -
TC/TT 431 1.08 (0.94-1.24) 0.300 _
TT 57 1.33 (0.99-1.79) 0.059 -
TC/TT 534 0.86 (0.75-0.99) 0.034 554
TT 91 1.00 (0.77-1.29) 0.984 -
TC/CC 754 1.02 (0.87-1.19) 0.792 _
CC 250 0.97 (0.82-1.15) 0.737 -
AG/AA 520 1.02 (0.89-1.18) 0.736 _
AA 91 1.30(1.03-1.65) 0.028 73
TC/TT 191 1.23(1.02-1.46) 0.026 193
TT 12 1.02 (0.53-1.97) 0.959 -
AC/AA 628 1.07 (0.93-1.24) 0.338 -
AA 143 0.99 (0.81-1.21) 0.895 -
Validation phase Combined
HR (95% Cl) P- HR (95% Cl) P-value Z2 RE 
value* P-value
1.04(0.85-1.26) 0.726
0.98(0.85-1.13) 0.732
1.68(1.29-2.17) <0.001 1.46(1.23-1.74) <0.001 49% 0.002
1.23(1.03-1.47) 0.022 1.23(1.08-1.39) 0.001 0% 0.001
136
rs10795668 AG/AA 509 0.89 (0.77-1.02) 0.094 - - - - - - -
AA 89 0.70 (0.54-0.92) 0.011 96 0.72 (0.55-0.95) 0.018 0.71 (0.59-0.86) 0.001 0% 0.001
rs3802842 AC/CC 564 1.00 (0.87-1.15) 0.973 _ _ - - - - -
CC 108 1.10(0.87-1.37) 0.431 - - - - - - -
rs4813802 GT/GG 718 1.02 (0.87-1.18) 0.843 _ _ _ _ - - -
GG 194 0.80 (0.67-0.96) 0.017 190 1.14(0.95-1.37) 0.148 - - - -
rs1957636 GA/GG 638 0.93 (0.81-1.08) 0.332 _ _ - - - - -
GG 143 1.15(0.93-1.41) 0.189 - - - - - - -
rs16969681 T o m ' 208 1.07 (0.90-1.27) 0.447 - - - - - -
TT 16 1.46 (0.89-2.40) 0.134 - - - - - - -
rs11632715 GA/GG 779 0.86 (0.74-1.01) 0.072 - _ . - - - -
GG 264 1.14(0.98-1.34) 0.099 - - - - - - -
Table 5.1 - Univariate prognostic analyses of OS. Analyses use Cox proportional-hazards models with the outcome of OS. Hazard 
ratios should be interpreted as the hazard in the genotype group indicated versus all other patients with a result for that SNP. 
‘ Correction for multiple testing was applied at this stage, though data is not shown. rs9929218 was the only SNP to remain 
significant (P<0.006) after this correction.
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Figure 5.2 - Kaplan-Meier curves for the effect of (A) rs9929218, (B) rs10411210 
and (C) rs10795668 on OS. *after correction for heterogeneity.
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COIN Arm n HR (95% Cl) P-value
rs9929218 A GG/GA
AA
611
61
1.00
1.76(1.32-2.34) <0.001
B GG/GA
AA
657
52
1.00
1.37(1.00-1.88) 0.048
C GG/GA
AA
646
51
1.00
1.29 (0.94-1.77) 0.116
rs10411210 A CC
CT/TT
558
113
1.00
1.33(1.06-1.68) 0.013
B CC
CT/TT
570
132
1.00
1.22 (0.98-1.51) 0.071
C CC
CT/TT
558
139
1.00
1.14(0.92-1.40) 0.241
rs10795668 A GG/GA
AA
571
60
1.00
0.82 (0.59-1.15) 0.248
B GG/GA
AA
624
58
1.00
0.73 (0.52-1.04) 0.082
C GG/GA
AA
605
67
1.00
0.64 (0.47 -  0.88) 0.005
Table 5.2 - Univariate analysis of rs9929218, rs10411210 and rs10795668 on OS 
according to COIN trial Arm
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5.3.3 Prognostic effects on response to, or side effects from, chemotherapy
We tested the CRC-susceptibility SNPs for their effects on response to, or side 
effects from, 12 weeks of fluoropyrimidine and oxaliplatin-based chemotherapy 
(Table 5.3). We found that patients homozygous for the rs9929218 minor allele had 
a poor prognosis for response to treatment in both the training and validation phases 
(combined OR 0.48, 95% Cl 0.31-0.75, P=0.001), as compared to patients that were 
heterozygous or homozygous wild-type (Table 5.4). In addition, we found that this 
subgroup of patients had an increased risk of skin toxicity, specifically HFS within the 
training phase (OR 6.04, 95% Cl 1.65-22.2, P=0.007), that strongly trended towards 
significance in the validation phase (OR 3.55, 95% Cl 0.92-13.7, P=0.065) and that 
was highly significant in the combined dataset (OR 4.68, 95% Cl 1.84-11.9,
P=0.001) (Table 5.4).
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Response
TP VP’
Gl toxicity 
TP VP*
Haematological toxicity
TP VP*
Skin toxicity 
TP VP*
rs6983267
rs11169552
rs7136702
rs6691170
rs6687758
rs10936599
rs4925386
TG/TT
TT
CT/TT
TT
CT/TT
TT
TG/TT
TT
AG/GG
GG
TC/TT
TT
TC/TT
TT
1.07 (0.76-1.52) 1.21 (0.76-1.93) 1.43 (0.8-2.55) 0.42 (0.12-1.39)
P=0.681 " P=0.423 '  P=0.229 '  P=0.154
0.73(0.49-1.09) 0.81 (0.47-1.39) 1.54(0.85-2.81) 2.12(0.61-7.39)
P=0.122 '  P=0.446 " P=0.154 '  P=0.239
1.11 (0.79-1.55) 1.17(0.76-1.81) 1.3(0.76-2.23) 1.46(0.44-4.84)
P=0.555 '  P=0.477 '  P=0.344 '  P=0.541
0.97(0.50-1.87) 1.01 (0.46-2.21) 0.96(0.35-2.68) 1.34(0.17-10.8)
P=0.923 '  P=0.974 " P=0.944 " P=0.786
0.89(0.63-1.25) 1.11 (0.71-1.72) 0.71 (0.41-1.23) 0.85(0.25-2.82)
P=0.489 ‘ P=0.652 " P=0.224 '  P=0.785
0.98(0.61-1.59) 1.21 (0.64-2.29) 0.97(0.44-2.14) 2.47(0.64-9.59)
P=0.950 " P=0.556 '  P=0.940 '  P=0.191
0.86(0.61-1.22) 1.10(0.70-1.73) 1.09(0.63-1.92) 2.42(0.52-11.3)
P=0.388 '  P=0.693 '  P=0.752 '  P=0.262
0.85(0.51-1.39) 1.36(0.71-2.58) 1.13(0.49-2.59) 5.38(1.49-19.5)
P=0.512 " P=0.352 '  P=0.780 '  P=0.010
0.92(0.66-1.29) 0.65(0.41-1.03) 0.87(0.50-1.52) 2.87(0.83-9.94)
P=0.638 " P=0.066 '  P=0.625 " P=0.096
0.62(0.29-1.32) 1.47(0.55-3.95) 1.66(0.51-5.39) 2.76(0.33-23.0)
P=0.214 '  P=0.446 ‘ P=0.401 '  P=0.348
1.08 (0.77-1.51) 
P=0.647 
1.40 (0.64-3.08) 
P=0.397
0.94 (0.61-1.45) 
P=0.780 
0.16(0.02-1.19) 
P=0.074
0.81 (0.47-1.39) 
P=0.434 
0.38 (0.08-1.72) 
P=0.210
0.50(0.13-1.93)
P=0.317
No pts.
1.11 (0.80-1.55) 1.02(0.66-1.58) 1.14(0.66-1.95) 0.94(0.28-3.15)
P=0.524 " P=0.933 " P=0.644 '  P=0.923
1.29(0.75-2.23) 1.04(0.52-2.06) 0.79(0.33-1.87) 1.73(0.36-8.27)
P=0.353 '  P=0.916 '  P=0.59 " P=0.494
0.95 (0.21-4.36) 
P=0.952
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Response
TP VP*
Gl toxicity
TP VP*
Haematological toxicity 
TP VP*
Skin toxicity 
TP VP*
rs4444235
TC/CC
CC
1.01 (0.70-1.46) 
P=0.944 
0.71 (0.49-1.05) 
P=0.084 -
1.18(0.71-1.94) 
P=0.520 
0.93 (0.57-1.51) 
P=0.762
“ 0.92 (0.51-1.66) P=0.788 
0.70(0.36-1.36) 
P=0.295
1.00(0.26-3.84) 
P=0.999 
1.79 (0.52-6.23) 
P=0.359
•
rs9929218
AG/AA
AA
1.10(0.79-1.53) 
P=0.564 
0.49 (0.27-0.89) 
P=0.O19
0.47, (0.24-0.91) 
P=0.026
1.10(0.72-1.69) 
P=0.661 
1.02 (0.50-2.08) 
P=0.962 -
1.20 (0.71-2.05) 
P=0.495 
0.92 (0.36-2.32) 
P=0.852 -
1.79 (0.52-6.21) 
P=0.356 
A:7*59, (2.23-25.9) 
f  J P=0.001
rs10411210
TC/TT
TT
1.05 (0.66-1.68) 
P=0.840 
1.09(0.18-6.57) 
P=0.926 -
0.97 (0.51-1.85) 
P=0.931 
11.2(0.94-132) 
P=0.056
- 1.93 (1.00-3.73) P=0.050
No pts.
1.35 (0.74-2.45) 
P=0.330
1.44 (0.30-6.90) 
P=0.645 
15.1 (1.46-156) 
P=0.023 No pts.
rs961253
AC/AA
AA
0.88 (0.63-1.23) 
P=0.447 
2.15(1.25-3.70) 
P=0.006
1.22 (0.76-1.96) 
P=0.404
1.01 (0.65-1.56) 
P=0.972 
0.53 (0.24-1.16) 
P=0.110
- 0.57 (0.33-0.97) P=0.039 
0.13(0.03-0.57) 
P=0.007
1.20 (0.70-2.07) 
P=0.506 
1.26 (0.62-2.53) 
P=0.522
3.13(0.67-14.7) 
P=0.148 
1.77 (0.37-8.41) 
P=0.475 -
rs10795668 AG/AA
AA
0.96 (0.68-1.34) 
P=0.791 
1.33 (0.75-2.34) 
P=0.332
- 1.33 (0.84-2.08) P=0.222 
1.18(0.60-2.32) 
P=0.629 -
1.57 (0.89-2.75) 
P=0.117 
0.64 (0.24-1.75) 
P=0.385 -
2.25 (0.59-8.60) 
P=0.237
No pts.
-
rs3802842 AC/CC
CC
0.98 (0.71-1.36) 
P=0.911 
1.24 (0.67-2.29) 
P=0.486
- 1.01 (0.66-1.55) P=0.969 
0.81 (0.34-1.92) 
P=0.638 -
1.03 (0.60-1.76) 
P=0.915 
0.78 (0.26-2.35) 
P=0.658
- 0.74 (0.22-2.47) P=0.628
No pts. -
rs4813802 GT/GG
GG
0.72(0.50-1.04) 
P=0.081 
1.05 (0.68-1.63) 
P=0.830
- 1.22 (0.75-1.98) P=0.423 
0.81 (0.45-1.46) 
P=0.492
- 0.80 (0.46-1.4) P=0.436 
0.48 (0.2-1.19) 
P=0.114 -
4.31 (0.55-34.0) 
P=0.166 
4.05 (1.21-13.6) 
P=0.024
0.69(0.15-3.13)
P=0.630
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Response
TP VP*
Gl toxicity
TP VP*
Haematological toxicity
TP VP*
Skin toxicity 
TP VP*
rs1957636 GA/GG
GG
0.99 (0.70-1.39) 
P=0.946 
0.82 (0.52-1.28) 
P=0.372
0.95 (0.61-1.46) 
P=0.804 
1.08 (0.61-1.91) 
P=0.792
0.77 (0.45-1.33) 
P=0.345 
0.72 (0.32-1.63) 
P=0.434
” 0.79 (0.24-2.64) P=0.707 
1.24 (0.26-5.86) 
P=0.785
rs16969681 TC/TT
TT
0.89 (0.59-1.33) 
P=0.556 
1.28 (0.37-4.42) 
P=0.696
0.75 (0.43-1.29) 
P=0.296 
3.08 (0.65-14.6) 
P=0.156
0.70 (0.34-1.45) 
P=0.335
No pts. -
0.75 (0.16-3.54) 
P=0.717
No pts.
rs11632715 GA/GG
GG
1.09 (0.75-1.58) 
P=0.666 
0.95 (0.65-1.39) 
P=0.785
1.05 (0.64-1.72) 
P=0.854 
0.89 (0.53-1.49) 
P=0.663
1.62 (0.85-3.08) 
P=0.145 
1.15(0.61-2.17) 
P=0.665
- 0.38 (0.11-1.28) P=0.120 
0.66 (0.14-3.12) 
P=0.603
Table 5.3 - Prognostic effects of CRC-risk SNPs on response to and side effects from 12 weeks of oxaliplatin and fluoropyrimidine based chemotherapy. 
Numbers represent HRs with 95% Cl in parenthesese. Hazard ratios should be interpreted as the hazard in the genotype group indicated versus all other 
patients with a result for that SNP. TP - Training phase, VP -  Validation phase. Significant results in both training and validation phases are shaded (f N.B. 
Patients carrying the AA genotype for rs9929218 were marginally over the 5% significance level for worse skin toxicity within the validation phase, but were 
highly significant in the subsequent meta-analyses [P<0.001]). No pts. -  no patients in that phase with that genotype. ‘ Though data is not shown, correction 
for multiple testing was applied after the VP. All observations were non-significant after this correction, though rs9929218 showed border-line significance 
(P=0.052) for prognostic effect on response.
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Training phase Validation phase Combined
n OR (95%CI) P-value n OR (95%CI)
P-
value OR (95%CI)
P-
value z2
RE
P-value
12-week
response
AG/
AA
AA
279
50
1.10 
(0.79-1.53) 
0.49 
(0.27 -  0.89)
0.564
0.019 40 0.47(0.24-0.91) 0.026
0.48 
(0.31 -0 .75) 0.001 0% 0.001
12-week
Gl
toxicity
AG/
AA
AA
257
50
1.10 
(0.72-1.69) 
1.02 
(0.50 -  2.08)
0.661
0.962
- - - - - - -
12-week
haemato-
logical
toxicity
AG/
AA
AA
274
55
1.20 
(0.71 -2 .05) 
0.92 
(0.36 -  2.32)
0.495
0.852
-
-
-
- -
- -
12-week
skin
toxicity
AG/
AA
AA
306
62
1.79 
(0.52-6.21) 
7.59 
(2.23 -  25.9)
0.356
0.001 44 3.35(0.88-12.7) 0.076
5.22
(2.12-12.9) <0.001 0% <0.001
12 week 
HFS
AG/
AA
AA
311
63
1 55 
(0.43 -  5.57) 
6.04 
(1.65-22.2)
0.500
0.007 44 3.55(0.92-13.7) 0.065
4.68
(1.84-11.9) 0.001 0% 0.001
Table 5.4 - Prognostic effect of rs9929218 in E-cadherin on response to and side 
effects from 12 weeks of oxaliplatin and fluoropyrimidine based chemotherapy. Odds 
ratios should be interpreted as the odds in the genotype group indicated versus all 
other patients with a result for that SNP.
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We investigated whether the somatic KRAS, BRAF and NRAS status of the CRCs 
influenced the prognostic effect of rs9929218 on response to treatment. In patients 
with KRAS, BRAF or NRAS mutant tumours, those who were homozygous for the 
rs9929218 minor allele in the germline showed worse response than those 
heterozygous or homozygous for the wild type allele (OR 0.25, 95% Cl 0.11-0.55, 
P=0.001). In contrast, amongst patients with KRAS, BRAF and NRAS wild type 
tumours, those who were homozygous for the rs9929218 minor allele did not have 
worse response than those heterozygous or homozygous for the wild type allele (OR 
0.85, 95% Cl 0.40-1.83, P= 0.69) The difference in response for patients 
homozygous for the rs9929218 minor allele with respect to somatic mutation status 
was significant (Pfor interaction 0.037).
5.3.4 Predictive effects on response to cetuximab
We tested whether any of the SNPs might also act as predictive factors for response 
to cetuximab (Table 5.5). rs9929218 was found to predict response within both the 
training and validation phases. After meta-analysis of the combined data, patients 
homozygous for the rs9929218 minor allele showed a significantly improved 
response (OR 1.69, 95% Cl 0.93-3.07 with cetuximab, OR 0.48, 95% Cl 0.31-0.75 
without for cetuximab; P for interaction = 0.001) (Table 5.6). Although an equivalent 
effect on OS was not observed (HR 1.38, 95% Cl 1.01-1.89 with cetuximab 
treatment and HR 1.53, 95% Cl 1.24-1.89 without cetuximab treatment; P for 
interaction 0.47), there was considerable heterogeneity in treatments after 12 weeks.
Patients homozygous for the rs9929218 minor allele also had reduced skin toxicity 
after 12 weeks of cetuximab treatment in the training and validation phases 
(combined OR 0.72, 95% Cl 0.32-1.61 with cetuximab, OR 5.22, 95% Cl 2.12-12.9 
without cetuximab; Pfor interaction <0.001) (Table 3), specifically, reduced HFS 
(combined OR 0.84, 95% Cl 0.25-2.83 with cetuximab, OR 4.68, 95% Cl 1.84-11.9 
without cetuximab; Pfor interaction 0.030) (Table 3).
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Response
TP VP*
Gl toxicity
TP
r
VP*
Haematological toxicity 
TP VP*
Skin toxicity 
TP VP*
rs6983267 TG/TT 1.06(0.59-1.91) 0.78 (0.38-1.62) 1.2 (0.46-3.15) 3.35 (0.84-13.4)P=0.849 P=0.508 P=0.706 P=0.088
TT 1.34 (0.68-2.66) 1.25 (0.53-2.94) 1.85 (0.67-5.07) 0.48 (0.11-2.13)1 1 P=0.402 P=0.615 P=0.234 P=0.331
rs11169552 CT/TT 0.73 (0.42-1.27) 0.77 (0.39-1.53) 0.61 (0.26-1.47) 0.58 (0.15-2.26)1 W    VWWVfa P=0.268 P=0.457 P=0.275 P=0.436
TT 1.11 (0.36-3.41) P=0.855 -
0.60 (0.13-2.84) 
P=0.523 -
1.21 (0.21-7.01) 
P=0.828 -
0.87 (0.08-9.05) 
P=0.906 -
rs7136702 CT/TT 1.08 (0.61-1.93) 0.99 (0.49-2.00) 1.31 (0.54-3.17) 0.88 (0.23-3.44)P=0.784 P=0.984 P=0.546 P=0.853
t t 1.66(0.74-3.76) 2.46 (0.97-6.24) 1.71 (0.52-5.63) 0.19(0.03-1.03)1 1 P=0.220 P=0.058 P=0.378 P=0.055
rs6691170 TG/TT 1.22 (0.69-2.16) 0.92 (0.46-1.85) 1.21 (0.49-2.99) 0.65 (0.12-3.47)P=0.500 P=0.817 P=0.686 P=0.616
t t 1.33 (0.59-2.99) 0.81 (0.29-2.26) 1.05 (0.31-3.56) 0.26 (0.06-1.22)1 1 P=0.492 P=0.693 P=0.943 P=0.088
rs6687758 AG/GG 0.99 (0.57-1.74) P=0.979 -
1.03 (0.51-2.09) 
P=0.932 -
1.07 (0.44-2.60) 
P=0.877 -
0.52 (0.13-2.10) 
P=0.359 -
a a 1.93 (0.53-7.00) 1.13(0.26-5.05) Ma a+c 0.32 (0.03-3.99)OO P=0.320 P=0.868 INU pio. P=0.376
rs10936599 TC/TT 0.97(0.56-1.68)P=0.903 -
0.98 (0.50-1.92) 
P=0.952 -
1.51 (0.64-3.55) 
P=0.348 -
2.65(0.61-11.6)
P=0.194 -
TT 0.76 (0.24-2.40) P=0.643 -
5.29 (0.57-49.2) 
P=0.143 -
0.73 (0.05-9.69) 
P=0.808 - No pts. -
rs4925386 TC/TT 1.31 (0.76-2.24) P=0.329 -
1.08(0.56-2.07)
P=0.819 -
0.7 (0.31-1.57) 
P=0.383 -
0.94 (0.25-3.59) 
P=0.927 -
TT 0.90 (0.36-2.22) P=0.820 -
0.53 (0.18-1.57) 
P=0.252 -
1.39 (0.36-5.31) 
P=0.63 -
0.75 (0.12-4.63) 
P=0.758 -
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Response
TP VP*
Gl toxicity
TP
«CL>
Haematoiogicai toxicity 
TP VP*
Skin toxicity
TP VP*
rs4444235 TC/CC
CC
1.17(0.64-2.15) 
P=0.603 
1.8 (0.95-3.41) 
P=0.070
1.16(0.55-2.46) 
P=0.701 
0.74(0.34-1.61) 
P=0.444 -
0.96 (0.38-2.44) 
P=0.939 
1.01 (0.35-2.9) 
P=0.99 -
1.14(0.25-5.17) 
P=0.864 
0.47 (0.11-1.93) 
P=0.292 -
rs9929218 AG/AA
AA
0.89 (0.52-1.52) 
P=0.674 
3.77(1.38-10:3) 
P=0.010
3.13 (1.04—9.42) 
P=0.042
1.16(0.61-2.23)
P=0.647
1.13(0.38-3.36)
P=0.819
- 0.41 (0.18-0.94) P=0.035 
1.09 (0.26—4.63) 
P=0.905
1.29 (0.59-2.82) 
P=0.521
0.44 (0.11-1.72) 
P=0.236 
0.14 (0.03-0.67)
p*o.or4
0.07 (0.01-0.55) .
...P&01.V
rs10411210 TC/TT
TT
1.10(0.53-2.27)
P=0.793
No pts.
- 0.84 (0.34-2.1) P=0.714 
0.31 (0.01-7.62) 
P=0.477 -
0.38(0.13-1.1)
P=0.074
No pts.
- 0.78 (0.14-4.32) P=0.775
No pts.
-
rs961253 AC/AA
AA
1.20 (0.68-2.12) 
P=0.533 
0.35 (0.16-0.78) 
P=0.010
1.00 (0.45-2.23) 
P=0.993
0.75 (0.38-1.49) 
P=0.414 
2.03 (0.71-5.83) 
P=0.187 -
1.22 (0.52-2.90) 
P=0.646 
8.32 (1.48-46.9) 
P=0.016
0.45 (0.12-1.68) 
P=0.237
0.31 (0.06-1.64) 
P=0.168 
0.52 (0.09-3.12) 
P=0.474
-
rs10795668 AG/AA
AA
1.41 (0.81-2.48) 
P=0.225 
2.20 (0.78-6.21) 
P=0.136
- 0.58(0.29-1.16) P=0.122 
1.35 (0.48-3.81) 
P=0.573 -
0.75(0.31-1.8) 
P=0.514 
2.4 (0.61-9.48) 
P=0.213
- 0.61 (0.14-2.68) P=0.513
No pts.
-
rs3802842 AC/CC
CC
0.89 (0.51-1.53) 
P=0.667 
0.72 (0.29-1.76) 
P=0.47
- 0.93 (0.47-1.81) P=0.824 
1.88 (0.62-5.72) 
P=0.264
- 0.77 (0.32-1.83) P=0.550 
0.25 (0.04-1.65) 
P=0.150 -
1.83 (0.47-7.08) 
P=0.38
No pts.
-
rs4813802 GT/GG
GG
1.71 (0.93-3.11) 
P=0.082 
1.15(0.59-2.25) 
P=0.688 -
0.95 (0.45-2.02) 
P=0.899 
1.33 (0.58-3.07) 
P=0.503 -
2.07 (0.81-5.34) 
P=0.130 
3.27 (1.00-10.7) 
P=0.050
2.14 (0.71-6.47) 
P=0.179
0.19(0.02-1.62) 
P=0.128 
0.22 (0.05-0.92) 
P=0.038
0.88 (0.16-4.91) 
P=0.884
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Response
TP VP*
Gl toxicity 
TP VP*
Haematological toxicity
TP VP*
Skin toxicity 
TP VP*
rs1957636 GA/GG
GG
0.85 (0.48-1.48) 
P=0.557 
1.39(0.62-3.12) 
P=0.421
0.93 (0.47-1.84) 
P=0.841 
1.44 (0.58-3.61) 
P=0.435
1.08 (0.46-2.56) 
P=0.858 
2.27 (0.67-7.64) 
P=0.186
0.87 (0.22-3.39) 
P=0.844 
0.22 (0.03-1.63) 
P=0.139 -
rs16969681 TC/TT
TT
1.00 (0.48-2.09) 
P=0.989 
0.26 (0.02-3.92) 
P=0.33
2.19(0.93-5.13) 
P=0.071 
1.43 (0.06-35.2) 
P=0.826
1.00 (0.32-3.11) 
P=0.995
No pts. -
1.87 (0.34-10.4) 
P=0.472
No pts. -
rs11632715 GA/GG
GG
0.56(0.30-1.06) 
P=0.074 
0.75 (0.41-1.40) 
P=0.372
1.62 (0.76-3.46) 
P=0.212 
0.52 (0.23-1.20) 
P=0.125
0.65(0.24-1.70) 
P=0.376 
0.97 (0.38-2.50) 
P=0.951
- 5.30 (1.29-21.8) P=0.021 
2.81 (0.53-15.0) 
P=0.226
No pts.
Table 5.5 - Predictive effects of CRC-risk SNPs on response to and side effects from 12 weeks of cetuximab treatment. Numbers represent HRs with 95% Cl 
in parenthesese. Hazard ratios are “interaction HRs”, and should be interpreted as the ratio of the HR (genotype group indicated versus all other patients with 
a result for that SNP) among patients receiving cetuximab to the HR among patients not receiving cetuximab. TP - Training phase, VP -  Validation phase. 
Significant results in both training and validation phases are shaded. No pts. -  no patients in that phase with that genotype. * Though data is not shown, 
correction for multiple testing was applied after the VP. All observations were non-significant after this correction, barring rs9929218 and its predictive effect 
on skin toxicity (P=0.022).
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Training phase Validation phase Combined
n OR (95% Cl) P
P
inter­
action
n OR (95% Ci) P
P
inter­
action
n OR (95% Cl) P
P
inter­
action
F REP-value
12-
week
response
AG/AA - cetuximab + cetuximab
279
170
1.10(0 .79-1 .53) 
0.98 (0 .64-1 .50)
0.564
0.913 0.688
— — -- — — — - -- --
AA - cetuximab + cetuximab
50
31
0.49 (0.27 -  0.89) 
1.86 (0 .82-4 .21)
0.019
0.135 0.010
40
24
0.47 (0 .24-0 .91) 
1.51 (0 .62-3 .64)
0.026
0.361 0.028
90
55
0.48 (0.31 -0 .75 ) 
1.69 (0 .93-3 .07)
0.001
0.086 0.001 0% 0.001
Skin
toxicity
AG/AA - cetuximab + cetuximab
306
111
1.55 (0.43-5.57) 
1 .12(0 .44-2 .87)
0.500
0.811 0.693
-- -- -- --
-- ~ -
-- - --
(including
AA - cetuximab 62 7.59 (2 .23-25 .9 ) 0.001 0.014 44 3.35 (0 .88-12 .7 ) 0.076 0.011 106 5.22 (2 .12-12 .9 ) <0.001 <0.001 0% <0.001HFS) + cetuximab 22 1.10(0 .42-2 .87) 0.851 19 0.26 (0 .06-1 .15) 0.075 41 0.72 (0 .32-1 .61) 0.42
12-
week
HFS
AG/AA - cetuximab + cetuximab
311
144
1.55 (0 .43-5 .57) 
1 .12(0 .44-2 .87)
0.500
0.811 0.693
- -- -- -- - - - - - -
AA - cetuximab + cetuximab
63
27
6 .04(1 .65-22.2 ) 
1.91 (0.51 -7 .10 )
0.007
0.334 0.225
44 3.55 (0 .92-13 .7 ) 0.065 - 10758
4.68 (1 .84-11 .9 ) 
0 .84(0 .25-2 .83)
0.001
0.778 0.030 - -
Table 5.6 - Predictive analyses of rs9929218 in E-cadherin on response to and side effects from 12 weeks of cetuximab treatment. 
Odds ratios should be interpreted as the odds in the genotype group indicated versus all other patients with a result for that SNP.
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We investigated whether the somatic mutation status of the CRCs influenced the 
predictive effect on response to cetuximab. Patients homozygous for the rs9929218 
minor allele in the germline and with KRAS, BRAF or NRAS mutant tumours showed 
a significantly improved response to cetuximab (OR 1.69, 95% Cl 0.61-4.74 with 
cetuximab; OR 0.25, 95% Cl 0.11-0.55 without cetuximab; P for interaction 0.004). In 
contrast, patients homozygous for the rs9929218 minor allele and with KRAS, BRAF 
and NRAS wild-type tumours did not show a statistically significant response (OR 
1.51, 95% Cl 0.48-4.70 with cetuximab; OR 0.85, 95% Cl 0.40-1.83 without 
cetuximab; P for interaction 0.35).
5.3.5 Delineating the mechanism underlying the response to cetuximab
rs9929218 lies within intron-2 of the CDH1 gene encoding E-cadherin, in strong LD 
with rs16260 (Pittman et al. 2009), also called -160C>A, in the CDH1 promoter 
(Figure 5.3). rs16260 has been shown to downregulate CDH1 expression (Li et al. 
2000). Therefore, we genotyped rs16260 in patients from COIN and COIN-B and 
observed strong LD with rs9929218 (1^=0.915, D-0.984). We found similar 
prognostic effects for rs16260, where patients homozygous for the minor allele (AA) 
(equating to ~7% of patients) showed a significant decline in OS as compared to 
patients with the CA or CC genotypes (HR 1.38, 95% Cl 1.15-1.67, P=0.001), 
equating to a median decrease in life expectancy of 3.9 months. Patients 
homozygous for the rs16260 minor allele had a poor prognosis for 12-week 
response to fluoropyrimidine and oxaliplatin-based treatment as compared to 
patients that were heterozygous or homozygous wild-type (OR 0.58, 95% Cl 0.37- 
0.93, P=0.022), and had an increased risk of skin toxicity (OR 5.29, 95% Cl 2.11- 
13.3, P<0.001), specifically HFS (OR 4.78, 95% Cl 1.80-12.7, P=0.002) (Table 5.7).
rs16260 also predicted response to cetuximab (Table 5.8). Patients homozygous for 
the rs16260 minor allele showed significantly improved 12-week response (OR 1.70, 
95% Cl 0.93-3.11 with cetuximab, OR 0.58, 95% Cl 0.37-0.93 without cetuximab; P 
for interaction=0.007) and this was most apparent in patients with KRAS, BRAF or 
NRAS mutant tumours (OR 1.47, 95% Cl 0.53-4.10 with cetuximab and OR 0.22, 
95% Cl 0.09-0.51 without cetuximab; P for interactions.005).
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Figure 5.3 -  Schematic representation of the CDH1 gene structure with exons shown by vertical blue lines. SNPs rs9929218 and 
rs16260 are indicated. Conservation across the gene (according to USCS Genome Bioinformatics database) is shown beneath the 
schematic, with blue peaks representing conserved islands. As expected, conserved islands align well with expressed sequence, 
and rs9929218. Other conserved islands are present within the second intron of the gene, though none coincide with SNPs in high 
LD (r^O.8) with rs9929218.
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n OR (95%CI) P-value
12-week response CA/AA
AA
524
79
1.09 (0.86-1.38) 
0.58 (0.37 -  0.93)
0.482
0.022
12-week Gl toxicity CA/AA
AA
464
74
1.33 (0.97-1.82) 
0.95 (0.51 -1 .74)
0.077
0.858
12-week 
haematological toxicity
CA/AA
AA
528
89
1.12(0.77-1.63)
1.15(0.57-2.32)
0.552
0.691
12-week skin toxicity CA/AA
AA
576
93
0.93 (0.41 -2 .10) 
5.29 (2.11-13.3)
0.868
0.001
12 week HFS CA/AA
AA
584
94
0.92 (0.40-2.16) 
4.78(1.80-12.7)
0.855
0.002
Table 5.7 - Prognostic effect of rs16260 in E-cadherin on response to and side 
effects from 12 weeks of oxaliplatin and fluoropyrimidine based chemotherapy. Odds 
ratios should be interpreted as the odds in the genotype group indicated versus all 
other patients with a result for that SNP.
n OR (95% Cl) P-value Pinteraction
CA/AA - cetuximab 524 1.09 (0 .8 6 -1 .3 8 )
0.482 0.891
12-week + cetuximab 328 1.06 (0 .7 9 -1 .4 3 ) 0.695
response AA - cetuximab + cetuximab
79
54
0.58 (0.37 -  0.93) 
1.70 (0 .9 3 -3 .1 1 )
0.022
0.087 0.007
12-week
CA/AA - cetuximab 
+ cetuximab
584
316
0.92 (0 .4 0 -2 .1 6 )  
0.96 (0.51 -1 .8 4 )
0.855
0.911
0.941
HFS AA - cetuximab 
+ cetuximab
94
55
4 .5 2 (1 .7 1 -1 1 .9 )  
0.89 (0 .2 6 -3 .0 1 )
0.002
0.854 0.040
Table 5.8 - Predictive analyses of rs16260 in E-cadherin on response to and side 
effects from 12 weeks of cetuximab treatment. Odds ratios should be interpreted as 
the odds in the genotype group indicated versus all other patients with a result for 
that SNP.
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5.4 Discussion
Here, we have shown that multiple low penetrance CRC-risk alleles affect survival in 
patients with aCRC, highlighting the relationship between genetic variants acting as 
both predisposition and prognostic alleles. Tenesa and colleagues (2010) previously 
analysed a population based cohort of 2,838 Scottish CRC patients but did not find 
any GWAS CRC-risk SNPs (including rs16892766, rs9929218, rs10411210 and 
rs10795668) associated with survival. However, their cohort primarily consisted of 
cases with Stage 1-3 disease and therefore had fewer cases that were very ill at 
presentation and died soon afterwards, so are likely to have had less power to 
identify the findings described herein. However, it must also be considered that some 
of the survival effects observed here might actually be the result of altered response 
to oxaliplatin and fluoropyrimidine based chemotherapy since we did not validate the 
prognostic effects across all arms of the trial. Furthermore, it must be considered that 
if multiple testing is accounted for, only a minority of the observations made here 
remain significant; specifically the prognostic effect on OS of rs9929218 and the 
prediction of improved skin toxicity again in homozygous carriers of the rs9929218 
minor allele. Though a number of observations are removed, it is still clear that 
rs9929218 in E-cadherin plays a critical role in defining prognosis and response in 
aCRC
E-cadherin functions as a transmembrane glycoprotein that is critical in the 
establishment and maintenance of intercellular adhesion, cell polarity and tissue 
morphology and regeneration (Takeichi, 1991). Inactivation of E-cadherin by 
promoter hypermethylation is a common event in CRC (Wheeler etal. 2001, Garinis 
et al. 2002) and its loss represents the defining feature of the epithelial to 
mesenchymal transition (EMT) - a change in cellular phenotype that sees a reduction 
in cell-cell adhesion structures, as well as alterations of polarity and cytoskeletal 
structure (Klymkowsky and Savagner, 2009). Here, we show that rs9929218 in E- 
cadherin is an independently validated predictive biomarker of response to 
cetuximab. Interestingly, other studies have also implicated E-cadherin in altering 
response to cetuximab. Urothelial carcinoma cells expressing E-cadherin were found 
to be sensitive to cetuximab whilst those lacking E-cadherin were resistant and 
knockdown of E-cadherin in the sensitive cells led to reduced response (Black et al. 
2008). In non-small cell lung cancer cell lines, high levels of E-cadherin expression
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correlated with sensitivity to cetuximab (Nikolova et al. 2009) and in KRAS wild-type 
epidermoid carcinoma cells cetuximab efficacy was dependent upon E-cadherin 
expression (Oliveras-Ferraros etal. 2010). However, the exact mechanism through 
which rs9929218 influences this response remains unclear. This is discussed further 
in chapter 7.
5.4.1 19q13 and 10p14
We found that two SNPs, rs10411210 at 19q13 and rs10795668 at 10p14, affected 
OS. Compared to the 8q23 (rs16892766) and 16q22 (rs9929218) loci, little is known 
about the mechanisms of risk at these loci. rs10411210 maps to an LD block that 
encompasses the Rho GTPase binding protein 2 gene (RHPN2). This encodes a 
Rho GTPase involved in regulation of the actin cytoskeleton and cell motility (Peck et 
al. 2002). RhoA proteins have previously been associated with CRC risk and 
prognosis (Bellovin et al. 2006). It is perhaps interesting that RHPN2, along with 
CDH1, encode proteins with overlapping functions in regulating the EMT process. In­
turn, our data points to a role for EMT in defining the course of the disease and 
patient prognosis, as well as to response to therapy.
rs10795668 maps to an 82kb block of LD at the 10p14 locus. Of note, there are no 
known protein coding transcripts within this region and the nearest predicted genes 
are located 0.4Mb proximal (BC031880) and 0.7Mb distal (LOC389936). As such, it 
will likely be very difficult to identify the causal mechanism at this locus. However, 
studies at 8q24 (Wright et al. 2010) prove that SNPs can have mechanistic effects 
across considerable distances.
5.4.2 Future work
Four independent loci have been found to alter survival in patients with aCRC. It will 
be important to determine what role these variants play in patients with earlier stages 
of CRC. It is likely that this will only be possible through the use of sufficiently large 
cohorts with large follow-up times. Further to this, and relating to the role these 
variants play in defining risk, it will be important to determine the mechanisms by 
which these variants confer their effects through the use of functional experiments 
(including expression analyses). Once a greater understanding of these mechanisms 
is obtained, it might be possible to target them for therapy.
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Chapter Six - Identifying biallelic high penetrance CRC susceptibility alleles in
the BER, MMR and OxDR pathways
6.1 Introduction
6.1.1 MUTYH and CRC predisposition
It has previously been shown that the pattern of somatic mutagenesis in colorectal 
tumours can be used to identify novel CRC predisposition genes (Al-Tassan et al. 
2002, reviewed in Cheadle and Sampson 2003). Investigators studied a British 
family (Family N) with three affected siblings with multiple CRAs and carcinoma that 
did not carry an inherited APC gene defect. To provide a clue as to the underlying 
genetic defect, the entire APC open reading frame was sequenced in eleven 
tumours from Family N, revealing eighteen somatic APC mutations, 15 of which were 
G:C->T:A transversions. This class of mutations accounted for only ~10% of 
reported somatic APC mutations, with frameshift mutations and LOH being the more 
usual classes of mutations leading to somatic inactivation of APC in colorectal 
tumours. Comparison of the findings in Family N with a database of somatic APC 
mutations from sporadic and FAP-associated colorectal tumours, confirmed that the 
excess of G:C->T:A transversions in Family N (‘the mutator phenotype’) was highly 
significant (P=10'12). Previous studies in bacteria and yeast had shown a mutator 
phenotype with this characteristic in MutY and Ogg1-deficient strains and 
subsequent studies of the corresponding human orthologues showed that patients 
from Family N were germline compound heterozygotes for the nonsynonymous 
variants Y179C and G396D (formerly Y165C and G382D) in the human orthologue 
of MutY (termed MUTYH). Further studies (Jones et al. 2002, Sampson et al. 2003) 
have confirmed that biallelic mutations in MUTYH predispose to colorectal tumours 
and account for around a quarter of APC mutation negative patients with over 10 
CRAs.
Together the two MUTYH nonsynonymous mutations Y179C and G396D (that have 
minor allele frequencies (MAFs) of ~0.5% and 1%, respectively, in European normal 
controls) account for over 80% of mutant alleles in the British population (Sampson 
etal. 2003; Cheadle and Sampson, 2007). Significantly, both of these variants were 
documented in the public domain database dbSNP prior to the discovery that they
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were colorectal tumour predisposition alleles suggesting that this database may be a 
rich source of other, as yet undiscovered, CRC predisposition alleles. MUTYH 
functions as a BER DNA glycosylase and functionally cooperates with the MMR 
system to recognise and repair oxidative DNA damage as described in chapter 1.
6.1.2 Aims
Here, we screened our collection of 2,186 aCRC and 2,176 control samples for all 
nonsynonymous SNPs annotated within dbSNP from every gene in the BER, MMR 
and oxidative damage repair pathways (OxDR) pathways to identify other autosomal 
recessive ‘MUTYH-like’ genes. We searched for biallelic combinations of high 
penetrance alleles within each gene that were only found in cases with CRAs or 
CRCs and never found together in controls
6.2 Materials and Methods
6.2.1 Samples
(i) Cases with advanced CRC and controls
All 2,186 aCRC cases and 2,176 UKBS healthy controls have previously been 
described (chapters 3, 4 and 5)
(ii) Cases with multiple CRAs and controls
We analysed 163 unrelated index cases with multiple CRAs with or without 
carcinoma that were recruited from either UK or Dutch polyposis registers. No cases 
carried biallelic MUTYH mutations, or a truncating mutation in APC. We also 
analysed DNA samples from a panel of 480 unrelated healthy Caucasian controls 
purchased from the Health Protection Agency (Salisbury, UK).
(iii) POPGEN cohort and controls
The POPGEN cohort consisted of 2,147 histologically proven colorectal carcinoma 
patients. Patients were operated on between 2002 and 2005 in surgical departments 
in northern Germany. HNPCC patients were excluded. The patient cohort had a 
median age at diagnosis of 63 years (ranging from 18 to 92 years) and consisted of 
45% females. 2,787 geographically matched control samples from northern 
Germany were also used.
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6.2.2 Power considerations
We searched for biallelic combinations of rare nonsynonymous, truncating or splice- 
site mutations within each gene that were only found in cases with CRAs or CRCs 
and never found together in controls. Such an approach would have led to the 
identification of MUTYH as a CRC predisposition gene as exemplified by the study of 
Farrington et al. (2005) who studied 2,239 cases with CRC and 1,845 controls. They 
found 11 cases harboured biallelic Y179C/G396D mutations whereas such 
combinations were never found in controls. With the sample size of 2,200 cases and 
2,200 controls we had >95% power to detect the previously observed difference 
between the proportions of cases and controls harbouring biallelic MUTYH mutations 
at a 0.05 significance level.
6.2.3 Genes/Variants chosen for analysis
Genes involved (or implicated) in the BER, MMR and OxDR pathways were selected 
from the comprehensive Wood’s list of repair genes (Woods et al. 2005) and through 
literature searches. Variants within these genes were searched for using dbSNP 
(build version 129) (http://www.ncbi.nlm.nih.gov/projects/SNP/) or through literature 
review. The criterion for inclusion in this project was nonsynonymous SNPs in BER, 
MMR and OxDR pathway genes with a frequency of up to 2%, or with no frequency 
data. SNPs chosen from the respective pathways are presented in Tables 6.1, 6.2 
and 6.3.
6.2.4 Exclusion criteria
Given the divergence of SNP frequencies between populations, we excluded known 
non-Caucasian samples from our analysis - these were identified by reviewing the 
original patient notes. In addition, genes previously associated with CRC were 
excluded from the analysis since we were targeting novel tumorigenic mechanisms. 
The only exception to this was MUTYH, in which we chose Y179C and G396D to act 
as positive controls.
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Gene
Name
(aka)
Function Evidence for 
involvement in 
BER
SNPs successfully 
analysed
SNPs that failed locus 
conversion or failed 
genotyping
References
APEX1
(APE1,
REF1)
Human
endonuclease. 
Incises DNA 
backbone at AP site
Purified human 
APEX1 is able to 
remove 3’-8oxoG 
lesions
No nonsynonymous 
SNPs (nsSNPs)
rs34632023, rs2307486, 
rs1803118, rs33956927
Parson et al. 
2005
APEX2 Human
endonuclease. 
Incises DNA 
backbone at AP site
APEX2 deficient 
mice are smaller 
than wild-type mice. 
Implicated in post- 
replicative BER
No nsSNPs rs11541055, rs2301416, 
rs3180303, rs3180304
Ide et al. 
2003
APTX Catalyses the 
release of adenylate 
groups covalently 
linked to 5’ 
phosphate termini
Reduced
observation of DNA 
nicks and increased 
ligation products 
through addition of 
Aptx in E.coli
L74M rs12001066 Rass et al. 
2007
ERCC6
(CSB)
Principal function in 
transcription coupled 
repair. May 
influence repair of 
oxidised lesions 
through interaction 
with lesion-specific 
DNA glycosylases
Deficient cells have 
reduced capacity to 
repair 8oxoG
No nsSNPs rs2228525, rs2229761, 
rs34704611, 
rs34917815, 
rs41281957, rs4253046, 
rs4253206, rs4253208, 
rs4253219, rs4253227, 
rs4253228, rs4253229, 
rs4253230
Dianov et al. 
1999
FEN1 Endonuclease that 
functions in long 
patch BER. 
Processes Okazaki 
fragments
FEN1 deficient cells 
display
hypersensitivity to 
H20 2, suggesting 
defective BER
rs7931165, rs4989588, 
rs11541090
rs1803573, rs4989587, 
rs4989586
Asagoshi et 
al. 2010
LIG1 Joins DNA 
fragments generated 
during DNA 
replication and 
repair
Extracts from cell 
lines defective in the 
LIG1/PCNA 
interaction are 
defective in long 
patch BER
V753M, rs3730947, 
rs3730980
rs11668325, 
rs11879148, 
rs12981963, 
rs34087182, rs3730855, 
rs3730863, rs3730911, 
rs3730933, rs3730966, 
rs3731003, rs3731008, 
rs4987070, rs4987181
Levin ef al. 
2000
LIG3 Forms a complex 
with XRCC1. Seals 
nicks formed during 
BER
Extracts from LIG3 
deficient cell lines 
undergo defective 
BER
rs1076992, rs36021499, 
rs 1802880, rs4986974, 
rs35956074
rs35501315, rs4986973 Tomkinson et 
al. 2001
MBD4 Mono-functional 
DNA glycosylase 
that removes 
thymine from T:G 
mispairs
Mbd4 mutant mice 
show a 2- to 3-fold 
increase in C>T 
transitions
No nsSNPs rs2307289, rs2307293, 
rs2307296, rs2307298
Wong et al. 
2002
MPG
(AAG)
Mono-functional 
DNA glycosylase.
Cells deficient in 
MPG are
No nsSNPs E240D, rs25671, 
rs2234949, rs2266607,
Engelward et 
al. 1997
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Excision of 3- and 7- 
methyladenine
hypersensitive to 
killing by alkylating 
agents
rs2308312, rs2308315, 
rs3176383, rs769193
MTH1 Hydrolyses 8-oxo- 
dGTP, removing it 
from the nucleotide 
pool
Knock-out mice 
displayed greater 
numbers of lung, 
liver and stomach 
tumours than 
controls
K155I, V83M rs11547459, 
rs57000894
Tsuzuki etal. 
2001
MUTYH Bi-functional DNA 
glycosylase that 
excises mispaired 
adenine opposite 
8oxoG
Defects in MUTYH  
contribute to 
defective BER and a 
subsequent increase 
in G>T transversions
rs36053993 (G396D), 
rs34612342 (Y179C)
No nsSNPs Al-Tassan et 
al. 2002
NEIL1 Bi-functional DNA 
glycosylase. 
Suggested to act as 
a ‘back-up’ system 
to OGG1 and NTH
Deficient murine ES 
cells are more 
sensitive to the 
cytotoxic effects of 
y-irradiation than 
controls
NEIL1_434+2T>C, 
R339Q, rs5745905, 
rs7183491
P208S, rs5745906, 
rs5745907
Morland et al. 
2002;
Rosenquist et 
al. 2003; 
Fortini et al. 
2003
NEIL2 Bi-functional DNA 
glycosylase. Active 
towards several 
cytosine-derived 
lesions
Activity of NEIL2 
increases following 
oxidative stress
R164T, rs8191611, 
rs8191664, rs8191666
rs35400293, rs8191612, 
rs8191613, rs57683451
Das et al. 
2007
NEIL3 Bi-functional DNA 
glycosylase that 
recognises specific 
oxidized purines (but 
not 8oxoG)
Expression of its 
homologue in E.coli 
lacking other 
glycosylases 
reduced 
spontaneous 
mutation frequency
R315Q, rs34112288, 
rs17064676, 
rs36005630
D132V, rs35418725, 
rs61748603, 
rs58603054, 
rs58437627, 
rs58297365
Liu et al. 
2010
NTHL1
(NTH1)
Bi-functional DNA 
glycosylase that can 
remove oxidized 
pyrimidines
Shown to excise 
multiple oxidized 
pyrimidines
Q90X, rs2233522, 
rs1805378
rs3087468, rs3211977, 
rs3087469
Aspinwall et 
al. 1997
0G G 1 Bi-functional DNA 
glycosylase. Excises 
8-oxo-G from DNA
Cell extracts 
containing OGG1 
display lyase activity 
towards the 8oxoG 
lesions. Introduction 
of OGG1 to a 
spontaneous 
mutator strain of 
E.coli rescues them 
- reducing the rate of 
mutation
R46Q, A153T, G308E, 
I321T
rs1052140, rs11548133, 
rs1801128, rs1805373, 
rs3219012, rs3219014, 
rs56053615
Aburatani et 
al. 1997; 
Radicella et 
al. 1997
PARP1 Binds with high 
affinity to double- 
and single-strand
Knockout cells are 
sensitive towards 
alkylating agents
No nsSNPs rs1059011, rs1059040, 
rs1136420, rs1805409, 
rs3219057, rs3219145,
Allinson et al. 
2003;
M6nessier-de
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DNA breaks. Acts to 
protect strand 
interruptions
and irradiation and 
display genomic 
instability.
rs3738708 Murcia et al. 
1997; Wang 
et al. 1997; 
Vodenicharov 
et al. 2000; 
Wood et al. 
2005
PARP2 Binds with high 
affinity to double- 
and single-strand 
DNA breaks. Acts to 
protect strand 
interruptions
Deficient cells have 
delayed DNA strand 
break re-sealing. 
Knock-out mice are 
sensitive to ionising 
radiation and display 
genomic instability
rs2275010 rs 1128782, rs3093905, 
rs3093906, rs3093925
Schreiber et 
al. 2002; 
M6nessier-de 
Murcia et al. 
1997
PCNA Required for the 
repair initiation step 
of MMR and repair 
DNA resynthesis
Extracts from cell 
lines defective in the 
LIG1/PCNA 
interaction are 
defective in long 
patch BER
rs1050525 No nsSNPs Levin et al. 
2000
PNKP
(PNK)
Kinase that removes 
3’ phosphate groups 
and adds 5’ 
phosphate groups to 
hydroxyl termini
Shown to remove 
the 3’ phosphate 
from NEIL1 
generated termini
No nsSNPs rs11555414, 
rs11671530, 
rs34472250, rs3739168, 
rs3739173, rs3739185, 
rs3739186, rs3739206
Wiederhold 
et al. 2004
POL/3 In short patch BER, 
extends the 3’-OH 
terminus and 
removes the 5’ 
phosphate
Cell lines carrying a 
homozygous 
deletion mutation in 
POL/3 show 
defective BER
rs56121607, 
rs12678588, 
rs10091081, rs3136797
No nsSNPs Sobol et al. 
1996
POLy Localised to 
mitochondria. 
Replicates and 
repairs
mitochondrial DNA
Shown to excise 
deoxyribose 
phosphate from AP 
sites
G268A, rs2307437, 
rs2307447, rs2307450, 
rs41549716, 
rs56119329, 
rs56410699, 
rs60636456, 
rs11546842
rs2307440, rs2307442, 
rs28567406, rs3087373, 
rs3176162, rs61472028, 
rs56047213
Longley et al. 
1998; Pinz 
and
Bogenhagen,
2006
SMUG1 Mono-functional 
DNA glycosylase. 
Targets uracil and 
uracil derivatives
Initially isolated 
through its ability to 
bind DNA damage 
lesions. Shown to 
target uracil 
residues
rs2233919 rs1043202, rs3136389, 
rs3087405, rs2233920
Haushalter et 
al. 1999; 
Matsubara et 
al. 2004
TDG Mono-functional 
DNA glycosylase. 
Targets thymine and 
uracil when 
mispaired with 
guanine
Purified protein 
excises mispaired 
thymine in HeLa 
cells
T19M, 1134V, Q391K rs 12367528,
rs17853764, rs3953596,
rs3953597, rs3953598
Neddermann 
and Jiricny, 
1993
TDP1 Member of the Shown to efficiently No nsSNPs rs34452707, Interthal et al.
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phospholipase D 
super-family that 
hydrolyses the 
phosphodiester 
bond between a 
DNA 3’ end and a 
tyrosyl moiety. 
Known to interact 
with BER proteins
cleave at AP sites 
using duplex DNA - 
efficiency similar to 
that of NEIL1. 
Mitochondrial BER 
depends on TDP1 
activity
rs35114462, 
rs35455108, 
rs35973343
2005; Brata 
Das et al. 
2010
UNG1 Mitochondrial. 
Mono-functional 
DNA glycosylase. 
Targets Uracil for 
excision.
Ung-/- mice exhibit a 
moderate increase 
in genome-wide 
spontaneous 
mutagenesis
No nsSNPs No nsSNPs An et al. 
2005; Hazra 
et al. 2007
UNG2 Nuclear. Repairs 
deaminated cytosine 
amongst other 
lesions. Binds 
PCNA.
Nuclear extracts of 
human UNG2 
initiates BER of 
plasmids containing 
U:A and U:G
No nsSNPs No nsSNPs Kavli et al. 
2002
XRCC1 Scaffolding protein 
involved in repair of 
single-strand 
breaks. Has no 
catalytic activity itself
xrccl mutant cells 
are partially 
defective in ligation 
of base excision 
repair patches. 
Interacts physically 
and functionally with 
OGG1
rs25474, rs2307184, 
rs2682557, rs2307167, 
rs2307186, rs2307191
rs2307177, rs2307166, 
rs41561817, rs2271980, 
rs2307188, rs2307180, 
rs2307171, rs11553659
Cappelli et al. 
1997; Marsin 
et al. 2003
Table 6.1 - Genes implicated in BER. Listed are SNPs (with MAFs <2%) 
successfully analysed and those that either failed in silico design or failed 
genotyping. Though they initially failed genotyping on the illumina platform, Y179C 
and G396D of MUTYH (bold) were successfully genotyped via combined use of 
restriction digest and Taqman based assays.
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Gene
Name
(aka)
Function Evidence for 
involvement in 
MMR
SNPs successfully 
analysed
SNPs that failed locus 
conversion or failed 
genotyping
References
BCL2 Proto-oncogene that 
may regulate 
MSH2/6 complex. 
Pro-survival factor 
implicated in a 
number of cancers.
Deletion of specific 
domains of Bcl2 
influences its 
interaction with 
MSH6 and 
associates with 
enhanced MMR 
efficiency
No nsSNPs rs1800477 Hou et al. 
2007
DNMT1 Maintains global 
methylation after 
DNA replication
Deficient cells 
exhibit higher MSI 
than normal cells
rs16999593, 
rs35622143, DNMT1
No nsSNPs Ge Guo et al. 
2004
E X 01 DNA exonuclease. 
Can physically 
interact with MMR 
proteins MSH2, 
MLH1 and MSH3
Mice lacking exon 6 
of Exo1 exhibited 
defective MMR
rs4149864, rs4149967 rs4149865, rs4149962,
rs4149964, rs60358723,
rs60320391,
rs60293068,
rs59790129,
rs59734256,
rs59699975,
rs57175702,
rs56561721, rs4149966,
rs4149978
Bardwell et al. 
2004
HMG1
(HMGB1)
Chromosomal 
proteins -  bind 
major groove of 
DNA causing local 
distortion of the 
double helix
Protein purified 
through its ability to 
repair mismatches in 
depleted HeLa cells
rs2388544 rs3956321, rs4597168, 
rs11546137
Zhang et al. 
2008; Yuan et 
al. 2004
MAX Transcription factor 
that associates with 
MSH2
May exert effects 
through its 
interaction with 
MSH2. May also 
help regulate MLH1 
and MSH2  
expression
rs17852278 No nsSNPs Partlin et al. 
2003; Bindra 
and Glazer, 
2007
MED1 Involved in 
regulating 
transcription. 
Interacts with MLH1. 
Associated with the 
integrity of the MMR 
system
Cells lacking MED1 
show decreased 
steady state 
amounts of MMR 
proteins (including 
Msh2, Msh6, Mlh1), 
possibly through a 
post-transcriptional 
mechanism
rs35668211, 
rs35379518, rs1139823, 
rs1139821, rs61673563
rs36022909, rs1139828, 
rs1139822, rs1139820
Corteilino et 
al. 2003; 
Bellacosa et 
al. 1999
MRE11 Nuclear protein 
involved in a number 
of maintenance 
processes. May be
MRE11 deficiency 
leads to a significant 
increase in MSI for 
both mono- and
R488C rs1061945, 
rs116679717, 
rs1805367
Vo et al. 
2005
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involved in 3' 
directed mismatch 
repair
dinucleotide 
sequences in HeLa 
cells
MSH4 Part of MMR 
machinery
No evidence for role 
in HNPCC. Included 
based on
relationship to other 
MMR proteins
rs5745329, rs17853142 rs5745311, rs5745324, 
rs60345283, 
rs60751948
MSH5 Part of MMR 
machinery
No evidence for role 
in HNPCC. Included 
based on
relationship to other 
MMR proteins
rs1802127, rs28381349, 
rs28399977,
rs28381358, rs56200818
rs28399976, 
rs45468693, MSH5
MYC Transcription factor 
associated with 
MLH1
Deregulated 
expression linked 
with influence on 
MMR activity
No nsSNPs rs114570780,
rs61755060, rs4645960,
rs4645968
Partlin et al. 
2003
PMS2L3
(PMS5,
PMSR3)
MutL homolog of 
unknown function
Mutagenised yeast 
led to isolation of 
PMS2L3, along with 
other known PMS 
proteins
No nsSNPs rs3203011, rs2599335, 
rs2599333, rs2599332, 
rs794377
Jeyaprakash 
et al. 1994
PMS2L4
(PMS6)
MutL homolog of 
unknown function
Mutagenised yeast 
led to isolation of 
PMS2L4, along with 
other known PMS 
proteins
rs7784159 rs7783101, rs7806476, 
rs1136533, rs10233400, 
rs11559285, 
rs17433617, 
rs58072630, 
rs12531701
Jeyaprakash 
eta l. 1994
P0L51 Directly involved in 
DNA replication -  
specifically lagging 
strand synthesis. 
Intrinsic proof 
reading 
exonucleases 
cooperate with MMR
Depleted HeLa cells 
had MMR activity 
restored by addition 
of calf thymus DNA 
polymerase delta
rs3218775, rs1052471, 
rs1726803, rs3219457, 
rs41563714, rs8105725, 
rs2230243
rs9282830, rs55955638, 
rs3218773, rs9282831, 
rs2230241, rs58282823, 
rs3218750, rs11550555, 
rs3218772, rs41554817
Longley et al. 
1997
POLe Directly involved in 
DNA replication -  
specifically leading 
strand synthesis. 
Intrinsic proof 
reading 
exonucleases 
cooperate with MMR
Like POL51, mutant 
mice display 
increased rate of 
mutation and 
spontaneous 
cancers
rs11146982, rs5744758, 
rs5744777, rs5744822, 
rs5744834, rs5744845, 
rs5744888, rs12315832, 
rs5744739, rs5744760, 
rs5744947, rs5744950, 
rs5744991, rs7487595, 
rs5744955, rs5744971, 
rs41561818, rs5744800, 
rs56102033
rs5745067, rs5744935, 
rs58151768, rs5744933, 
rs36120395, rs5744752, 
rs60851699, 
rs57754437, 
rs57061760, 
rs56903770, 
rs56081968, 
rs11146986, rs5744972, 
rs5744943, rs5744856, 
rs5744801, rs5744734, 
rs5744799, rs5744904, 
rs5744948, rs5745021, 
rs5745068, rs58916399
Albertson et 
al. 2009
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RECQL
(RECQ1)
DNA helicase. 
Interacts with MMR 
factors
Stimulates the 
MSH2/6 complex
rs1065751, rs2230003, 
rs3207640
rs6499, rs17849407, 
rs4987215, rs6501, 
rs3983531
Doherty et al. 
2005
RFC
(RFC1)
Multi-subunit 
ATPasethat 
functions in DNA 
replication and 
repair. Required for 
PCNA loading
A mutant allele of 
RFC1 associates 
with a 10-fold 
increase in number 
of dinucleotide 
repeat instability
rs12502450,
rs17288828,rs17335452, 
rs2066791,rs2306598, 
rs28903095, rs1057749, 
rs1057751 ,rs17854711, 
rs55704262, rs55734630
rs28903096, rs1135544, 
rs1057747, rs56273953, 
rs17419994, 
rs34586398
Masih et al. 
2008; Xie et 
al. 1999
R FX
(RFX1)
Transcription factor. 
Stimulates 5' to 3' 
mismatch provoked 
excision in vitro
RFX knock-out in 
HeLa cells creates 
MSI phenotype
rs2305780 rs60197642 Zhang et al. 
2008
RPA
(RPA1)
Stimulates excision, 
stabilises the 
ensuing gap against 
endonuclease attack 
and promotes repair 
DNA synthesis
Wild-type, but not 
mutant, RPA 
rescues MMR in 
RPA-depleted cell 
lysate
rs12449332, rs41547814 rs56805137,
rs55800538
Lin et al. 1998
Table 6.2 - Genes implicated in MMR. Listed are SNPs (with MAFs £2%) 
successfully analysed and those that either failed in silico design or failed 
genotyping. There was a small overlap between the BER and MMR pathways. The 
following genes from the BER pathway have also been implicated in MMR but were 
not included here; FEN1, LIG1, MBD4, PCNA.
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Gene
Name
(aka)
Function Evidence for 
involvement in 
OxDR
SNPs successfully 
analysed
SNPs that failed locus 
conversion or failed 
genotyping
References
JWA Reacts as part of 
cellular response to 
environmental 
exposures such as 
heat and chemical 
stress
JWA upregulated in 
oxidative stress cell 
culture models.
rs6803501, rs11542218 rs11542221, rs1802400 Chen et al. 
2007
POLL DNA polymerase 
that functions in 
non-homologous 
end joining and 
DSBR
Fibroblasts from 
POLL null mice are 
hypersensitive to 
oxidative DNA 
damaging agents
rs55727130 rs55978126, rs3209099 Braithwaite et 
al. 2005
TIGAR p53 inducible protein 
that regulates 
glycolysis and 
protects against 
oxidative stress
Expression levels 
influence 
intracellular ROS 
levels
No nsSNPs No nsSNPs Bensaad et 
al. 2006
Table 6.3 - Genes implicated in OxDR. Listed are SNPs (with MAFs £2%) 
successfully analysed and those that either failed in silico design or failed 
genotyping. There was significant overlap between OxDR, BER and MMR pathways. 
The following genes from the BER and MMR pathways have also been implicated in 
general OxDR but were not included here; APEX1, FEN1, HMG1, LIG3, MTH1, 
MUTYH, NEIL1, NEIL2, NEIL3, NTHL1, OGG1, PCNA, POLp, POL51, RFC,
SMUG1, UNG1, XRCC1.
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6.2.5 Genotyping
Genotyping was performed by lllumina's Fast-Track Genotyping Services (San 
Diego, CA) using their high throughput BeadArray™ technology.
Since genotyping of the Y179C and G396D control variants failed on the illumina 
chip we used a combination of restriction digest and Taqman-based assays. For 
restriction digests, PCR amplification was performed in 25pl reaction volumes using 
standard reaction conditions. For Y179C we amplified exon 7 and carried out 
restriction digests using Mwol (NEB). For G396D we amplified exon 13 and carried 
out restriction digests using Bglll (Pharmacia). Restriction digest of OGG1 samples 
that failed genotyping of G308E on the Illumina platform was carried out using Avail 
(NEB).
6.2.6 Genotyping of the POPGEN samples
Genotyping of OGG1 G308E variant was carried out using a custom designed 
Taqman SNP genotyping assay (Applied Biosystems).
6.2.7 Sanger sequencing
We sequenced the ORFs and splice sites of those patients that carried single 
heterozygous MUTYH (Y179C and G396D), OGG1 (G308E) and MTH1 (V83M) 
variants. Primer sequences used for amplification and sequencing are shown in 
Tables 6.4, 6.5 and 6.6. Sequencing was performed using Applied Biosystems ABI 
Prism 3100 genetic analyzer. Sequences were analysed using Sequencher software 
(Sequencher 4.6 - Build 2496).
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Exon Forward primer sequence Reverse primer sequence
1 CTT CCCCT CT CCCAGAGC AT CCCCGACT GCCT GAACC
2 CT GC ATTT GGCT GGGT CTTT CGCACCTGGCCCTTAGTAAG
3 GGCCAGAAACTTAGCCACAG CAACCCCAGATGAGGAGTTAGG
4 CT CAT CT GGGGTT GCATT GA GGGTT GGCAT GAGGAC ACT G
5 GGGCAGGT CAGCAGTGTC TACACCCACCCCAAAGTAGA
6 T ACTTT GGGGT GGGT GTAGA AAGAGATCACCCGTCAGTCC
7 GGGACT GACGGGT GAT CT CT TT GGAGT GCAAGACT C AAGATT
8 CCAGG AGT CTT GGGT GT CTT AG AGGGGCC AAAG AGTT AGC
9 AACT CTTT GGCCCCT CT GT G GAAGGG AAC ACT GCT GT G AA
10 GT GCTT CAGGGGT GTCTGC T GT CAT AGGGCAG AGT CACT CC
11 T AAGGAGT G ACT CT GCCCT AT G ACT GGAAT GGGGCTT CT GAC
12 AGCCCCT CTT GGCTT GAGT A TGCCGATTCCCTCCATTCT
13 AGGGC AGT GGC AT G AGT AAC GGCT ATT CCGCTGCT C ACTT
14 I I GGC I FTTGAGGCTATATCC CAT GTAGG AAAC AC AAGG AAGT A
15 TGAAGTTAAGGGCAGAACACC GTT CACCC AGAC ATT CGTTAGT
16 AGGAC AAGGAG AGGATT CT CT G GGAATGGGGGCTTTCAGA
Table 6.4 -  Primers used in the amplification and sequencing of MUTYH
Exon Forward primer sequence Reverse primer sequence
1 CTTTGGGCGTCGACGAG GAGGGG AC AGGCTT CT CAG
2(1) ATT GAGT GCC AGGGTT GT CA CGG AACCCC AGT GGT GAT AC
2(2) T GT ACT AGCGG AT C AAGT AT T G GC AAAACT GAGT CATAG
3(1) GTCTGGT GTT GCTTT CT CTAAC GT GAT GCGGGCGAT GTT
3(2) TCTCCAGGTGTGCGACTGC AGGAAGCCTT GAGAAGGT AACC
4 GGAAGAACTT GAAGAT GCCT GCT CATTTCCT GCT CTCC
5 CCGGCTTT GGGGCT AT A GTTTCTACCATCCCAGCCCA
6(1) TACTTCTGTTGATGGGTCAC TGGAGGAGAGGAAACCTAG
6(2) AGT CACCTCTCCCTCAGACC GGCT GGAGAGT CCTTTAGGG
7(1) ACCT CCCAACACTGTCACTA T G AACCGGGAGTTT CT CT GC
7(2) AGGCTT AGCACTT GC ACTT CC AGGGAT CCTTACT GAAGGAC
8(1) CT GT GGCCCACGCACTT GT G ACGT CCTT GGT CCAGC AGT GGT
8(2) GAG AGGGGATT CACAAGGT G GCCATTAGCTCCAGGCTTAC
Table 6.5 -  Primers used in the amplification and sequencing of OGG1
Exon Forward primer sequence Reverse primer sequence
2 GC AAGG AC AG AGGGCTTT CT G CCAGC AGGCC AT C AACT GAT
3 GC ACGT CAT GGCT G ACT CT CTGGGAAAGCCGGTTCTAT
4 TCCCTGGGCTGTGTGTAGAT GAGATGGGACCCGCATAGT
5 T G AAGTTT GGGTT GC ACCT C AGAT GGTTTGCGGCT GTT C
Table 6.6 -  Primers used in the amplification and sequencing of MTH1 (exon 1 non­
coding).
167
6.2.8 Cloning
Three patients carried potential bi-allelic mutations (MUTYH G396D and R426L in 
the first, MUTYH G396D and A473T in the second and OGG1 G308E and A288V in 
the third). We used cloning to determine if the variants were on the same or opposite 
DNA strands. Purified amplification products were transformed into high competence 
JM109 cells which were grown on agar plates. DNA from single colonies was 
extracted and sequenced using the ABI 3100 system. Sequences were viewed using 
Sequencher software.
6.2.9 in silico  analysis of variants
We used a combination of computational programs that predict the functional 
consequence of amino acid changes based on complex algorithms. These were 
Polyphen (http://genetics.bwh.harvard.edu/pph/), Align GVGD 
(http://agvgd.iarc.fr/index.php) and SIFT (http://sift.jcvi.org/). Determination of the 
conservation of a given sequence between various organisms was carried out using 
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
6.2.10 Somatic analyses
Where available, tumour DNA from samples of interest was analysed for somatic 
mutations of OGG1. Tumour DNA was extracted as described in chapter 3.
6.2.11 Statistical analysis
Differences between the proportions of cases and controls with each variant were 
analysed using the Fisher’s exact test.
6.3 Results
6.3.1 Use of the MUTYH variants as controls
Genotyping of the MUTYH variants Y179C and G396D failed on the Illumina golden 
gate platform. We proceeded to genotype them using a combination of restriction 
digest and TaqMan assay methods. Three hundred and sixty seven samples were 
genotyped via both methods to ensure accurate genotyping, showing 100% 
genotype concordance. The genotype success rates for Y179C and G396D were 
99.7% (4351/4362 samples were successfully genotyped) and 99.5% (4340/4362
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samples successfully genotyped), respectively. In total, only 27 (0.6%) aCRC 
samples failed genotyping.
6.3.2 Analysis of MUTYH
Amongst the 2,159 successfully analysed aCRC samples, we identified 11 
heterozygotes and one homozygote for Y179C, 33 heterozygotes and one 
homozygote for G396D, and no compound heterozygotes (Table 6.7). We found 
similar numbers of Y179C and G396D heterozygotes in cases and controls (no 
controls were homozygous or compound heterozygous for the MUTYH mutations).
All heterozygous samples (cases and controls) were sequenced for the entire 
MUTYH open reading frame (ORF) to identify potential biallelic mutations. Apart from 
the well characterised common polymorphisms V22M and Q338H, we identified a 
single case of R426L in exon 13 and A473T in exon 14, in different patient samples 
that also carried G396D.
6.3.3 Cloning and sequencing of MUTYH
Cloning and sequencing of the genomic regions spanning exons 13 and 14 in the 
relevant patient samples showed that both R426L and A473T were on opposite 
strands to G396D indicating that these patients were R426L/G396D and 
A473T/G396D compound heterozygotes, respectively. Upon review of the pathology 
notes, the patient homozygous for Y179C and the R426L/G396D compound 
heterozygote were reported as having ‘multiple adenomas’ and ‘multiple polyps’, 
respectively. No information was available on the two remaining patients. In total 
therefore, we identified four biallelic MUTYH patients (the R426L/G396D and 
A473T/G396D compound heterozygotes and the Y179C and G396D homozygotes) 
across our cohort of 2,186 cases.
6.3.4 in s ilico  analysis
R426L was predicted as likely to have a functional effect by Align-GVGD and to be 
‘possibly damaging’ by Polyphen and A473T was predicted to have a possible effect 
by Align-GVGD but tolerated by Polyphen.
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6.3.5 Identifying novel CRC predisposition alleles
Of the 349 SNPs that passed our exclusion criteria, 193 (55.3%) failed in silico 
conversion and 30 (8.6%) were analysed on the chip but the assay failed, leaving 
126 (36.1%) SNPs successfully genotyped. The majority of SNPs that failed in silico 
analysis did so either due to their close proximity (<60bp) to other SNPs analysed on 
the chip or the prediction software deemed them likely to fail analysis. Sixty-one, 70 
and 74 SNPs were successfully analysed from the BER, MMR and OxDR pathways 
respectively.
6.3.6 Bi-allelic variants
In total, 13 genes from the three repair pathways were found to contain two or more 
mutations in cases. Of the 11 involved in BER, 9 (APEX1, UG1, MBD4, NEIL1, 
NEIL3, PARP2, ERCC6, POLG, TSHZ3) had combinations that were also seen in 
controls thus excluding these combinations from having a role in CRC predisposition. 
All 6 of the genes involved in MMR (EX01, UG1, MBD4, MSH4, MSH5, POLs) had 
biallelic combinations that were observed in both cases and controls. For the OxDR 
pathway, 4 of the 6 genes (APEX1, NEiL1, NEIL3, XRCC1) had combinations 
observed in both cases and controls. No combinations of variants were unique to 
controls.
Two genes were found to contain a combination of two rare nonsynonymous variants 
that were only found in cases with CRAs or CRCs and never found together in 
controls. These were OGG1 and MTH1. Details of the biallelic variants, and their 
biallelic nature, are presented in Table 6.7. These two genes are involved in the BER 
and the OxDR mechanisms.
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Gene
Name
Genotype
aCRC
cases
(n-2186)
UKBS
controls
(n=2176)
Y179C/wt 11 10
Y179C/Y179C 1 0
MUTYH G396D/wt 33 29
G396D/G396D 1 0
Y179C/G396D 0 0
G308E/wt 35 15
OGG1
G308E/G308E 1 0
V83M/wt 24 20
MTH1
V83M 1 0
Table 6.7 - Genes with combinations of two rare nonsynonymous variants that were 
only found in CRC cases and never found together in controls, wt -  wild-type
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6.3.7 Biallelic variants of OGG1
The 0GG1 variant G308E (rs113561019) was found to exist in a homozygous state 
in one case but no controls.
6.3.8 Analysis of OGG1
All G308E heterozygous samples (CRC and CRA cases and controls) were 
sequenced for the entire OGG1 ORF and splice regions to identify potential biallelic 
mutations. In total we identified 4 variants across the ORF of OGG1. These were the 
exon 3 variant R134Q which was observed in one control sample, the exon 5 variant 
A288V which was observed in one case sample, the common exon 6 variant P332A 
which was observed in 6 cases and 4 controls, and the synonymous P477P variant 
which was seen in 4 cases and 1 control.
6.3.9 Cloning and sequencing of OGG1
Cloning and sequencing of the genomic region spanning exons 5 and 6 in the 
relevant patient samples showed that A288V was on the opposite strand to G308E, 
indicating that this patient was a A288V/G308E compound heterozygote. Therefore, 
we identified two biallelic OGG1 patients (A288V/G308E and the G308E 
homozygote) as compared to no biallelic controls.
6.3.10 Somatic sequencing of OGG1
We sought evidence of a second hit of OGG1 by screening 23 samples carrying 
heterozygous G308E (tumour material was not available for the remaining samples). 
The A400T variant was found in one case. The functional consequence of this 
variant is unknown.
6.3.11 In silico analysis
G308E was predicted to be damaging by all in silico analysis programs used. 
Conservation of the base was compared across a series of species including yeast, 
mouse, bovine, drosophila and humans (Figure 6.1). It was found to be conserved 
across all species considered. We also carried out in silico analysis of the A288V 
variant and found that it was predicted to be benign and damaging by Polyphen and 
AlignGVGD respectively. The same analysis of the somatic variant A400T found that 
it was predicted to be benign and likely to be damaging.
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6.3.12 0GG1 overrepresentation and validation in the POPGEN population
We compared the frequency of G308E in aCRC cases (1 homozygous and 35 
heterozygous) and controls (0 homozygous and 15 heterozygous) and found that it 
was overrepresented in aCRC (X2=9.6, P=0.002). In addition, we screened for 
G308E in OGG1 in 163 patients with CRAs and 480 healthy controls. We identified 3 
cases carrying this variant as compared to 1 control sample (P=0.05), suggesting 
that this variant may also predispose to CRAs.
To clarify the contribution of OGG1 G308E to CRC risk, we attempted to validate the 
initial association in a separate cohort. We analysed 2,169 samples from unrelated 
patients with CRC from the POPGEN cohort. Of the 2,122 successfully analysed 
cases, 15 were heterozygous and none were homozygous mutant for G308E. Of the 
2,741 successfully analysed controls, 26 were heterozygous and none were 
homozygous mutant. Therefore G308E was not overrepresented in this setting 
(X2=0.8, P=0.362)
6.3.13 Pattern of somatic mutagenesis
We reviewed data from the COIN trial (Chapter 3) to determine if a pattern of 
somatic mutagenesis was present in the two patients carrying biallelic mutations of 
OGG1. Both patients carried the G12D mutation of KRAS which is a G>A transition.
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Human
Orang-utan
Rhesus Macaque
Cow
Dog
Mouse
Rat
Chicken
Frog
Zebra-fish
Salmon
Drosophila
Arabidopsis
Yeast
Fungus
WHIAQRDYSWHPTTSQ1KGPSPQTNKE-------------- LGNFFRSLW
WQIAQRDYSWHPTTSQ|KGPSPQTNKE-------------- LGNFFRSLW
WQIAQRDYSWHPTTSQ|KGPSPQSNKE-------------- LGNFFRSLW
WQIAQRDYSWHPTTSQIKGPSPQANKE-------------- LGNFFRNLW
WQIAQRDYSWHPSTSQiKGPSPQTNKE-------------- LGNFFRSLW
WQIAHRDYGWHPKTSQ|KGPSPLANKE-------------- LGNFFRNLW
WQIAHRDYGWQPKTSQTKGPSPLANKE-------------- LGNFFRNLW
WHIARQRYGAALG |RSLTARVHQE-------------- IGDFFRELW
WQVAKRD YL PQLGS -GNKTLT DRVYRE-------------- TGDFFHNLW
WQIAKRDYNFAPGT-SQKTLTDRVYKE---------------IGDFYRKLW
WQIAKRDYSCAAGN-GQKSLTDKVHRQ---------------IGDFFRQLW
YRIAQN— YYLPHLTGQKNVTKKIYEE-------------- VSKHFQKLH
WQIATN— YLLPDLAG-AKLTPKLHGR-------------- VAEAFVSKY
SRIAKRDYQISANKNHLKELRTKYNALPISRKKINLELDHIRLMLFKKW
YQIAVRDYKFKGNK-SMKTLNKETYAA-------------- IRLFFKDIF. . *
PYAGWAQAVL 318
PYAGWAQAVL 318
PHAGWAQAVL 318
PYAGWAQAVL 320
PYAGWAQAVL 308
PYAGWAQAVL 318
PYAGWAQAVL 318
PYAGTAE 297
PYAGWAQSVL 357
PYAGWAQSVL 344
PYAGWAHSVL 345
KYAGWAQAIL 317
EYAGWAQTLL 327
SYAGWAQGVL 323
EYAGWAQSVL 306 
. *  *  *
Figure 6.1 - Conservation analysis of the OGG1A288V (green) and G308E (red) variants across a series of species. An amino 
acid conserved across all species is indicated with an asterisk (*). Though not shown, conservation analysis of the rest of the gene 
was carried out and residues conserved across all species tested are relatively uncommon (45/345 human residues).
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6.3.14 Biallelic variants of MTH1
The MTH1 variant V83M (rs4866) was found to exist in a homozygous state in one 
case. The SNP was also found in a heterozygous state in 24 cases (CRC) and 20 
controls (MAF of 0.5%). This SNP was not overrepresented in CRC cases as 
compared to controls (X2=0.8, P=0.381) nor in CRAs.
6.3.15 Analysis of MTH1
We sequenced the ORF and splice regions of V83M heterozygous cases (CRC and 
CRA) and controls. Besides a synonymous aspartic acid variant at codon 142 
(D142D) which was observed in 3 cases and 5 controls, no new variants were 
observed.
6.3.16 In Silico analysis
We carried out in silico analysis of the MTH1 variant V83M. It was found to be 
conserved across human, bovine and mouse. V83M was predicted to be benign by 
both Polyphen and AlignGVGD.
6.4 Discussion
6.4.1 MUTYH proof of principle
The established pathogenic MUTYH variants Y179C and G396D were included in 
this analysis as ‘proof-of-principle’ controls. We found two CRC cases that were 
homozygous for these variants and proceeded to identify two further patients that 
were R426L/G396D and A473T/G396D compound heterozygotes. No controls 
contained a biallelic combination of MUTYH variants. Whilst the number of biallelic 
mutation carriers was less than expected, we nonetheless prove that this screening 
approach would have highlighted the importance of rare MUTYH variants in 
predisposition to CRC.
6.4.2 Prognostic effect of MAP
We compared the frequency of patients with biallelic MUTYH mutations in the aCRC 
setting to previous studies of CRC patients with earlier stages of disease. Cleary and 
colleagues (2009) studied 3,811 cases with CRC collected from a multisite CRC 
registry from Canada, the United States and Australia. In total, 42.8% of their cases
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had Stage 1 disease, 30.1% had Stage 2 disease, 22.2% had Stage 3 disease and 
5.6% had Stage 4 disease/aCRC. Overall, they identified a total of 27 cases with 
biallelic MUTYH mutations, which included one of the 212 patients with aCRC. We 
found that patients with biallelic MUTYH mutations were much rarer in the advanced 
as compared to the earlier (Stages 1-3) disease setting (4/2,159 vs. 26/3,623,
P= 3.58x1 O'3, using our aCRC data; and 5/2,371 vs. 26/3,623, P=4.53x10‘3with the 
aCRC data combined).
Other large population based studies of CRC have also screened for MUTYH 
mutations and although none give comprehensive breakdowns of their disease 
spectrum, it is likely that both have distributions similar to the registers described 
above. Seventeen patients with biallelic MUTYH mutations were identified amongst 
3,145 Scottish CRC cases (Farrington etal. 2005; Tenesa etal. 2006) (P=3.18x10'2 
compared to the advanced disease setting) and 8 patients with biallelic MUTYH 
mutations were identified amongst 1,116 Spanish CRC cases (P=2.14x10'2 
compared to the advanced disease setting). Although Lubbe and colleagues (2009) 
identified 27 patients with biallelic MUTYH mutations amongst 9,268 British CRC 
cases (which is not significantly different compared to the advanced disease setting), 
this study did not screen their one-hundred and ninety-eight Y179C or G396D single 
heterozygotes for biallelic mutations, so the true number of biallelic MUTYH cases is 
likely to be significantly under-represented. Therefore, patients with biallelic germline 
MUTYH mutations have a significantly improved prognosis as compared to patients 
that do not carry these mutations.
6.4.3 OGG1
The OGG1 gene was found to carry biallelic variants in two aCRC cases and in no 
controls. One case was a carrier of homozygous G308E, while the other was a 
compound heterozygote for G308E and A288V. OGG1 plays a critical role in the 
BER process, excising the 8oxoG lesion from the 8oxoG:C duplex that results from 
oxidative damage. Given this role in a repair pathway that has already been linked 
with CRC predisposition, OGG1 represented an excellent candidate for further study.
G308E was first observed in a screen of OGG1 in patients with head and neck 
cancer (Blons et al. 1999). Glycine 308 is a conserved amino acid in a range of
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diverged species (human to yeast to drosophila). Blons and colleagues produced 
GST fusion proteins (representing the normal and variant protein) and tested their 
activity through in vitro and in vivo substrate cleavage assays. They found that 
purified protein containing the variant displayed an ability to cleave a double­
stranded DNA 34-mer containing an 8oxoG:C base pair, that was equivalent to 
protein containing the wild-type amino acid sequence. Beyond this initial data, little is 
known about the effect of G308E though it results in the substitution of an aliphatic 
residue with an acidic residue and is predicted to be damaging by a range of 
prediction software.
A288V has been linked with reduced glycosylase activity. In their study of 
Alzheimer’s patients, Mao and colleagues (2007) screened 14 patients for OGG1 
mutations. One of the four variants they identified was A288V which showed 
decreased glycosylase activity (50-60% activity as compared to wild-type protein). 
They suggest that this variant probably functions by reducing the affinity of the 
glycosylase for the DNA substrate. Indeed the crystal structure of the protein would 
suggest this as alanine 288 comes into direct contact with DNA. A recent kinetic 
analysis of this variant (Sidorenko et al. 2009) confirmed reduced protein activity 
(~30% less efficient compared to wild-type) through an oligonucleotide cleavage 
assay. This was not, however, confirmed by an irradiated DNA assay where its 
cleavage capacity was comparable to wild-type protein. The 3D locations of this 
variant, and G308E, are highlighted in Figure 6.2.
We analysed COIN trial data (chapter 3) to determine if a pattern of somatic 
mutagenesis was observed in the two patients carrying a biallelic combination of 
variants. Based on the functional overlap OGG1 has with MUTYH, we expected to 
see G to T transversions. Instead we observed that both cases carried G to A 
transitions in KRAS. The significance of this is unknown though G to A transitions 
can result from 8oxoG:T mispairs which are a secondary target of OGG1 (Bjoras et 
ai. 1997). Bjoras and colleagues suggest that there are potential issues for strand 
discrimination when OGG1 encounters less common mispairs such as 8oxoG:T and 
it would be interesting to see if G308E is capable of influencing this.
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0GG1 G308E was initially found to be over-represented in aCRC cases as 
compared to healthy controls (X2=9.6, P=0.002). Despite this, we did not show an 
association in an independent cohort of 2,713 histologically proven colorectal 
carcinoma patients and 2,145 controls (X2=0.8, P=0.366). It is possible that the 
effects of OGG1 G308E are specific to the metastatic/advanced diseased state and 
as such this requires further investigation.
6.4.4 MTH1
The MTH1 V83M variant was found to exist in a biallelic state (i.e. homozygous) in 
one case and no controls. Like OGG1, MTH1 has a critical role within the BER 
process, functioning to remove 8-oxodGTP from the nucleotide pool. Interestingly, 
V83M has been associated with an increased risk of small cell lung carcinoma 
(Kohno etal. 2006) and gastric cancer (Kimura et al. 2004). V83M containing protein 
has been reported to be structurally and catalytically more thermolabile than the wild- 
type protein (Yakushiji etal. 1997). Coincident with its association with gastric 
cancer, the presence of the 83M variant correlates with somatic mutation of the p53 
tumour suppressor gene, specifically G:C->T:A and A:T->C:G transversions 
(Tsuzuki etal. 2001b; Kimura etal. 2004). Interestingly, our patient that was 
homozygous for V83M was found to have a somatic G>T mutation in KRAS. The role 
of this variant in CRC predisposition requires further study.
6.4.5 Future work
Based on the strong biological rational that already exists for a role of BER pathway 
components in CRC risk, it will be important to determine if the biallelic mutations 
observed in OGG1 and MTH1 do alter protein function and in-turn risk. This will 
require the use of a series of functional experiments to determine if these mutations 
alter expression, repair capacity, localisation etc. Of note was the fact that OGG1 
G308E was over-represented in cases vs. controls within the advanced disease 
setting. An important next step will be to attempt to validate this observation in an 
independent cohort of advanced cases.
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Active site
G308E
A288V
Figure 6.2 - Crystal structure of the OGG1 protein cross-linked with guanine- 
containing DNA. The A 288 and G 308 amino acids are highlighted in yellow and 
indicated by arrows. A 288 comes into direct contact with DNA (brown and blue 
strands) with the A 288V  variant influencing catalytic activity. G 308E  lies on the 
surface of the protein and has no obvious functional consequence.
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Chapter Seven - General Discussion
7.1 Factors affecting patient survival (Table 7.1)
7.1.1 Germline factors
The data presented in this thesis represent the first report of a role for germline CRC 
susceptibility alleles in influencing patient survival. In all, prognostic roles have been 
identified for four of the fourteen currently known GWAS loci. These were validated 
in an independent cohort of patients. The four loci are 16q22 (rs9929218), 19q13 
(rs10411210), 10p14 (rs10795668) and 8q23 (rs16892766). Interestingly, others 
(Tenesa etal. 2010; Cicek etal. 2009; Xing etal. 2011) have scrutinised GWAS risk 
loci for prognostic roles but have reported no convincing evidence for prognostic 
influence. It is likely that the discordance between our findings and those of Tenesa 
and colleagues lies in the difference in stage of patients screened, with the latter 
using patients with largely stages 1-3 CRC. As such, they likely had less power to 
observe effects over OS. Of note, however, the prognostic effects of rs16892766, 
rs9929218 and rs10411210 observed here were not significant across all trial arms. 
Since different amounts of the chemotherapeutic backbone were used across these 
arms, we cannot rule out that the difference in survival outcome is a result of altered 
response to therapy.
It is likely that the upcoming years will see GWAS technology employed in the 
identification of genetic factors associated with CRC survival. GWAS for survival 
alleles have been carried out in other cancers, specifically breast (Azzato et al. 2010) 
and prostate (Penney et al. 2010). Neither study managed to identify germline 
variants though both had only limited power to detect modest effects on survival for 
common variants.
7.1.2 Mechanism at the 8q23 locus
rs16892766 lies downstream of the EIF3H gene, at 8q23, which has previously been 
shown to have oncogenic potential (Zhang et al. 2007). Further scrutiny of this gene 
revealed another SNP (rs28649280) that was in moderate LD with rs16892766 and 
that also acted as a susceptibility allele. Furthermore, in silico analysis suggested 
that rs28649280 lies in the promoter region of the EIF3H gene, in a binding site for 
the SP1 transcription factor. Using a luciferase assay we found that there was an
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allele specific effect upon expression -  with the risk allele associating with 
significantly increased luciferase activity. Of note, both rs28649280 and the 
rs16892766 carried a negative prognostic effect on OS. It is possible that a multitude 
of elements individually and collectively regulate EIF3H expression, including the 
rs28649280 and rs 16888589 SNPs described by ourselves and Pittman and 
colleagues (2010) (Figure 7.1). When one or more risk alleles are present, they 
modestly alter expression of EIF3H which subtly contributes to the progression of 
CRC through increased expression of transcription factors and proto-oncogenes. 
Ultimately, this alters the risk and prognosis of the disease.
7.1.3 Distinct mechanisms of colorectal tumourigenesis and their prognostic 
influence
We have shown a scarcity of biallelic carriers of MUTYH variants in the advanced 
disease setting. We suggest that this rarity may be explained by a significantly 
improved prognosis for these patients as compared to those without MUTYH 
mutations. Improved survival had previously been shown in a comparison of 147 
MAP patients with CRC and 272 matched patients with CRCs (five year survival 
being 78% and 63% respectively) (Nielsen etal. 2010). This observation was 
significant (HR 0.48, 95% Cl 0.32-0.72, P<0.001) after adjustment for multiple factors 
including age, stage, sex, tumour sub-site, country and year of diagnosis. Closer 
scrutiny of prognostic impact for stage specific cancers revealed that the survival 
benefit for MAP patients compared with controls was greater for patients with early- 
stage CRC (HR 0.45, 95% Cl 0.23-0.91) than those with later stage disease (HR 
0.64, 95% Cl 0.34-1.20). The authors acknowledge that there are a number of 
weaknesses to this study, including multiple selection biases (including the earlier 
clinical attention given to members of ‘predisposed’ families, polyp status of MAP 
cases and discrepancies between time of diagnosis for MAP and population based 
CRC sufferers) and differences in immune response. Nonetheless, the data points to 
a significantly better survival for MAP patients than for matched control patients with 
CRC. The MAP data presented in this thesis combined with that of Nielsen and 
colleagues (2010) and data from HNPCC-associated tumours and sporadic CRCs 
with MSI indicate that distinct mechanisms of colorectal tumourigenesis may directly 
influence patient survival.
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Figure 7.1 - Diagrammatic representation of two potential EIF3H regulatory mechanisms. The main 
transcript of EIF3H, and its exons, is represented with a blue line drawn to scale. SNPs are shown 
with a red cross. The EIF3H promoter region is represented by a light purple line that is not drawn to 
scale. Conservation at various sites is shown by the blue and red jagged line -  a blue peak highlights 
areas that are heavily conserved. We propose a model in which rs16892766 is in moderate LD with 
another SNP that physically lies in the promoter region, rs28649280. This SNP lies in a conserved 
potential binding site for the SP1 transcription factor and alters expression. In the mechanisms 
proposed by Pittman and colleagues (2010), a SNP (rs16888589) in high LD with rs16892766 was 
found to lie in a conserved enhancer element. Furthermore, they show that this conserved island 
physically interacts with the promoter region of the EIF3H gene.
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7.1.4 Somatic factors
Whilst the prognostic effect of BRAF mutations had previously been established, the 
role of KRAS mutations was unclear. As part of the COIN trial, we found that patients 
with somatic mutations of KRAS (median OS 14 months) and, in particular, BRAF 
(median OS 8.8 months) in their tumours had a worse prognosis than those patients 
all wild-type for KRAS, BRAF and NRAS (median OS 20.1 months) irrespective of 
treatment given. PIK3CA mutations had no prognostic influence.
It is unclear why somatic mutations of KRAS and BRAF should have such varying 
effects on prognosis. It must be considered that, despite being neighbours in RAS- 
RAF-MAPK signalling, both enzymes have differing functional interactions, and as 
such, roles within the cell. For example, Preto and colleagues (2008) show that 
BRAF harbouring V600E is important in regulating proliferation through interactions 
with p29Kip1 and cyclin D1. KRAS harbouring G13D however do not affect these 
proteins. They also suggest that CRC tumour cells with activated BRAF are more 
dependent on the BRAF-ERK pathway for proliferation than those with activated 
KRAS which may signal to other pathways, including the PI3K-PTEN-Akt and 
RalGDS pathways (Solit et al. 2006; Schubbert et al. 2007).
It is likely that the particular interactions and mechanisms that selectively occur in 
BRAF mutant tumours are conducive to a more aggressive phenotype than in 
tumours harbouring mutations of KRAS. This ultimately reduces the survival time of 
patients with this somatic mutation. Similarly, the course taken by tumour with a 
KRAS mutation is likely to be more aggressive than that taken by a tumour without a 
KRAS mutation. The complexity of prognostic roles for the somatic phenotypes is 
further highlighted by the fact that the negative prognostic value of mutant BRAF 
may be restricted to patients that are MSS (Roth et al. 2010). Therefore the 
molecular signature of a tumour influences patient survival -  with different mutations 
affecting individual and interacting pathways.
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Factors affecting patient survival
Survival
Loci SN P/Gene Mechanism HR 95% Cl P value
Difference
(median
months)
8q23 rs16892766
Altered EIF3H 
expression
1.27 1.12-1.44 <0.001 -2.9
8q23 rs28649280
Altered EIF3H 
expression
1.26 1.12-1.43 <0.001 -2.9
8q23 rs16888589
Altered EIF3H 
expression
1.21 1.07-1.37 0.002 -2.7
16q22 rs9929218
Altered CDH1 
expression
1.46 1.23-1.74 0.002 -4.3
16q22 rs16260
Altered CDH1 
expression
1.38 1.15-1.67 0.001 -3.9
19q13 rs10411210 Unknown 1.23 1.08-1.39 0.001 -2.5
10p14 rs10795668 Unknown
Constitutive
0.71 0.59-0.86 0.001 +6.2
12p12 KRAS Ras-Raf-MAPK
signalling
Constitutive
1.34 1.18-1.52 <0.001 -3.2
7q34 BRAF Ras-Raf-MAPK 
signalling 
Impaired ability
2.00 1.61-2.50 <0.001 -7.9
1 p34 MUTYH*
to repair 
G:C-»T:A 
transversions.
- - - -
Table 7.1 -  Summary of factors affecting patient survival studied in this thesis, 
‘ patients with biallelic MUTYH mutations associate with a significantly improved 
prognosis as compared to patients without these mutations.
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7.2 Factors affecting response to and side effects from chemotherapy (Table 
7.2)
We tested all SNPs across the 14 CRC risk loci for their effects on response to, and 
side effects from 12 weeks of standard oxaliplatin and fluoropyrimidine based 
chemotherapy. We found that patients homozygous for the rs9929218 minor allele 
had a poor prognosis for response to treatment as compared to patients’ 
heterozygous or homozygous wild-type. These patients also had an increased risk of 
skin toxicity, specifically HFS. The strongly linked variant rs16260 had a similar effect 
on response and side effects. Though rs16892766 did not have an effect, we found 
that rs28649280 and rs16888589 at 8q23 did alter response to treatment at 12 
weeks.
It is unclear as to why these variants should alter response to therapy. There is no 
data to suggest why EIF3H might alter response and no obvious biological rationale. 
However, it has been suggested that the levels of E-cadherin expression can alter 
response to cytotoxic agents (including oxaliplatin and 5FU) in breast cancer, with 
cells expressing E-cadherin showing a trend towards improved response (Koo et al.
2009). Meanwhile, studies of CRC cells that developed resistance to oxaliplatin 
showed that they underwent EMT, with an associated reduction of E-cadherin 
expression (Yang et al. 2006).
185
Factors affecting response to and side effects from chemotherapy
Loci SNP/Gene Parameter Mechanism OR 95% Cl P value
8q23 rs28649280 Response
Altered EIF3H 
expression
0.60 0.43-0.83 0.002
8q23 rs16888589 Response
Altered EIF3H 
expression
0.72 0.54-0.97 0.031
16q22 rs9929218
Response
HFS
Altered CDH1 
expression
0.48
4.68
0.31-0.75
1.84-11.90
0.001
0.001
16q22 rs16260
Response
HFS
Altered CDH1 
expression
0.68
4.78
0.37-0.93
1.80-12.7
0.022
0.002
Table 7.2 -  Summary of factors affecting response to and side effects from 
chemotherapy studied in this thesis.
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7.3 Predictive factors affecting response to cetuximab (Table 7.3)
7.3.1 The COIN trial
The negative outcome of the COIN trial highlights how much there is yet to learn 
about the correct use of cetuximab in the management of mCRC. Against 
expectations, the trial showed no benefit for cetuximab administration in patients that 
were wild-type for KRAS. This was also the case in patients all wild-type for KRAS, 
BRAF and NRAS. The reasons for this negative outcome remain unclear. It is 
possible that the apparent lack of benefit from cetuximab is merely an artefact of 
reduced fluoropyrimidine application (the dose of capecitabine was reduced due to 
toxicity issues). Also the COIN data suggests that capecitabine, a popular choice of 
fluoropyrimidine since it is administered orally, may interact with cetuximab. This is 
possible since the drugs have overlapping toxicity profiles; Cetuximab induces 
increased diarrhoea, potentially impacting on the amount of capecitabine that is 
absorbed through the gut. A recent comparison of cetuximab plus OxCap and 
cetuximab plus CAPIRI (capecitabine + irinotecan) in 177 mCRC patients found no 
improvement in treatment efficacy in KRAS wild-type patients as compared to KRAS 
mutant (Moosmann et al. 2011) in the OxCap group. Though this was an under­
powered study with no control arm, this data compliments the COIN trial results. 
However, it should be noted that the authors did not observe increased 
nonhematological or gastrointestinal toxicity with OxCap suggesting the interaction 
between agents may be a mechanistic one.
If patients that received capecitabine are excluded, the COIN trial data more closely 
resembles that of the majority of other clinical trials of cetuximab efficacy. A most 
responsive cohort was identified that contained patients wild-type for KRAS, BRAF 
and NRAS, contained £1 metastatic sites and received OxFU and these patients did 
show improved PFS in response to cetuximab treatment (HR 0.55, 95% Cl 0.35- 
0.87, P=0.01).
Though data has not yet been published, the results from the NORDIC VII study 
have recently been presented at the ESMO 2010 meeting. This trial tested the 
addition of cetuximab to NORDIC FLOX (5FU/Folinic Acid and Oxaliplatin) in mCRC 
patients. NORDIC VII, like COIN, showed no statistically significant difference in 
PFS, OS, or ORR between patients that received cetuximab and those that did not
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even when considering KRAS status. Of note, no patients were administered 
capecitabine suggesting that oxaliplatin, and not capecitabine, may be contributing a 
lack of response to cetuximab.
7.3.2 The role of E-cadherin in response to cetuximab
Our study of risk loci for predictive influences revealed that the rs9929218 
polymorphism at 16q22 confers altered response to cetuximab and risk of HFS at 12 
weeks. This variant maps to the second intron of the CDH1 gene which encodes E- 
cadherin. E-cadherin is a transmembrane glycoprotein that is critical in the 
establishment and maintenance of intercellular adhesion, cell polarity and tissue 
morphology and regeneration (Takeichi, 1991). It localises at adherens junctions 
where it interacts, through its cytoplasmic component, with p-catenin. This in turn 
associates with a-catenin which mediates its linkage with the cell’s cytoskeletal 
structure (Tsanou et al. 2008). Loss of E-cadherin represents the defining feature of 
the ‘epithelial to mesenchymal transition’ (EMT) -  a change in cell phenotype that 
sees cells down-regulate cell-cell adhesion structures, as well as alter their polarity 
and cytoskeletal structure (Klymkowsky and Savagner, 2009). EMT is a common 
event during epithelial-derived tumour progression.
rs9929218 lies in a region of CDH1 that contains several cis-regulatory elements 
(Stemmier et al. 2005) and is in strong LD with rs16260 in its promoter, the minor 
allele of which down-regulates E-cadherin expression (Li et al. 2000). Patients 
homozygous for the rs9929218 minor allele (~8% of patients), showed a poor 
prognosis with standard oxaliplatin and 5FU-based chemotherapy, but showed 
significant benefit from treatment with cetuximab. Interestingly, these patients would 
be predicted to have reduced E-cadherin expression (from linkage to rs16260) and 
consequently expected to have poor response to cetuximab (see chapter 3). 
Furthermore, we show that the benefit was greatest in those patients that also had 
KRAS, BRAF or NRAS mutant tumours, again in contrast with expectations (De 
Roock et al. 2010a). We therefore suggest that cetuximab may be benefiting these 
patients by a novel mechanism similar to the synthetic sickness/lethalilty phenotype 
observed in BRCA1 or BRCA2 mutant cells with PARP1 inhibition, MSH2 mutant 
cells with POLB inhibition and MLH1 mutant cells with POLG inhibition (Martin et al.
2010) (Figure 7.2A). We propose that a combination of reduced E-cadherin
188
expression, activation of the Ras-Raf-MAPK signalling pathway and EGFR blockade 
(via cetuximab) creates a cellular environment incompatible with survival which 
causes the tumour to shrink (Figure 7.2B). Further studies are therefore warranted to 
exploit this potential therapeutic opportunity.
7.4 Aims of this thesis
In section 1.7, a series of aims were described for this thesis. These aims have been 
addressed as follows;
Chapter 03 -  Through the COIN trial, we have contributed to the understanding of 
the role played by somatic mutations within key components of the EGFR signalling 
pathways, in altering response to cetuximab. Though overall the data suggests that 
these variants play no role in altering response, it is likely that a number of 
confounding factors are masking the true effects these mutations play. This analysis 
allowed the comparison of pyrosequencing and Sequenom for the high-throughput 
analysis of somatic variants, with results suggesting high genotyping success rate 
and concordance between both technologies.
Chapter 04 -  The genotyping of COIN patients and UKBS controls allowed for the 
determination of the role played by a series of variants in defining CRC risk within 
the advanced disease setting. Through a series of functional experiments, we show 
that EIF3H may be involved in altering this risk (and patient survival) through its 
linkage to a SNP in the EIF3H promoter region.
Chapter 05 -  We have identified a series of prognostic effects for SNPs at the 8q23, 
16q22, 19q13 and 10p14 loci. Furthermore, exploiting the design of the COIN trial, 
we show that the rs9929218 SNP alters both prognostic response to standard 
chemotherapy and predictive response to cetuximab. These effects are also shown 
by the rs16260 SNP in the CDH1 promoter region.
Chapter 06 -  We aimed to identify novel high penetrance alleles that predispose to 
CRC from the BER, MMR and OxDR pathways. Genes found to carry biallelic 
mutation in cases and not controls included MUTYH, OGG1 and MTH1 which 
operate as a triumvirate of repair genes in the BER pathway. Further work is needed 
to determine if the OGG1 G308E and MTH1 V83M mutations do contribute to CRC 
risk. By virtue of its significant under-representation in the advanced disease setting, 
we suggest that MAP confers a positive prognosis upon CRC survival.
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Figure 7.2 -  Synthetic lethality. A, the Mechanism put forward by Martin and colleagues (2010). Here, 
repair of oxidized DNA lesions can be performed by either MSH2/MLH1 dependent processes or 
BER. In wild-type cells, inhibition of BER (through POLB and/or POLG) does not result in cell death 
since repair can be carried out by MSH2/MLH1. In MSH2 mutant cells, inhibition of POLB results in 
the accumulation of 8oxoG within nuclear DNA which may cause cellular arrest or death. In MLH1 
mutant cells, inhibition of POLG results in the accumulation of 8oxoG in mitochondrial DNA which 
again results in reduced replicative potential or death. B, Diagram representing the possible 
mechanism through which tumour cells respond to cetuximab in an rs9929218 and KRAS, BRAF, 
NRAS mutant dependent manner. In the first scenario, blockade of EGFR signalling by cetuximab 
results in death of the tumour cell. However, when KRAS is mutated, cetuximab is rendered 
ineffective and tumour cells proliferate unchecked. In the third scenario, and as suggested by Black 
and colleagues (2008), cells lacking E-cadherin are resistant to cetuximab. Finally, the combination of 
reduced E-cadherin expression, activation of the Ras/Raf signalling pathway and EGFR blockade 
creates a cellular environment incompatible with tumour cell survival.
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Factors affecting patient response to cetuximab
Aim Effect HR/OR 95% Cl P value Mechanism
To determine if there was improved 
response to cetuximab in CRC patients..
.wild-type for 
KRAS
No effect 
(OS) 1.04 0.87-1.23 0.67
...wild-type for 
KRAS, BRAF, 
NRAS
...wild-type for 
KRAS, BRAF 
NRAS, with £1 
metastatic site 
and that 
received OxFLI 
therapy
...wild-type for 
PIK3CA
No effect 
(OS)
Improved
response
(PFS)
No effect 
(OS)
..wild-type for Noeffect
PIK3CA and
KRAS (Ub)
1.02 0.83-1.24 0.86
0.55 0.35-0.87 0.01
1.01
1.03
0.88-1.16
0.86-1.24
0.89
0.75
There may have been an 
interaction between 
capecitabine and cetuximab 
(perhaps through 
overlapping toxicities).
The role of PIK3CA 
mutations in altering 
response to cetuximab is 
unclear. Our data suggests 
that it does not have an 
effect, regardless of KRAS 
status.
Of the 14 CRC risk loci, an effect on response 
was observed in CRC patients...
..homozygous 
for the minor 
allele of 
rs9929218...
...combined 
with mutant 
KRAS, BRAF or 
NRAS
Improved
response 1.69 0.93-3.07 0.001’
Improved
response 1.69 0.61-4.74 0.004*
rs9929218 lies in 2nd intron 
of CDH1. It is possible that 
tumour cells are killed by a 
synthetic lethality 
mechanism. Alone mutations 
of E-cadherin and Ras-Raf 
signalling are not sufficient 
to induce tumour cell death, 
but combined these 
mutations are incompatible 
with tumour survival upon 
EGFR blockade.
Table 7.3 -  Summary of factors affecting response to cetuximab studied in this 
thesis. * P for interaction.
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